GB2122201A - Carbacyclin intermediates - Google Patents
Carbacyclin intermediates Download PDFInfo
- Publication number
- GB2122201A GB2122201A GB08319030A GB8319030A GB2122201A GB 2122201 A GB2122201 A GB 2122201A GB 08319030 A GB08319030 A GB 08319030A GB 8319030 A GB8319030 A GB 8319030A GB 2122201 A GB2122201 A GB 2122201A
- Authority
- GB
- United Kingdom
- Prior art keywords
- formula
- compounds
- ethyl acetate
- compound
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000543 intermediate Substances 0.000 title description 30
- XZFRIPGNUQRGPI-WLPVIMDJSA-N Carbacyclin Chemical compound C1\C(=C\CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 XZFRIPGNUQRGPI-WLPVIMDJSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 399
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 84
- 239000001257 hydrogen Substances 0.000 claims abstract description 83
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 49
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 32
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims abstract 5
- -1 phenoxy, phenyl Chemical class 0.000 claims description 196
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 44
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 33
- 125000001424 substituent group Chemical group 0.000 claims description 22
- 125000001153 fluoro group Chemical group F* 0.000 claims description 14
- 125000001797 benzyl group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 10
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 9
- 229910052731 fluorine Chemical group 0.000 claims description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 5
- 239000011737 fluorine Chemical group 0.000 claims description 5
- 125000000286 phenylethyl group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000004344 phenylpropyl group Chemical class 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 642
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 412
- 229940093499 ethyl acetate Drugs 0.000 description 213
- 235000019439 ethyl acetate Nutrition 0.000 description 213
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 203
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 178
- 238000000034 method Methods 0.000 description 178
- 239000000047 product Substances 0.000 description 174
- 239000000741 silica gel Substances 0.000 description 167
- 229910002027 silica gel Inorganic materials 0.000 description 167
- 230000009102 absorption Effects 0.000 description 143
- 238000010521 absorption reaction Methods 0.000 description 143
- 239000000243 solution Substances 0.000 description 134
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 132
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 126
- 239000012267 brine Substances 0.000 description 124
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 105
- 239000000203 mixture Substances 0.000 description 97
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 93
- 238000005481 NMR spectroscopy Methods 0.000 description 84
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 69
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 69
- 239000007795 chemical reaction product Substances 0.000 description 66
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 66
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- 229960004132 diethyl ether Drugs 0.000 description 57
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 56
- 239000012299 nitrogen atmosphere Substances 0.000 description 56
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical class O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 54
- 239000002253 acid Substances 0.000 description 54
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 53
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 50
- 150000004702 methyl esters Chemical class 0.000 description 50
- 125000004432 carbon atom Chemical group C* 0.000 description 40
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 38
- 238000006243 chemical reaction Methods 0.000 description 36
- 239000000725 suspension Substances 0.000 description 36
- 239000003921 oil Substances 0.000 description 34
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 32
- 238000002360 preparation method Methods 0.000 description 32
- 238000003756 stirring Methods 0.000 description 32
- 230000009466 transformation Effects 0.000 description 31
- 239000012230 colorless oil Substances 0.000 description 29
- 229920006395 saturated elastomer Polymers 0.000 description 28
- 239000007787 solid Substances 0.000 description 28
- 229960000583 acetic acid Drugs 0.000 description 27
- 238000001819 mass spectrum Methods 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 26
- 125000006239 protecting group Chemical group 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- 150000001408 amides Chemical class 0.000 description 25
- 238000004587 chromatography analysis Methods 0.000 description 25
- 150000002148 esters Chemical class 0.000 description 25
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 25
- 235000019341 magnesium sulphate Nutrition 0.000 description 25
- 235000017557 sodium bicarbonate Nutrition 0.000 description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 24
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 23
- 238000011282 treatment Methods 0.000 description 23
- 239000002904 solvent Substances 0.000 description 22
- 239000000284 extract Substances 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 238000002844 melting Methods 0.000 description 20
- 230000008018 melting Effects 0.000 description 20
- XZFRIPGNUQRGPI-WBQKLGIQSA-N Carbaprostacyclin Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 XZFRIPGNUQRGPI-WBQKLGIQSA-N 0.000 description 19
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 18
- 229960001123 epoprostenol Drugs 0.000 description 18
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- 235000011152 sodium sulphate Nutrition 0.000 description 17
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 150000008064 anhydrides Chemical class 0.000 description 15
- 230000007062 hydrolysis Effects 0.000 description 15
- 238000006460 hydrolysis reaction Methods 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 14
- 229960001701 chloroform Drugs 0.000 description 14
- 239000010410 layer Substances 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 13
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- 239000012312 sodium hydride Substances 0.000 description 13
- 229910000104 sodium hydride Inorganic materials 0.000 description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 12
- 150000001299 aldehydes Chemical class 0.000 description 11
- 239000012300 argon atmosphere Substances 0.000 description 11
- 150000003138 primary alcohols Chemical class 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 11
- 239000002585 base Substances 0.000 description 10
- 125000001309 chloro group Chemical group Cl* 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000005909 Kieselgur Substances 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- JCSGAUKCDAVARS-SOUFLCLCSA-N chembl2106517 Chemical compound C1([C@@H](O)[C@H]2C3)=CC=CC(O)=C1C(=O)C2=C(O)[C@@]1(O)[C@@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C1=O JCSGAUKCDAVARS-SOUFLCLCSA-N 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
- 238000005886 esterification reaction Methods 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 150000003512 tertiary amines Chemical class 0.000 description 9
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical class C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 8
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 230000032050 esterification Effects 0.000 description 8
- 239000002024 ethyl acetate extract Substances 0.000 description 8
- 150000002576 ketones Chemical class 0.000 description 8
- 239000002480 mineral oil Substances 0.000 description 8
- 235000010446 mineral oil Nutrition 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 239000000376 reactant Substances 0.000 description 8
- JTNCEQNHURODLX-UHFFFAOYSA-N 2-phenylethanimidamide Chemical compound NC(=N)CC1=CC=CC=C1 JTNCEQNHURODLX-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 7
- 150000001450 anions Chemical class 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 150000001768 cations Chemical class 0.000 description 7
- 239000012362 glacial acetic acid Substances 0.000 description 7
- 150000002596 lactones Chemical class 0.000 description 7
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 7
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000000844 transformation Methods 0.000 description 7
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 239000003810 Jones reagent Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 6
- 125000003368 amide group Chemical group 0.000 description 6
- 235000019270 ammonium chloride Nutrition 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 6
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 6
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 6
- 125000003884 phenylalkyl group Chemical group 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 6
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 6
- AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical compound C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 5
- 0 C*CCC(C(Cc1cccc(*)c1)[C@](C)*IC(C(*C)=I)=N)C=O Chemical compound C*CCC(C(Cc1cccc(*)c1)[C@](C)*IC(C(*C)=I)=N)C=O 0.000 description 5
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 229960000711 alprostadil Drugs 0.000 description 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 5
- 150000001735 carboxylic acids Chemical class 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 229940117975 chromium trioxide Drugs 0.000 description 5
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 5
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 239000012280 lithium aluminium hydride Substances 0.000 description 5
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 5
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 235000011181 potassium carbonates Nutrition 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000006884 silylation reaction Methods 0.000 description 5
- 229940124530 sulfonamide Drugs 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 229940086542 triethylamine Drugs 0.000 description 5
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- IWHLYPDWHHPVAA-UHFFFAOYSA-N 6-hydroxyhexanoic acid Chemical compound OCCCCCC(O)=O IWHLYPDWHHPVAA-UHFFFAOYSA-N 0.000 description 4
- 229910000761 Aluminium amalgam Inorganic materials 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 4
- VONWDASPFIQPDY-UHFFFAOYSA-N dimethyl methylphosphonate Chemical compound COP(C)(=O)OC VONWDASPFIQPDY-UHFFFAOYSA-N 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 150000003456 sulfonamides Chemical class 0.000 description 4
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 4
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 4
- 125000003944 tolyl group Chemical group 0.000 description 4
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 3
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 3
- 101100297345 Caenorhabditis elegans pgl-2 gene Chemical class 0.000 description 3
- 239000012027 Collins reagent Substances 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000005903 acid hydrolysis reaction Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001263 acyl chlorides Chemical class 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000000924 antiasthmatic agent Substances 0.000 description 3
- 125000005002 aryl methyl group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 3
- 229940043279 diisopropylamine Drugs 0.000 description 3
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- XHFXMNZYIKFCPN-UHFFFAOYSA-N perchloryl fluoride Chemical group FCl(=O)(=O)=O XHFXMNZYIKFCPN-UHFFFAOYSA-N 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 229910003446 platinum oxide Inorganic materials 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 3
- 229910000105 potassium hydride Inorganic materials 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 150000003815 prostacyclins Chemical class 0.000 description 3
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 3
- NPRDHMWYZHSAHR-UHFFFAOYSA-N pyridine;trioxochromium Chemical compound O=[Cr](=O)=O.C1=CC=NC=C1.C1=CC=NC=C1 NPRDHMWYZHSAHR-UHFFFAOYSA-N 0.000 description 3
- 238000007127 saponification reaction Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- RXYPXQSKLGGKOL-UHFFFAOYSA-N 1,4-dimethylpiperazine Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 2
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical compound CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 2
- IVVBMGAANBIBOA-UHFFFAOYSA-N 2-amino-1-(2-hydroxyphenyl)ethanone Chemical compound NCC(=O)C1=CC=CC=C1O IVVBMGAANBIBOA-UHFFFAOYSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- SWHVFXIPSSRRIK-UHFFFAOYSA-N 3-amino-1-(4-methoxyphenyl)propan-1-one Chemical compound COC1=CC=C(C(=O)CCN)C=C1 SWHVFXIPSSRRIK-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- RHLVCLIPMVJYKS-UHFFFAOYSA-N 3-octanone Chemical compound CCCCCC(=O)CC RHLVCLIPMVJYKS-UHFFFAOYSA-N 0.000 description 2
- LEHPQAGVBUSNMT-UHFFFAOYSA-N 5-amino-1-(3-methylphenyl)pentan-1-one Chemical compound CC1=CC=CC(C(=O)CCCCN)=C1 LEHPQAGVBUSNMT-UHFFFAOYSA-N 0.000 description 2
- XYQUGPPNXPPHSC-UHFFFAOYSA-N 5-amino-1-(4-ethylphenyl)pentan-1-one Chemical compound CCC1=CC=C(C(=O)CCCCN)C=C1 XYQUGPPNXPPHSC-UHFFFAOYSA-N 0.000 description 2
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo(3.3.1)nonane Chemical compound C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical class NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 2
- 208000005156 Dehydration Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- TYBCSQFBSWACAA-UHFFFAOYSA-N Nonan-4-one Chemical compound CCCCCC(=O)CCC TYBCSQFBSWACAA-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 2
- GOPYZMJAIPBUGX-UHFFFAOYSA-N [O-2].[O-2].[Mn+4] Chemical class [O-2].[O-2].[Mn+4] GOPYZMJAIPBUGX-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 125000004212 difluorophenyl group Chemical group 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- 125000005594 diketone group Chemical group 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical group [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960002179 ephedrine Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- ZHQLTKAVLJKSKR-UHFFFAOYSA-N homophthalic acid Chemical compound OC(=O)CC1=CC=CC=C1C(O)=O ZHQLTKAVLJKSKR-UHFFFAOYSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002664 inhalation therapy Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 2
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960002523 mercuric chloride Drugs 0.000 description 2
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 2
- MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical compound [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 description 2
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- MOSWMBWMCPHPCL-UHFFFAOYSA-N non-1-ene Chemical compound [CH2]CCCCCCC=C MOSWMBWMCPHPCL-UHFFFAOYSA-N 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- OALPPYUMFWGHEK-UHFFFAOYSA-M potassium;benzenethiolate Chemical compound [K+].[S-]C1=CC=CC=C1 OALPPYUMFWGHEK-UHFFFAOYSA-M 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 150000003333 secondary alcohols Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 229910001023 sodium amalgam Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 125000005555 sulfoximide group Chemical group 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- AAAQKTZKLRYKHR-UHFFFAOYSA-N triphenylmethane Chemical compound C1=CC=CC=C1C(C=1C=CC=CC=1)C1=CC=CC=C1 AAAQKTZKLRYKHR-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- PFJVIOBMBDFBCJ-UHFFFAOYSA-N (1z)-1-diazobutane Chemical compound CCCC=[N+]=[N-] PFJVIOBMBDFBCJ-UHFFFAOYSA-N 0.000 description 1
- DVGVUEKIOAHHSC-UHFFFAOYSA-N (1z)-1-diazodecane Chemical compound CCCCCCCCCC=[N+]=[N-] DVGVUEKIOAHHSC-UHFFFAOYSA-N 0.000 description 1
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- QFUSOYKIDBRREL-NSCUHMNNSA-N (e)-but-2-en-1-amine Chemical compound C\C=C\CN QFUSOYKIDBRREL-NSCUHMNNSA-N 0.000 description 1
- KEXFRBIOHPDZQM-UHFFFAOYSA-N 1,1-bis(2,2-dimethylpropoxy)-n,n-dimethylmethanamine Chemical compound CC(C)(C)COC(N(C)C)OCC(C)(C)C KEXFRBIOHPDZQM-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 229940005561 1,4-benzoquinone Drugs 0.000 description 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- PDLGREGRADYARF-UHFFFAOYSA-N 1-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NC(O)C(CO)CO PDLGREGRADYARF-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- BTUGGGLMQBJCBN-UHFFFAOYSA-N 1-iodo-2-methylpropane Chemical compound CC(C)CI BTUGGGLMQBJCBN-UHFFFAOYSA-N 0.000 description 1
- HZFQGYWRFABYSR-UHFFFAOYSA-N 1-methoxycyclohexene Chemical compound COC1=CCCCC1 HZFQGYWRFABYSR-UHFFFAOYSA-N 0.000 description 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- YQOPNAOQGQSUHF-UHFFFAOYSA-N 1-propan-2-ylpyrrolidine Chemical compound CC(C)N1CCCC1 YQOPNAOQGQSUHF-UHFFFAOYSA-N 0.000 description 1
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
- XVXGXOJNGBLOKR-UHFFFAOYSA-N 2,2-dimethylcyclohexan-1-amine Chemical compound CC1(C)CCCCC1N XVXGXOJNGBLOKR-UHFFFAOYSA-N 0.000 description 1
- NODFGJYBXPEUCQ-UHFFFAOYSA-N 2,2-dimethylcyclopentan-1-amine Chemical compound CC1(C)CCCC1N NODFGJYBXPEUCQ-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- NPLSMQWSKZXZPD-UHFFFAOYSA-N 2,3-dihydropyrrol-1-amine Chemical compound NN1CCC=C1 NPLSMQWSKZXZPD-UHFFFAOYSA-N 0.000 description 1
- ULLMWEQEVXWLIQ-UHFFFAOYSA-N 2,3-dimethylcyclopentan-1-amine Chemical compound CC1CCC(N)C1C ULLMWEQEVXWLIQ-UHFFFAOYSA-N 0.000 description 1
- WKSFMZZYLMIEKD-UHFFFAOYSA-N 2-(2-aminoacetyl)benzoic acid Chemical compound NCC(=O)C1=CC=CC=C1C(O)=O WKSFMZZYLMIEKD-UHFFFAOYSA-N 0.000 description 1
- BKDJKRWZGJRHEA-UHFFFAOYSA-N 2-(3-aminopropanoyl)benzoic acid Chemical compound NCCC(=O)C1=CC=CC=C1C(O)=O BKDJKRWZGJRHEA-UHFFFAOYSA-N 0.000 description 1
- 125000003602 2-(3-thienyl)ethoxy group Chemical group [H]C1=C([H])C(=C([H])S1)C([H])([H])C([H])([H])O* 0.000 description 1
- OFWZQJPCIRQIGJ-UHFFFAOYSA-N 2-(4-aminobutanoyl)benzoic acid Chemical compound NCCCC(=O)C1=CC=CC=C1C(O)=O OFWZQJPCIRQIGJ-UHFFFAOYSA-N 0.000 description 1
- CBTXIYVBTFLKOO-UHFFFAOYSA-N 2-(5-aminopentanoyl)benzoic acid Chemical compound NCCCCC(=O)C1=CC=CC=C1C(O)=O CBTXIYVBTFLKOO-UHFFFAOYSA-N 0.000 description 1
- LELORYPQDQKENB-UHFFFAOYSA-N 2-(methoxyamino)-1-phenylethanone Chemical compound CONCC(=O)C1=CC=CC=C1 LELORYPQDQKENB-UHFFFAOYSA-N 0.000 description 1
- VVFCJVLORNFVHI-UHFFFAOYSA-N 2-(methylamino)-1-phenylethanone Chemical compound CNCC(=O)C1=CC=CC=C1 VVFCJVLORNFVHI-UHFFFAOYSA-N 0.000 description 1
- NNWUEBIEOFQMSS-UHFFFAOYSA-N 2-Methylpiperidine Chemical compound CC1CCCCN1 NNWUEBIEOFQMSS-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- LXZAAAUGPREPGR-UHFFFAOYSA-N 2-[2-(hydroxymethyl)phenyl]ethanol Chemical compound OCCC1=CC=CC=C1CO LXZAAAUGPREPGR-UHFFFAOYSA-N 0.000 description 1
- YXGCDKBYOHJHPR-UHFFFAOYSA-N 2-[2-[tert-butyl(dimethyl)silyl]oxyethyl]benzaldehyde Chemical compound CC(C)(C)[Si](C)(C)OCCC1=CC=CC=C1C=O YXGCDKBYOHJHPR-UHFFFAOYSA-N 0.000 description 1
- RAQDKJJAUOPRQM-UHFFFAOYSA-N 2-[n-(2-hydroxyethyl)-4-(2-methylbutan-2-yl)anilino]ethanol Chemical compound CCC(C)(C)C1=CC=C(N(CCO)CCO)C=C1 RAQDKJJAUOPRQM-UHFFFAOYSA-N 0.000 description 1
- XHYOSFBUKHFEES-UHFFFAOYSA-N 2-amino-1-(2,4,6-trichlorophenyl)ethanone Chemical compound NCC(=O)C1=C(Cl)C=C(Cl)C=C1Cl XHYOSFBUKHFEES-UHFFFAOYSA-N 0.000 description 1
- VYQSJEQBJVHARP-UHFFFAOYSA-N 2-amino-1-(2,4-dichlorophenyl)ethanone Chemical compound NCC(=O)C1=CC=C(Cl)C=C1Cl VYQSJEQBJVHARP-UHFFFAOYSA-N 0.000 description 1
- PYQZHWGHYDTNJK-UHFFFAOYSA-N 2-amino-1-(2,4-dimethoxyphenyl)ethanone Chemical compound COC1=CC=C(C(=O)CN)C(OC)=C1 PYQZHWGHYDTNJK-UHFFFAOYSA-N 0.000 description 1
- KWZWUFCLUMUDRD-UHFFFAOYSA-N 2-amino-1-(3,4,5-trimethoxyphenyl)ethanone Chemical compound COC1=CC(C(=O)CN)=CC(OC)=C1OC KWZWUFCLUMUDRD-UHFFFAOYSA-N 0.000 description 1
- OCHREGYEOMPRIT-UHFFFAOYSA-N 2-amino-1-(3-methylphenyl)ethanone Chemical compound CC1=CC=CC(C(=O)CN)=C1 OCHREGYEOMPRIT-UHFFFAOYSA-N 0.000 description 1
- NXCCDPOCDBAGFX-UHFFFAOYSA-N 2-amino-1-(3-nitrophenyl)ethanone Chemical compound NCC(=O)C1=CC=CC([N+]([O-])=O)=C1 NXCCDPOCDBAGFX-UHFFFAOYSA-N 0.000 description 1
- KIFWACLIANOVDG-UHFFFAOYSA-N 2-amino-1-(4-chlorophenyl)ethanone Chemical compound NCC(=O)C1=CC=C(Cl)C=C1 KIFWACLIANOVDG-UHFFFAOYSA-N 0.000 description 1
- JTKYCUVENBFCFP-UHFFFAOYSA-N 2-amino-1-(4-ethylphenyl)ethanone Chemical compound CCC1=CC=C(C(=O)CN)C=C1 JTKYCUVENBFCFP-UHFFFAOYSA-N 0.000 description 1
- HQWNLTBXRHICQP-UHFFFAOYSA-N 2-amino-1-[4-(hydroxymethyl)phenyl]ethanone Chemical compound NCC(=O)C1=CC=C(CO)C=C1 HQWNLTBXRHICQP-UHFFFAOYSA-N 0.000 description 1
- HEQOJEGTZCTHCF-UHFFFAOYSA-N 2-amino-1-phenylethanone Chemical compound NCC(=O)C1=CC=CC=C1 HEQOJEGTZCTHCF-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- JCBPETKZIGVZRE-UHFFFAOYSA-N 2-aminobutan-1-ol Chemical compound CCC(N)CO JCBPETKZIGVZRE-UHFFFAOYSA-N 0.000 description 1
- MWGATWIBSKHFMR-UHFFFAOYSA-N 2-anilinoethanol Chemical compound OCCNC1=CC=CC=C1 MWGATWIBSKHFMR-UHFFFAOYSA-N 0.000 description 1
- KGHGZRVXCKCJGX-UHFFFAOYSA-N 2-bromo-1-(4-phenylphenyl)ethanone Chemical compound C1=CC(C(=O)CBr)=CC=C1C1=CC=CC=C1 KGHGZRVXCKCJGX-UHFFFAOYSA-N 0.000 description 1
- QUQNCDYVMCPWHV-UHFFFAOYSA-N 2-dimethoxyphosphoryloctane Chemical compound CCCCCCC(C)P(=O)(OC)OC QUQNCDYVMCPWHV-UHFFFAOYSA-N 0.000 description 1
- ANGGPYSFTXVERY-UHFFFAOYSA-N 2-iodo-2-methylpropane Chemical compound CC(C)(C)I ANGGPYSFTXVERY-UHFFFAOYSA-N 0.000 description 1
- KVTHPKXDLVYNCH-UHFFFAOYSA-N 2-iodoethylbenzene Chemical compound ICCC1=CC=CC=C1 KVTHPKXDLVYNCH-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- TYDMZADCGUWTCH-UHFFFAOYSA-N 2-methylcyclopentan-1-amine Chemical compound CC1CCCC1N TYDMZADCGUWTCH-UHFFFAOYSA-N 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- RGHPCLZJAFCTIK-UHFFFAOYSA-N 2-methylpyrrolidine Chemical compound CC1CCCN1 RGHPCLZJAFCTIK-UHFFFAOYSA-N 0.000 description 1
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 1
- NNOHXABAQAGKRZ-UHFFFAOYSA-N 3,5-dinitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC(C(Cl)=O)=CC([N+]([O-])=O)=C1 NNOHXABAQAGKRZ-UHFFFAOYSA-N 0.000 description 1
- IUWXVUQWEZTBCT-UHFFFAOYSA-N 3-[(z)-diazomethyl]heptane Chemical compound CCCCC(CC)C=[N+]=[N-] IUWXVUQWEZTBCT-UHFFFAOYSA-N 0.000 description 1
- AEUWKERRFUWVSZ-UHFFFAOYSA-N 3-[[tert-butyl(dimethyl)silyl]oxymethyl]benzaldehyde Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC=CC(C=O)=C1 AEUWKERRFUWVSZ-UHFFFAOYSA-N 0.000 description 1
- RPYZARAPPYRDIW-UHFFFAOYSA-N 3-amino-1-(2,4,6-trichlorophenyl)propan-1-one Chemical compound ClC1=C(C(=O)CCN)C(=CC(=C1)Cl)Cl RPYZARAPPYRDIW-UHFFFAOYSA-N 0.000 description 1
- OCPYNKRPBRYAIH-UHFFFAOYSA-N 3-amino-1-(2,4-dichlorophenyl)propan-1-one Chemical compound NCCC(=O)C1=CC=C(Cl)C=C1Cl OCPYNKRPBRYAIH-UHFFFAOYSA-N 0.000 description 1
- DEKFTPFQDDIRKW-UHFFFAOYSA-N 3-amino-1-(2,4-dimethoxyphenyl)propan-1-one Chemical compound COc1ccc(C(=O)CCN)c(OC)c1 DEKFTPFQDDIRKW-UHFFFAOYSA-N 0.000 description 1
- ZLOOJQVCQJKDCI-UHFFFAOYSA-N 3-amino-1-(2-hydroxyphenyl)propan-1-one Chemical compound NCCC(=O)C1=CC=CC=C1O ZLOOJQVCQJKDCI-UHFFFAOYSA-N 0.000 description 1
- GWNOGPNGHZUGGO-UHFFFAOYSA-N 3-amino-1-(3,4,5-trimethoxyphenyl)propan-1-one Chemical compound COC1=CC(C(=O)CCN)=CC(OC)=C1OC GWNOGPNGHZUGGO-UHFFFAOYSA-N 0.000 description 1
- ZJXZZGOBXLBAJW-UHFFFAOYSA-N 3-amino-1-(3-chlorophenyl)propan-1-one Chemical compound NCCC(=O)C1=CC=CC(Cl)=C1 ZJXZZGOBXLBAJW-UHFFFAOYSA-N 0.000 description 1
- RIRKDNNEWHJNFE-UHFFFAOYSA-N 3-amino-1-(3-methylphenyl)propan-1-one Chemical compound CC1=CC=CC(C(=O)CCN)=C1 RIRKDNNEWHJNFE-UHFFFAOYSA-N 0.000 description 1
- GTWCXCGQKJSZBY-UHFFFAOYSA-N 3-amino-1-(3-nitrophenyl)propan-1-one Chemical compound NCCC(=O)C1=CC=CC([N+]([O-])=O)=C1 GTWCXCGQKJSZBY-UHFFFAOYSA-N 0.000 description 1
- UPMSXYUQAGTNJD-UHFFFAOYSA-N 3-amino-1-(4-chlorophenyl)propan-1-one Chemical compound NCCC(=O)C1=CC=C(Cl)C=C1 UPMSXYUQAGTNJD-UHFFFAOYSA-N 0.000 description 1
- SZAVIWYFEBRQME-UHFFFAOYSA-N 3-amino-1-(4-ethylphenyl)propan-1-one Chemical compound CCC1=CC=C(C(=O)CCN)C=C1 SZAVIWYFEBRQME-UHFFFAOYSA-N 0.000 description 1
- LDGRABXSOLPOHT-UHFFFAOYSA-N 3-amino-1-(4-methylphenyl)propan-1-one Chemical compound CC1=CC=C(C(=O)CCN)C=C1 LDGRABXSOLPOHT-UHFFFAOYSA-N 0.000 description 1
- SDUBWOXRSDHILY-UHFFFAOYSA-N 3-amino-1-[4-(hydroxymethyl)phenyl]propan-1-one Chemical compound NCCC(=O)C1=CC=C(CO)C=C1 SDUBWOXRSDHILY-UHFFFAOYSA-N 0.000 description 1
- FVXBTPGZQMNAEZ-UHFFFAOYSA-N 3-amino-2-methylpropan-1-ol Chemical compound NCC(C)CO FVXBTPGZQMNAEZ-UHFFFAOYSA-N 0.000 description 1
- VACJHIUSZPBOOF-UHFFFAOYSA-N 3-aminopropane-1,1-diol Chemical compound NCCC(O)O VACJHIUSZPBOOF-UHFFFAOYSA-N 0.000 description 1
- MNOJRWOWILAHAV-UHFFFAOYSA-N 3-bromophenol Chemical compound OC1=CC=CC(Br)=C1 MNOJRWOWILAHAV-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- LTCDIKCILSGJJD-UHFFFAOYSA-N 3-propan-2-ylcyclohexan-1-amine Chemical compound CC(C)C1CCCC(N)C1 LTCDIKCILSGJJD-UHFFFAOYSA-N 0.000 description 1
- JURFPUSNTWSSPJ-UHFFFAOYSA-N 3-pyridin-4-ylpropan-1-amine Chemical compound NCCCC1=CC=NC=C1 JURFPUSNTWSSPJ-UHFFFAOYSA-N 0.000 description 1
- FTNCLUXXFWNCTL-UHFFFAOYSA-N 3-tert-butylcyclopentan-1-amine Chemical compound CC(C)(C)C1CCC(N)C1 FTNCLUXXFWNCTL-UHFFFAOYSA-N 0.000 description 1
- VYWWRLNFSJIJPA-UHFFFAOYSA-N 4-(4-aminobutanoyl)benzoic acid Chemical compound NCCCC(=O)C1=CC=C(C(O)=O)C=C1 VYWWRLNFSJIJPA-UHFFFAOYSA-N 0.000 description 1
- RBDPQTUPMAMNFI-UHFFFAOYSA-N 4-amino-1-(2,4,6-trichlorophenyl)butan-1-one Chemical compound ClC1=C(C(=O)CCCN)C(=CC(=C1)Cl)Cl RBDPQTUPMAMNFI-UHFFFAOYSA-N 0.000 description 1
- JCZWVPSAYTZKOV-UHFFFAOYSA-N 4-amino-1-(2,4-dichlorophenyl)butan-1-one Chemical compound NCCCC(=O)C1=CC=C(Cl)C=C1Cl JCZWVPSAYTZKOV-UHFFFAOYSA-N 0.000 description 1
- GGIRDYRXJNBKNJ-UHFFFAOYSA-N 4-amino-1-(2,4-dimethoxyphenyl)butan-1-one Chemical compound COC1=CC=C(C(=O)CCCN)C(OC)=C1 GGIRDYRXJNBKNJ-UHFFFAOYSA-N 0.000 description 1
- OYMGXQYZLRTNCD-UHFFFAOYSA-N 4-amino-1-(2-hydroxyphenyl)butan-1-one Chemical compound NCCCC(=O)C1=CC=CC=C1O OYMGXQYZLRTNCD-UHFFFAOYSA-N 0.000 description 1
- YFZANWCQPFAJRN-UHFFFAOYSA-N 4-amino-1-(3-chlorophenyl)butan-1-one Chemical compound NCCCC(=O)C1=CC=CC(Cl)=C1 YFZANWCQPFAJRN-UHFFFAOYSA-N 0.000 description 1
- WLFZJHBGHOFQLO-UHFFFAOYSA-N 4-amino-1-(3-nitrophenyl)butan-1-one Chemical compound NCCCC(=O)C1=CC=CC([N+]([O-])=O)=C1 WLFZJHBGHOFQLO-UHFFFAOYSA-N 0.000 description 1
- LUZKCUBLVBFKCV-UHFFFAOYSA-N 4-amino-1-(4-chlorophenyl)butan-1-one Chemical compound NCCCC(=O)C1=CC=C(Cl)C=C1 LUZKCUBLVBFKCV-UHFFFAOYSA-N 0.000 description 1
- ZRBUNYFAHHKTCG-UHFFFAOYSA-N 4-amino-1-(4-methoxyphenyl)butan-1-one Chemical compound COC1=CC=C(C(=O)CCCN)C=C1 ZRBUNYFAHHKTCG-UHFFFAOYSA-N 0.000 description 1
- PBAPNJKVFDMAMA-UHFFFAOYSA-N 4-amino-1-(4-methylphenyl)butan-1-one Chemical compound CC1=CC=C(C(=O)CCCN)C=C1 PBAPNJKVFDMAMA-UHFFFAOYSA-N 0.000 description 1
- NDCQPZLTZOJRQU-UHFFFAOYSA-N 4-amino-1-[4-(hydroxymethyl)phenyl]butan-1-one Chemical compound NCCCC(=O)C1=CC=C(CO)C=C1 NDCQPZLTZOJRQU-UHFFFAOYSA-N 0.000 description 1
- SUVYXKDAVYFUMG-UHFFFAOYSA-N 4-aminobutan-2-one Chemical compound CC(=O)CCN SUVYXKDAVYFUMG-UHFFFAOYSA-N 0.000 description 1
- WCVPFJVXEXJFLB-UHFFFAOYSA-N 4-aminobutanamide Chemical compound NCCCC(N)=O WCVPFJVXEXJFLB-UHFFFAOYSA-N 0.000 description 1
- XGYKKVTZDQDYJQ-UHFFFAOYSA-N 4-aminobutanenitrile Chemical compound NCCCC#N XGYKKVTZDQDYJQ-UHFFFAOYSA-N 0.000 description 1
- MLOSJPZSZWUDSK-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 MLOSJPZSZWUDSK-UHFFFAOYSA-N 0.000 description 1
- KTOSFDDONGKMID-UHFFFAOYSA-N 4-ethyl-n-propylbenzamide Chemical compound CCCNC(=O)C1=CC=C(CC)C=C1 KTOSFDDONGKMID-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- FSMHNRHLQAABPS-UHFFFAOYSA-N 4-methoxy-3,6-dihydro-2h-pyran Chemical compound COC1=CCOCC1 FSMHNRHLQAABPS-UHFFFAOYSA-N 0.000 description 1
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 1
- BGNLXETYTAAURD-UHFFFAOYSA-N 4-tert-butylcyclohexan-1-amine Chemical compound CC(C)(C)C1CCC(N)CC1 BGNLXETYTAAURD-UHFFFAOYSA-N 0.000 description 1
- CMBRHZNVJPNHLZ-UHFFFAOYSA-N 5-amino-1-(2,4,6-trichlorophenyl)pentan-1-one Chemical compound ClC1=C(C(=O)CCCCN)C(=CC(=C1)Cl)Cl CMBRHZNVJPNHLZ-UHFFFAOYSA-N 0.000 description 1
- WHTKFNOGMLEYNG-UHFFFAOYSA-N 5-amino-1-(2,4-dichlorophenyl)pentan-1-one Chemical compound ClC1=C(C(=O)CCCCN)C=CC(=C1)Cl WHTKFNOGMLEYNG-UHFFFAOYSA-N 0.000 description 1
- YXEIGWBWWRTFRE-UHFFFAOYSA-N 5-amino-1-(2,4-dimethoxyphenyl)pentan-1-one Chemical compound COC1=C(C(=O)CCCCN)C=CC(=C1)OC YXEIGWBWWRTFRE-UHFFFAOYSA-N 0.000 description 1
- YCQUWEFQYMHDJJ-UHFFFAOYSA-N 5-amino-1-(3,4,5-trimethoxyphenyl)pentan-1-one Chemical compound COC=1C=C(C(=O)CCCCN)C=C(C=1OC)OC YCQUWEFQYMHDJJ-UHFFFAOYSA-N 0.000 description 1
- KPWLCBMHVJRSFE-UHFFFAOYSA-N 5-amino-1-(3-chlorophenyl)pentan-1-one Chemical compound NCCCCC(=O)C1=CC=CC(Cl)=C1 KPWLCBMHVJRSFE-UHFFFAOYSA-N 0.000 description 1
- CSLASGVRTAERQW-UHFFFAOYSA-N 5-amino-1-(4-nitrophenyl)pentan-1-one Chemical compound NCCCCC(=O)C1=CC=C([N+]([O-])=O)C=C1 CSLASGVRTAERQW-UHFFFAOYSA-N 0.000 description 1
- FJQOKRUPEXTMRR-UHFFFAOYSA-N 5-amino-1-phenylpentan-1-one Chemical compound NCCCCC(=O)C1=CC=CC=C1 FJQOKRUPEXTMRR-UHFFFAOYSA-N 0.000 description 1
- VTHKLCWOLNQWHB-UHFFFAOYSA-N 5-aminopentan-2-one Chemical compound CC(=O)CCCN VTHKLCWOLNQWHB-UHFFFAOYSA-N 0.000 description 1
- OTIAVLWNTIXJDO-UHFFFAOYSA-N 5-aminopentanamide Chemical compound NCCCCC(N)=O OTIAVLWNTIXJDO-UHFFFAOYSA-N 0.000 description 1
- JJUPHRIAFLAURY-UHFFFAOYSA-N 5-aminopentanenitrile Chemical compound NCCCCC#N JJUPHRIAFLAURY-UHFFFAOYSA-N 0.000 description 1
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-UHFFFAOYSA-N 6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNCC(O)C(O)C(O)C(O)CO MBBZMMPHUWSWHV-UHFFFAOYSA-N 0.000 description 1
- HDLUVUAAPJKOBQ-UHFFFAOYSA-N 6-aminohexan-2-one Chemical compound CC(=O)CCCCN HDLUVUAAPJKOBQ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- FOGDWPRYGZOGJK-UHFFFAOYSA-N COC=1C=C(C(=O)CCCN)C=C(C=1OC)OC Chemical compound COC=1C=C(C(=O)CCCN)C=C(C=1OC)OC FOGDWPRYGZOGJK-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- WJYIASZWHGOTOU-UHFFFAOYSA-N Heptylamine Chemical compound CCCCCCCN WJYIASZWHGOTOU-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 1
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 241000218069 Kokia Species 0.000 description 1
- 229920006063 Lamide® Polymers 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- AKNUHUCEWALCOI-UHFFFAOYSA-N N-ethyldiethanolamine Chemical compound OCCN(CC)CCO AKNUHUCEWALCOI-UHFFFAOYSA-N 0.000 description 1
- QCOGKXLOEWLIDC-UHFFFAOYSA-N N-methylbutylamine Chemical compound CCCCNC QCOGKXLOEWLIDC-UHFFFAOYSA-N 0.000 description 1
- XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 1
- DKCQDMGOEDIPTL-UHFFFAOYSA-N N=S(=O)C1=CC=CC=C1 Chemical class N=S(=O)C1=CC=CC=C1 DKCQDMGOEDIPTL-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010050902 Postoperative thrombosis Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- BSEVQMPCBCCWLE-UHFFFAOYSA-N [1-fluoro-5-(oxan-2-yloxy)pentyl]-methylimino-oxo-phenyl-$l^{6}-sulfane Chemical compound C=1C=CC=CC=1S(=O)(=NC)C(F)CCCCOC1CCCCO1 BSEVQMPCBCCWLE-UHFFFAOYSA-N 0.000 description 1
- LIWXUMXAGNCABJ-UHFFFAOYSA-N [2-[2-[tert-butyl(dimethyl)silyl]oxyethyl]phenyl]methanol Chemical compound CC(C)(C)[Si](C)(C)OCCC1=CC=CC=C1CO LIWXUMXAGNCABJ-UHFFFAOYSA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- YWMLORGQOFONNT-UHFFFAOYSA-N [3-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=CC(CO)=C1 YWMLORGQOFONNT-UHFFFAOYSA-N 0.000 description 1
- MVIQUDNKABQIRT-UHFFFAOYSA-N [3-[[tert-butyl(dimethyl)silyl]oxymethyl]phenyl]methanol Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC=CC(CO)=C1 MVIQUDNKABQIRT-UHFFFAOYSA-N 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BCDGQXUMWHRQCB-UHFFFAOYSA-N aminoacetone Chemical compound CC(=O)CN BCDGQXUMWHRQCB-UHFFFAOYSA-N 0.000 description 1
- DFNYGALUNNFWKJ-UHFFFAOYSA-N aminoacetonitrile Chemical compound NCC#N DFNYGALUNNFWKJ-UHFFFAOYSA-N 0.000 description 1
- RLQMACPTWZLKDP-UHFFFAOYSA-N aminomethanediol Chemical compound NC(O)O RLQMACPTWZLKDP-UHFFFAOYSA-N 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003931 anilides Chemical class 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- YOUGRGFIHBUKRS-UHFFFAOYSA-N benzyl(trimethyl)azanium Chemical compound C[N+](C)(C)CC1=CC=CC=C1 YOUGRGFIHBUKRS-UHFFFAOYSA-N 0.000 description 1
- RSDOASZYYCOXIB-UHFFFAOYSA-N beta-alaninamide Chemical compound NCCC(N)=O RSDOASZYYCOXIB-UHFFFAOYSA-N 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- ZQNPDAVSHFGLIQ-UHFFFAOYSA-N calcium;hydrate Chemical compound O.[Ca] ZQNPDAVSHFGLIQ-UHFFFAOYSA-N 0.000 description 1
- 125000005242 carbamoyl alkyl group Chemical group 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004966 cyanoalkyl group Chemical group 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- ZIQIQOUPRHPOIT-UHFFFAOYSA-N cyclobutylazanide Chemical compound [NH-]C1CCC1 ZIQIQOUPRHPOIT-UHFFFAOYSA-N 0.000 description 1
- TXGVDTJWMZUNMP-UHFFFAOYSA-N cyclodecanamine Chemical compound NC1CCCCCCCCC1 TXGVDTJWMZUNMP-UHFFFAOYSA-N 0.000 description 1
- VXVVUHQULXCUPF-UHFFFAOYSA-N cycloheptanamine Chemical compound NC1CCCCCC1 VXVVUHQULXCUPF-UHFFFAOYSA-N 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- APXZYWJATMOMHR-UHFFFAOYSA-N cyclononanamine Chemical compound NC1CCCCCCCC1 APXZYWJATMOMHR-UHFFFAOYSA-N 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- HSOHBWMXECKEKV-UHFFFAOYSA-N cyclooctanamine Chemical compound NC1CCCCCCC1 HSOHBWMXECKEKV-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- YVHAIVPPUIZFBA-UHFFFAOYSA-N cyclopentaneacetic acid Natural products OC(=O)CC1CCCC1 YVHAIVPPUIZFBA-UHFFFAOYSA-N 0.000 description 1
- 150000001940 cyclopentanes Chemical class 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- HWDVTQAXQJQROO-UHFFFAOYSA-N cyclopropylazanide Chemical compound [NH-]C1CC1 HWDVTQAXQJQROO-UHFFFAOYSA-N 0.000 description 1
- 230000020176 deacylation Effects 0.000 description 1
- 238000005947 deacylation reaction Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000012024 dehydrating agents‎ Substances 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000005828 desilylation reaction Methods 0.000 description 1
- RICNAEXRYUNDCD-UHFFFAOYSA-N diazocyclohexane Chemical compound [N-]=[N+]=C1CCCCC1 RICNAEXRYUNDCD-UHFFFAOYSA-N 0.000 description 1
- WLXALCKAKGDNAT-UHFFFAOYSA-N diazoethane Chemical compound CC=[N+]=[N-] WLXALCKAKGDNAT-UHFFFAOYSA-N 0.000 description 1
- CRGRWBQSZSQVIE-UHFFFAOYSA-N diazomethylbenzene Chemical compound [N-]=[N+]=CC1=CC=CC=C1 CRGRWBQSZSQVIE-UHFFFAOYSA-N 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical class C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 125000004188 dichlorophenyl group Chemical group 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 1
- 125000004990 dihydroxyalkyl group Chemical group 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- VUXSSBDWTGVNIW-UHFFFAOYSA-N dodecylazanide Chemical compound CCCCCCCCCCCC[NH-] VUXSSBDWTGVNIW-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- DTYKTFHKOAPBCJ-UHFFFAOYSA-N ethylaminomethanol Chemical compound CCNCO DTYKTFHKOAPBCJ-UHFFFAOYSA-N 0.000 description 1
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000005191 hydroxyalkylamino group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- PCEBAZIVZVIQEO-UHFFFAOYSA-N iodocyclopentane Chemical compound IC1CCCC1 PCEBAZIVZVIQEO-UHFFFAOYSA-N 0.000 description 1
- VLODBNNWEWTQJX-UHFFFAOYSA-N iodocyclopropane Chemical compound IC1CC1 VLODBNNWEWTQJX-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- XJTQJERLRPWUGL-UHFFFAOYSA-N iodomethylbenzene Chemical compound ICC1=CC=CC=C1 XJTQJERLRPWUGL-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- ILRSCQWREDREME-UHFFFAOYSA-N lauric acid amide propyl betaine Natural products CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- VVNXEADCOVSAER-UHFFFAOYSA-N lithium sodium Chemical compound [Li].[Na] VVNXEADCOVSAER-UHFFFAOYSA-N 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- XMYQHJDBLRZMLW-UHFFFAOYSA-N methanolamine Chemical compound NCO XMYQHJDBLRZMLW-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- YYMZPEYBKWXPSL-UHFFFAOYSA-N methyl 3-(3-aminopropanoyl)benzoate Chemical compound COC(=O)C1=CC=CC(C(=O)CCN)=C1 YYMZPEYBKWXPSL-UHFFFAOYSA-N 0.000 description 1
- DZLKTTKTDKIPIA-UHFFFAOYSA-N methyl 3-(5-aminopentanoyl)benzoate Chemical compound COC(=O)C1=CC=CC(C(=O)CCCCN)=C1 DZLKTTKTDKIPIA-UHFFFAOYSA-N 0.000 description 1
- YHIDWINLPJYINB-UHFFFAOYSA-N methyl 3-(methylcarbamoyl)benzoate Chemical compound CNC(=O)C1=CC=CC(C(=O)OC)=C1 YHIDWINLPJYINB-UHFFFAOYSA-N 0.000 description 1
- FFIYCJSQHSXXDA-UHFFFAOYSA-N methyl-[methyl(2,2,4,4-tetramethylpentan-3-yl)silyl]oxyperoxy-(2,2,4,4-tetramethylpentan-3-yl)silane Chemical compound C(C)(C)(C)C([SiH](OOO[SiH](C)C(C(C)(C)C)C(C)(C)C)C)C(C)(C)C FFIYCJSQHSXXDA-UHFFFAOYSA-N 0.000 description 1
- OQWUXWSLVBGOIX-UHFFFAOYSA-N methyl-methylimino-oxo-phenyl-$l^{6}-sulfane Chemical compound CN=S(C)(=O)C1=CC=CC=C1 OQWUXWSLVBGOIX-UHFFFAOYSA-N 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- XUXJHBAJZQREDB-UHFFFAOYSA-N methylbutylamide Natural products CCC(C)C(N)=O XUXJHBAJZQREDB-UHFFFAOYSA-N 0.000 description 1
- HUCZYQRHWIGNDG-UHFFFAOYSA-N methylimino-[5-(oxan-2-yloxy)pentyl]-oxo-phenyl-$l^{6}-sulfane Chemical compound C=1C=CC=CC=1S(=O)(=NC)CCCCCOC1CCCCO1 HUCZYQRHWIGNDG-UHFFFAOYSA-N 0.000 description 1
- MKQLBNJQQZRQJU-UHFFFAOYSA-N morpholin-4-amine Chemical compound NN1CCOCC1 MKQLBNJQQZRQJU-UHFFFAOYSA-N 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- GNVRJGIVDSQCOP-UHFFFAOYSA-N n-ethyl-n-methylethanamine Chemical compound CCN(C)CC GNVRJGIVDSQCOP-UHFFFAOYSA-N 0.000 description 1
- QHCCDDQKNUYGNC-UHFFFAOYSA-N n-ethylbutan-1-amine Chemical compound CCCCNCC QHCCDDQKNUYGNC-UHFFFAOYSA-N 0.000 description 1
- AGVKXDPPPSLISR-UHFFFAOYSA-N n-ethylcyclohexanamine Chemical compound CCNC1CCCCC1 AGVKXDPPPSLISR-UHFFFAOYSA-N 0.000 description 1
- XCVNDBIXFPGMIW-UHFFFAOYSA-N n-ethylpropan-1-amine Chemical compound CCCNCC XCVNDBIXFPGMIW-UHFFFAOYSA-N 0.000 description 1
- UZWAQQSVGQEZRY-UHFFFAOYSA-N n-methyl-4-nitrobenzamide Chemical compound CNC(=O)C1=CC=C([N+]([O-])=O)C=C1 UZWAQQSVGQEZRY-UHFFFAOYSA-N 0.000 description 1
- JSIGUUUNVYUWQT-UHFFFAOYSA-N n-methylcyclobutanamine Chemical compound CNC1CCC1 JSIGUUUNVYUWQT-UHFFFAOYSA-N 0.000 description 1
- KKTBUCVHSCATGB-UHFFFAOYSA-N n-methylcyclopentanamine Chemical compound CNC1CCCC1 KKTBUCVHSCATGB-UHFFFAOYSA-N 0.000 description 1
- XJINZNWPEQMMBV-UHFFFAOYSA-N n-methylhexan-1-amine Chemical compound CCCCCCNC XJINZNWPEQMMBV-UHFFFAOYSA-N 0.000 description 1
- GVWISOJSERXQBM-UHFFFAOYSA-N n-methylpropan-1-amine Chemical compound CCCNC GVWISOJSERXQBM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- CWYZDPHNAGSFQB-UHFFFAOYSA-N n-propylbutan-1-amine Chemical compound CCCCNCCC CWYZDPHNAGSFQB-UHFFFAOYSA-N 0.000 description 1
- 125000006502 nitrobenzyl group Chemical group 0.000 description 1
- FJDUDHYHRVPMJZ-UHFFFAOYSA-N nonan-1-amine Chemical compound CCCCCCCCCN FJDUDHYHRVPMJZ-UHFFFAOYSA-N 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- KVNYFPKFSJIPBJ-UHFFFAOYSA-N ortho-diethylbenzene Natural products CCC1=CC=CC=C1CC KVNYFPKFSJIPBJ-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- ABOYDMHGKWRPFD-UHFFFAOYSA-N phenylmethanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=CC=C1 ABOYDMHGKWRPFD-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- IYPZRUYMFDWKSS-UHFFFAOYSA-N piperazin-1-amine Chemical compound NN1CCNCC1 IYPZRUYMFDWKSS-UHFFFAOYSA-N 0.000 description 1
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000063 preceeding effect Effects 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- LIKJQRZCRBNKSW-UHFFFAOYSA-N propylaminomethanol Chemical compound CCCNCO LIKJQRZCRBNKSW-UHFFFAOYSA-N 0.000 description 1
- NJSJBTVAKUBCKG-UHFFFAOYSA-N propylazanide Chemical compound CCC[NH-] NJSJBTVAKUBCKG-UHFFFAOYSA-N 0.000 description 1
- 230000001110 prostacyclinlike Effects 0.000 description 1
- DZUXGQBLFALXCR-CDIPTNKSSA-N prostaglandin F1alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CCCCCCC(O)=O DZUXGQBLFALXCR-CDIPTNKSSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- SBMSLRMNBSMKQC-UHFFFAOYSA-N pyrrolidin-1-amine Chemical compound NN1CCCC1 SBMSLRMNBSMKQC-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- BUXTXUBQAKIQKS-UHFFFAOYSA-N sulfuryl diisocyanate Chemical compound O=C=NS(=O)(=O)N=C=O BUXTXUBQAKIQKS-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- JJPVWQWOOQYHCB-UHFFFAOYSA-N triethyl(phenyl)azanium Chemical compound CC[N+](CC)(CC)C1=CC=CC=C1 JJPVWQWOOQYHCB-UHFFFAOYSA-N 0.000 description 1
- RKBCYCFRFCNLTO-UHFFFAOYSA-N triisopropylamine Chemical compound CC(C)N(C(C)C)C(C)C RKBCYCFRFCNLTO-UHFFFAOYSA-N 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- QFKMMXYLAPZKIB-UHFFFAOYSA-N undecan-1-amine Chemical compound CCCCCCCCCCCN QFKMMXYLAPZKIB-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/005—Analogues or derivatives having the five membered ring replaced by other rings
- C07C405/0075—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system
- C07C405/0083—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system which is only ortho or peri condensed, e.g. carbacyclins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Abstract
Compounds of the formula <IMAGE> wherein Q<1> is hydrogen and Q<2> is alkyl or CH2OH, or Q<1> and Q<2> together form a second bond or -CH2-, Q<3> is blocked CH2OH or a blocked alkyl- terminated prostaglandin side-group or derivative, n is 1 or 2, and R18 is H or optionally blocked OH or CH2OH.
Description
SPECIFICATION
Carbacyclin intermediates
This invention relates to compounds which can be used as intermediates in the preparation of the carbacyclin analogues described and claimed in British Patent Application No. 8102901 (Serial No.
2070597), either directly or via the intermediates described and claimed in another divisional thereof, filed on the same date as this divisional, with the Agents Reference GJE 70/2151/01.
For convenience, the prostacyclin and carbacyclin analogues described herein will be referred to by the trivial, art-recognized system of nomenclature described by N. A. Nelson, J. Med. Chem. 17:911 (1974) for prostaglandins. Accordingly, all of the novel prostacyclin derivatives herein will be named as 9-deoxy-PGF-type compounds, PGl2 derivatives, or preferably as OBA1 or CBA2 derivatives.
In the formulas herein, broken line attachments to a ring indicate substituents in the "alpha" (a) configuration, i.e., below the plane of said ring. Heavy solid line attachments to a ring indicate substituents in the "beta" (p) configuration, i.e., above the plane of said ring. The use of wavy line ("") herein will represent attachment of substituents in the alpha or beta configuration or attached in a mixture of alpha and beta configurations. Alternatively wavy lines will represent either an E or Z geometric isomeric configuration or the mixture thereof.
A side chain hydroxy at C-i 5 in the formulas herein is in the S or R configuration as determined by the Cahn-lngold-Prelog sequence rules, J. Chem. Ed. 41:16 (1964). See also Nature 212:38 (1966)for discussion of the stereochemistry of the prostaglandins which discussion applies to the novel prostacyclin or carbacyciin analogs herein. Molecules of prostacyclin and carbacyclin each have several centers of asymmetry and therefore can exist in optically inactive form or in either of two enantiomeric (optically active) forms, i.e., the dextrorotatory and laveorotatory forms. As drawn, the formula for PGl2 corresponds to that endogenously produced in the mammalian species.In particular, refer to the stereochemical configuration at C-8 (a), C-9 (a), C-11 () and C-12 (p) of endogenously produced prostacyclin. The mirror image of the above formula for prostacyclin represents the other enantiomer.
The racemic form of prostacyclin contains equal numbers of both enantiomeric molecules.
For convenience, reference to prostacyclin and carbacyclin will refer to the optically active form thereof. Thus, with reference to prostacyclin, reference is made to the form thereof with the same absolute configuration as that obtained from the mammalian species.
The term "prostacyclin-type" product, as used herein, refers to any cyclopentane derivative herein which is useful for at least one of the same pharmacological purposes for which prostacyclin is employed. A formula as drawn herein which depicts a prostacyclin-type product or an intermediate useful in the preparation thereof, represents that particular stereoisomer of the prostacyclin-type product which is of the same relative stereochemical configuration as prostacyclin obtained from mammalian tissues or the particular stereoisomer of the intermediate which is useful in preparing the above stereoisomer of the prostacyclin type product.
The term "prostacyclin analog" or "carbacyclin analog" represents that stereoisomer of a prostacyciin-type product which is of the same relative stereochemical configuration as prostacyclin obtained from mammalian tissues or a mixture comprising stereoisomer and the enantiomers thereof. In particular, where a formula is used to depict a prostacyclin type product herein, the term "prostacyclin analog" or "carbacyclin analog" refers to the compound of that formula or a mixture comprising that compound and the enantiomer thereof.
Carbacyclin and closely related compounds are known in the art. See Japanese Kokia 63,059 and 63,060, also abstracted respectively as Derwent Farmdoc OPI Numbers 481 54B/26 and 481 55B/26.
See also British published specifications 2,012,265 and German Offenlegungsschrift 2,900,352, abstracted as Derwent Farmdoc OPI Number 54825B/30. See also British published applications 2,017,699,2,014,143and2,013,661.
The synthesis of carbacyclin and related compounds is also reported in the chemical literature, as follows: Morton, D. R., et al., J. Organic Chemistry, 44:2880 (1979); Shibaski, M., et al. Tetrahedron Letters, 433-436 (1979); Kojima, K., et al., Tetrahedron Letters, 3743-3746 (1978); Nicolau, K. C., et al., J. Chem. Soc., Chemical Communications, 1067--1068 (1978); Sugie, A., et al., Tetrahedron
Letters 2607-2610 (1979); Shibaski, M., Chemistry Letters, 1299-1300 (1979), and Hayashi, M.,
Chem. Lett. 1437-40 (1979); and Li, Tsung-tee, "A Facile Synthesis of 9(0)-Methano-prostacyclin",
Abstract No. 378, (Organic Chemistry), and P. A.Aristoff, "Synthesis of 6a-Carbaprostacyclin 12",
Abstract No. 236 (Organic Chemistry) both at Abstract of Papers (Part II) Second Congress of the North
American Continent, San Francisco, California (Las Vegas, Nevada), USA, 24-29 August 1 980.
7-Oxo and 7-hydroxy-CBA2 compounds are apparently disclosed in United States Patent 4,192,891.19-Hydroxy-CBA2 compounds are disclosed in United States Serial No. 054,811, filed 5
July 1979. CBA2 aromatic esters are disclosed in United States Patent 4,180,657. 1 1-Deoxy-A10- or A11-CBA2 compounds are described in Japanese Kokai 77/24,865, published 24 February 1 979.
The present specification particularly provides:
(a) a carbacyclin intermediate of formula IV, V, VI, VII, VI II, or IX; and
(b) a carbacyclin analog of formula X or Xl; wherein g is 0, 1, 2, or 3;
wherein n is one or 2;
wherein L1 is α-R3;ss-R4, α-R4:ss-R3, or a mixture of α-R3:ss-R4 and α-R4:ss-R3, wherein R3 and R4 are hydrogen, methyl, or fluoro, being the same or different, with the proviso that one of R3 and R4 is fluoro only when the other is hydrogen or fluoro;
wherein M1 is α-OH:ss-R5 or a-R5:,B-OH, wherein R5 is hydrogen or methyl;
wherein M6 is α-OR10:ss0R5 or α::ss-OR10, wherein R5 is hydrogen or methyl and R10 is an acid hydrolyzable protective group;
wherein R7 is
(1)-CmH2m-CH3, wherein mis an integer from one to 5, inclusive,
(2) phenoxy optionally substituted by one, two or three chloro, fluoro, trifluoromethyl, (C1-C3)alkyl, or (C1-C3)alkoxy, with the proviso that not more than two substituents are other than alkyl, with the proviso that R7 is phenoxy or substituted phenoxy, only when R3 and R4 are hydrogen or methyl, being the same or different,
(3) phenyl, benzyl, phenylethyl, or phenylpropyl optionally substituted on the aromatic ring by one, two or three chloro, fluoro, trifluoromethyl, (C1-C3)alkyl, or (C1-C3)alkoxy, with the proviso that not more than two substituents are other than alkyl,
(4) cis-CH=CH-CH2-CH3, (5) -(CH2)2-CH(OH)-CH3, or (6) -(CH2)3-CH=C(CH3)2; wherein -C(L1)-R7 taken together is
(1) (C4-C7)cycloalkyl optionally substituted by one to 3 (C1-C5)alkyl; (2) 2-(2-furyl)ethyl,
(3) 2-(3-thienyl)ethoxy, or
(4) 3-thienyloxymethyl;
wherein R8 is hydroxy, hydroxymethyl, or hydrogen;
wherein R15 is hydrogen or fluoro;
wherein R16 is hydrogen or R16 and R17 taken together are -CH2- or R16 and R47 taken together form a second valence bond between C-6a and C-9 or are -CH2-;; wherein R17 is as defined above or is
(1) hydrogen, or
(2) (C1-C4)alkyl; wherein R18 is hydrogen, hydroxy, hydroxymethyl, -OR10 or -CH2OR10, wherein R10 is an acidhydrolyzable protective group;
wherein
(1)R20, R21, R22, R23, and R24 are all hydrogen with R22 being either a-hydrogen or p-hydrogen, (2) R20 is hydrogen, R21 and R22 taken together form a second valence bond between C-9 and C6a, and R23 and R24 taken together form a second valence bond between C-8 and C-9 or are both hydrogen, or
(3) R22, R23, and R24 are all hydrogen, with R22 being either a-hydrogen or p-hydrogen, and
(a) R20 and R21 taken together are oxo, or
(b) R20 is hydrogen and R21 is hydroxy, being a-hydroxy or hydroxy;; wherein R27 is the same as R7 except that -(CH2)2-CH(0H)-CH3 is-(CH2)-CH(OR11)-CH3; wherein R32 is hydrogen or R31, wherein R31 is a hydroxyl hydrogen replacing group;
wherein R33 is -CHO or or-CH2OR32, wherein R32 is as defined above;
wherein R47 is as defined above or is (1) (C1-C4)alkyl, or (2) -CH2OH;; wherein X1 is
(1)-coor1, wherein R1 is
(a) hydrogen,
(b) (C1-C12) alkyl,
(c) (C3-C10)cycloalkyl, (d) (C7-C12)aralkyl, (e) phenyl, optionally substituted with one, 2 or 3 chloro or (C1-C3)alkyl,
(f) phenyl substituted in the para position by (i) -NH-CO-R25,
(ii) -CO-R26, (iii) -O-CO-R54, or (iv) -CH=N-NH-CO-NH2 wherein R25 is methyl, phenyl, acetamidophenyl, benzamidophenyl, or - NH2 ; R26 is methyl, phenyl, -NH2, or methoxy; and R54 is phenyl or acetamidophenyl; or
(g) a pharmacologically acceptable cation; (2) -CH2OH, (3) -COL4, wherein L4 is (a) amino of the formula -NR51R52, wherein R51 and R52 (i) hydrogen,
(ii) (C1-C12)alkyl, (iii) (C3-C10)cycloalkyl, (iv) (C7-C12)aralkyl, (v) phenyl, optionally substituted with one, 2 or 3-chloro, (C1-C3)alkyl, hydroxy, carboxy, (C2-C5)alkoxycarbonyl, or nitro,
(vi) (C2-C5)carboxyalkyl, (vii) (C2-C5)carbamoylalkyl, (viii) (C2-C5)cyanoalkyl, (ix) (C3-C6)acetylalkyl, (x) (C7-C11)benzoalkyl, optionally substituted by one, 2 or 3 chloro, (C1-C3)alkyl, hydroxy, (C1-C3)alkoxy, carboxy, (C2-C5)alkoxycarbonyl, or nitro,
(xi) pyridyl, optionally substituted by one, 2 or 3 chloro, (C1-C3)alkyl or (C1-C3)alkoxy, (xii) (C6-C9)pyridylalkyl optionally substituted by one, 2 or 3 chloro, (C1-C3)alkyl, hydroxy, or (C1-C3)alkyl, (xiii) (C1-C4)hydroxyalkyl, (xiv) (C1-C4)dihydroxyalkyl, (xv) (C1-C4)trihydroxyalkyl, with the further proviso that not more than one of R5, and R52 is other than hydrogen or alkyl,
(b) cycloamino selected from the group consisting of pyrolidino, piperidino, morpholino,
piperazino, hexamethyleneimino, pyrrolino, or 3,4-didehydropiperidinyl optionally substituted by one or
2 (C1-C12)alkyl of one to 12 carbon atoms,
(c) carbonylamino of the formula -NR53C0R51, wherein R23 is hydrogen or (C1-C4)alkyl and R5, is
other than hydrogen, but otherwise as defined above,
(d) sulfonylamino of the formula -NR53S02R51, wherein R21 and R23 are as defined in (c), (4) -CH2NL2L3, wherein L2 and L3 are hydrogen or (C1-4)alkyl, being the same or different, or
the pharmacologically acceptable acid addition salts thereof when X1 is -CH2NL2L3, wherein Y1 is trans-CH=CH-, cis-CH=CH-, -CH2CH2-, or -C-C-; wherein Z1 is (1) -CH2-(CH2)fC(R2)2, wherein R2 is hydrogen orfluoro and f is zero, one, 2, or 3,
(2) trans-CH2-CH=CH-, (3)-(Ph)-(CH2)3-, wherein (Ph) is 1,2-, 1,3-, or 1,4-phenylene and g is zero, one, 2, or 3;;
wherein Z4 is-CH2-or-(CH2)4-CF2, wherein f is as defined above;
with the overall proviso that (1)R15, R16, and R17 are all hydrogen only when Z1 is-(Ph)-(CH2)8-, and
(2) Z1 is (Ph)(CH2)a only when R15 is hydrogen.
With regard to the divalent substituents described above (e.g., L1 and m1), these divalent radicals
are defined as α-R1:ss-R1, wherein R1 represents the substituent of the divalent moiety in the alpha
configuration with respect to the plane of the C-8 to C-1 2 cyclopentane ring and Rj represents the
substituent of the divalent moiety in the beta configuration with respect to the plane of the ring.
Accordingly, when M1 is defined as α-OH:ss-R5, the hydroxy of the M1 moiety is in the alpha
configuration, i.e., as in PGI2 above, and the R5 substituent is in the beta configuration.
The carbon atom content of various hvdrocarbon-containing moieties is indicated by a prefix
designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix (C1-C1)
indicates a moiety of the integer "i" to the integer "j" carbon atoms, inclusive. Thus (C1-C3)alkyl refers to alkyl of one to 3 carbon atoms, inclusive, or methyl, ethyl, propyl, and isopropyl.
Certain novel prostacyclin analogs herein, i.e., formula X compounds, are all named as CBA1 or
CBA2 compounds, respectively, by virtue of the substitution of methylene for oxa in the heterocyclic ring of prostacyclin and the substitution, CBA2 compounds are those exhibiting the olefinic double bond at
C-5,6, while CBA, compounds are those saturated at C-5,6. Formula XI compounds are named as PGE, or PGF, derivatives as hereinafter described.
Novel compounds wherein Z1 is (Ph)(CH2)g are designated inter-o-, inter-m-, or inter-pphenylene depending on whether the attachment between C-S and the (CH2)g moiety is ortho, meta, or para, respectively.
For those compounds wherein g is zero, one, 2 or 3, the carbacyclin analogs so described are further characterized as 2,3,4-trinor-, 3,4-dinor-, or 4-nor, since in this event the X1-terminated side chain contains (not including the phenylene) 2, 3, or 4 carbon atoms, respectively, in place of the five carbon atoms contained in PGl2. The missing cabon atom or atoms are considered to be at the C-4 to
C-2 positions such that the phenylene is connected to the C-5 and C-3 positions. Accordingly these compounds are named as 1,5-, 2,5-, 3,5-, and 4,5-inter-phenylene-CBA compounds when g is zero, one,2, or 3, respectively.
Those CBA analogs wherein Z1 is-CH2-(CH2)f-CF2-are characterized as "2,2-difluoro-" compounds. For those compounds wherein f is zero, 2, or 3, the carbacyclin analogs so described are further characterized as 2-nor, 2a-homo, or 2a,2b-dihomo, since in this event the X1-terminated side chain contains 4, 6, or 7 carbon atoms, respectively, in place of the five carbon atoms contained in
CBA2. The missing carbon atom is considered to be at the C-2 position such that the C-1 carbon atom is connected to the C-3 position. The additional carbon atom or atoms are considered as though they were inserted between the C-2 and C-3 positions. Accordingly these additional carbon atoms are referred to as C-2a and C-2b, counting from the C-2 to the C-3 position.
Those CBA analogs wherein Z1 is trans-CH2-CH=CH- are described as "trans-2,3-didehydro
CBA" compounds.
Those novel compounds where n is 2 are further characterized as 7a-homo-CBA compounds by virtue of the cyclohexyl ring replacing the heterocyclic ring of prostacyclin.
Further, the novel compounds are named as 9ss-alkyl-CBA compounds when R17 is alkyl.
When R16 and R17 taken together are -CH2-(methylene), the novel compounds so described are "6ass,9ss-methano-CBA" compounds by virtue of the methylene bridge between C-6a and C-9.
When R15 is fluoro, "5-fluoro-CBA" compounds are described.
The formula Xl CBA analogs wherein R20, R21, R22, R23, and R24 are all hydrogen with R22 being ,B- hydrogen are characterized as "9-deoxy-2',9α-methano-3-oxa-4,5,6-trinor-3,7-(1 ',3'-inter-phenylene)
PGF1,, compounds. Corresponding compounds wherein R22 is hydrogen are characterized as "9deoxy-2',9ss-methano-3-oxa-4,5,6-trinor-3,7-( ',3'-inter-phenylene)-PGF," compounds. CBA analogs wherein R20, R23, and R24 are all hydrogen and R21 and R22 taken together form a valence bond between
C-9 and C-6a are characterized as "9-deoxo-2',9-metheno-3-oxo-3,4,5-trinor-3,7-(1',3'-inter- phenylene)-PGF1,, compounds.CBA analogs wherein R20 is hydrogen and R21 and R22 taken together form a second valence bond between C-9 and C-6a and R23 and R24 taken together form a second valence bond between C-7 and C-8 are characterized as "9-deoxo-2',9-metheno-3-oxa-3,4,5-trinor- 3,7-(1 ',3'-inter-phenylene)-7,8-didehydro-PGE1" compounds. The formula Xl CBA analogs wherein R22, R23, and R24 are all hydrogen and R20 and R21 taken together are oxo are characterized as "6a-oxo-9- deoxy-2',9α-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-inter-phenylene)-PGF1" or 6a-oxo-9-deoxy-2',9ssmethano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylene)-PGF1" depending on whether R22 is hydrogen or ,B-hydrogen, respectively.Formula Xl CBA analogs wherein R20, R22, R23 and R24 are all hydrogen and
R21 is hydroxy are characterized as "6aα-hydroxy-9-deoxy-2',9α-methano-3-oxa-4,5,6-trinor-3,7- (1',3'-interphenylene)-PGF1" or "6aα-hydroxy-9-deoxy-2',9ss-methano-3-oxa-4,5,6-trinor-3,7-(1',3'- inter-phenylene)-PGF1,, compounds depending on whether R22 is a-hydrogen or p-hydrogen, respectively.Finally, formula Xl TXA analogs wherein R20, R22, R23, and R24 are all hydrogen and R21 is jB- hydroxy are characterized as "Gap-hydroxy-9-deoxy-2",9P-methano-3-ox 1 ',3'-inter- phenylene)-PGF1" or "6ass-hydroxy-9-deoxy-2',9α-methano-3-oxa-4,5,6-trinor-3,7-(1',3'- interphenylene)-PGF1,, compounds depending on whether R22 is hydrogen or p-hydrogen, respectively. When Z4 (s-(CH2)1-CF2 and f is zero, the formula XI CBA analogs are additionally characterized as "2,2-difluoro" compounds. When f is one, 2, or 3, such compounds are additionally characterized as "2a-homo", "2a,2b-dihomo" or "2a,2b,2c-trihomo" compounds.
When R5 is methyl, the carbacyclin analogs are all named as "15-methyl-CBA" compounds.
Further, except for compounds wherein Y1 is cis-CH=CH-, compounds wherein the M1 moiety contains an hydroxyl in the beta configuration are additionally named as "15-epi-CBA" compounds.
For the compounds wherein Y1 is cis-CH=CH-, then compounds wherein the M1 moiety contains
an hydroxyl in the alpha configuration are named as "1 5-epi-CBA" compounds. For a description of this convention of nomenclature for identifying C-15 epimers, see U.S. Patent 4,016,184, issued 5 April
1977, particularly columns 24-27 thereof.
The novel carbacyclin analogs herein which contain -(CH2)2-, cis-CH=CH-, or -C-C- as the
Y1 moiety, are accordingly referred to as "13,14-dihydro", "cis-1 3", or "13,14-didehydro" compounds, respectively.
When R7 is straight chained Cm112 CHs, wherein m is as defined above, the compounds so described are named as "19,20-dinor", "20-nor", "20-methyl" or "20-ethyl" compounds when m is one, 2, 4 or 5, respectively. When R7 is branched chain-CmH2m-CH3, then the the compounds so described are "17-, 18-, 19-, or 20-alkyl" or "17,17-, 17,18-, -17,19-, 17,20-, 18,18-, 18,19-, 18,20-,
19,19-, or 19,20-dialkyl" compounds when m is 4 or 5 and the unbranched portion of the chain is at least n-butyl, e.g., 17,20-dimethyl" compounds are described when m is 5 (1-methylpentyl).
When R7 is phenyl and neither R3 nor R4 is methyl, the compounds so described are named as "16phenyl-17,18,19,20-tetranor" compounds. When R7 is substituted phenyl, the corresponding compounds are named as "18-(substituted phenyl)-1 7,18,1 9,20-tetranor" compounds. When one and only one of R3 and R4 is methyl or both R3 and R4 are methyl, then the corresponding compounds wherein R7 is as defined in this paragraph are named as "1 6-phenyl or 16-(substituted phenyl)
18,19,20-trinor" compounds or "1 6-methyl-1 6-phenyl- or 16-(substituted phenyl)-1 8,1 9,20-trinor" compounds respectively.
When R7 is benzyl, the compounds so described are named as "17-phenyl-18,19,20-trinor" compounds. When R7 is substituted benzyl, the corresponding compounds are named as "17 (substituted phenyl)-1 8,1 9,20-trinor" compounds.
When R7 is phenylethyl, the compounds so described are named as "1 8-phenyl-1 9,20-dinor" compounds. When R7 is substituted phenylethyl, the corresponding compounds are named as "18 (substituted phenyl)-1 9,20-dinor" compounds.
When R7 is phenylpropyl, the compounds so described are named as "1 9-phenyl-20-nor" compounds. When R7 is substituted phenylpropyl the corresponding compounds are named as "19 (substituted phenyl)-20-nor" compounds.
When R, is phenoxy and neither R3 nor R4 is methyl, the compounds so described are named as "16-phenoxy-17,18,1 9,20-tetranor" compounds. When R7 is substituted phenoxy, the corresponding compounds are named as "16-(substituted phenoxy)-1 7,18,1 9,20-tetranor" compounds. When one and only one of R3 and R4 is methyl or both R3 and R4 are methyl, then the corresponding compounds wherein R7 is as defined in this paragraph are named as "1 6-phenoxy or 16-(substituted phenoxy)18,19,20-trinor" compounds or "1 6-methyl-1 6-phenoxy- or 16-(substituted phenoxy) 1 8,1 9,20-trinor" compounds, respectively.
When R7 is cis-CH=CH-CH2CH3,the compounds so described are named as "cis-1 7,1 8- didehydro" compounds.
When R7 is -(CH2)2-CH(OH)-CH3, the compounds so described are named as "1 9-hydroxy" compounds.
When R7 is -(CH2)3-CH=C(CH3)2, the compounds so described are named as "20isopropylidene" compounds.
When -C(L1)-R7 is optionally substituted cycloalkyl, 2-(2-furyl)ethyl, 2-(3-thienyl)ethyl, or 3thienyloxymethyl, the compounds so described are respectively 15-cycloalkyl-16,17,18,19,20- pentanor compounds, 1 7-(2-furyl)-1 8,1 9,2O-trinor-CBA compounds, 1 7-(3-thienyl)-1 8,1 9,20-trinor compounds, or 1 6-(3-thienyl)oxy-1 7,18,1 9,20-tetranor compounds.
When at least one of R3 and R4 is not hydrogen then (except for the 1 6-phenoxy or 16-phenyl compounds discussed above) there are described the "1 6-methyl" (one and only one of R3 and R4 is methyl), "16,1 6-dimethyl" (R3 and R4 are both methyl), "1 6-fluoro" (R3 or R4 is fluoro), "16,1 6-difluoro" (R3 and R4 are both fluoro) compounds. For those compounds wherein R3 and R4 are different, the prostaglandin analogs so represented contain an asymmetric carbon atom at C-16:Accordingly, two epimeric configurations are possible: "(16S)" and "(16R)". Further, there is described by this invention the C-1 6 epimeric mixture: "(16RS)".
When X1 is -CH2OH, the compounds so described are named as "2-decarboxy-2-hydroxymethyl" compounds.
When X1 isCH2NL2L3, the compounds so described are named as "2-decarboxy-2aminomethyl" or "2-(substituted amino)methyl" compounds.
When X1 is -COL4,the novel compounds herein are named as CBA-type amides. Further, when
X1 is -COOR1,the novel compounds herein are named as CBA-type esters and CBA-type salts.
Examples of phenyl esters substituted in the para position (i.e., X1 is -COOR1, R1 is p-substituted phenyl) include p-acetamidophenyl ester, p-benzamidophenyl ester, p-(p-acetamidobenzamido)phenyl ester, p-(p-benzamidobenzamido)phenyl ester, p-amidocarbonylaminophenyl ester, p-acetylphenyl ester, p-benzylphenyl ester, p-amidocarbonylphenyl ester, p-methoxycarbonylphenyl ester, pbenzoyloxyphenyl ester, p-(p-acetamidobenzoyloxy)phenyl ester, and p-hydroxybenzaldehyde semicarbazone ester.
Examples of novel amides herein (i.e., X1 is -COL4) include the following:
(1) Amides within the scope of alkylamino groups of the formula-NR51R52 are methylamide, ethylamide, n-propylamide, n-butylamide, n-pentylamide, n-hexylamide, n-heptylamide, n-octylamide, n-nonylamide, n-decylamide, n-undecylamide, and n-dodecylamide, and isomeric forms thereof, Further examples are dimethylamide, diethylamide, di-n-propylamide, di-n-butylamide, methylethylamide, methylpropylamide, methylbutylamide, ethylpropylamide, ethylbutylamide, and propylbutylamide.
Amides within the scope of cycloalkylamino are cyclopropylamide, cyclobutylamide, cyclopentylamide, 2,3-dimethylcyclopentylamide, 2,2-dimethylcyclopentylamide, 2-methylcyclopentylamide, 3-tert- butylcyclopentyl amide, cyclohexylamide, 4-tert-butylcyclohexylamide, 3-isopropylcyclohexylamide, 2,2-dimethylcyclohexylamide, cycloheptylamide, cyclooctylamide, cyclononylamide, cyclodecylamide,
N-methyl-N-cyclobutylamide, N-methyl-N-cyclopentylamide, N-methyl-N-cyclohexylamide, N-ethyl-Ncyclopentylamide, and N-ethyl-N-cyclohexylamide. Amides within the scope of aralkylamino are benzylamide, 2-phenylethylamide, and N-methyl-N benzyl-amide.Amides within the scope of substituted phenylamide are p-chloroanilide, m-chloroanilide, 2,4-dichloroanilide, 2,4,6-trichloroanilide, m-nitroanilide, p-nitroanilide, p-methoxyanilide, 3,4-dimethoxyanilide, 3,4,5-trimethoxyanilide, phydroxymethylanilide, p-methylanilide, m-methyl anilide, p-ethylanilide, p-carboxyanilide, pmethoxycarbonyl anilide, p-carboxyanilide and o-hydroxyanilide. Amides within the scope of carboxyalkylamino are carboxyethylamide, carboxypropylamide and carboxymethylamide, carboxybutylamide. Am ides within the scope of carbamoylalkylamino are carbamoylmethylamide, carbamoylethylamide, carbamoylpropylamide, and carbamoylbutylamide. Amides within the scope of cya noal kylamino are cyanomethylamide, cyanoethy lamide, cyanopropylamide, and cyanobutylamide.
Amides within the scope of acetylalkylamino are acetylmethylamide, acetylethylamide, acetylpropylamide, and acetylbutylamide. Amides within the scope of benzoylalkylamino are benzoylmethylamide, benzoylethyiamide, benzoylpropyiamide, and benzoylbutylamide.Amides within the scope of substituted benzoylalkylamino are p-chlorobenzoylmethylamide, mchlorobenzoylmethylamide, 2,4-dichlorobenzoylmethylamide, 2,4,6-trichlorobenzoylmethylamide, m nitrobenzoyl methylamide, p-nitrobenzoyl methylamide, p methoxybenzoylmethylamide, 2,4 2,4-dimethoxy benzoylmethylamide, 3,4,5-trimethoxybenzoylmethylamide, p-hydroxymethylbenzoylmethylamide, p
methylbenzoylmethylamide, m-methylbenzoylmethylamide, p-ethylbenzoylmethylamide, pcarboxybenzoyl methyl a mide, m-methoxycarbonylbenzoyl methylamide, o-carboxybenzoylmethylamide, o-hydroxybenzoylmethylamide, p-chlorobenzoylethylamide, m-chlorobenzoylethylamide, 2,4- dichlorobenzoylethylamide, 2,4,6-trichlorobenzoylethylamide, m-nitrobenzoylethylamide, pnitrobenzoylethylamide, p-methoxybenzoylethylamide, p-methoxybenzoylethylamide, 2,4- dimethoxybenzoylethylamide, 3,4,5-trimethoxybenzoylethylamide, p-hydroxymethylbenzoylethylamide, p-methylbenzoylethylamide, m-methylbenzoylethylamide, p-ethylbenzoylethylamide, p carboxybenzoylethyla mide, m-methoxycarbonylbenzoylethylamide, o-carboxybenzoylethylamide, o- hydroxybenzoylethylamide, p-chlorobenzoylpropylamide, m-chlorobenzoylpropylamide, 2,4- dichlorobenzoylpropylamide, 2,4,6-trichlorobenzoylpropylamide, m-nitrobenzoylpropylamide, pnitrobenzoylpropylamide, p-methoxybenzoylpropylamide, 2,4-dimethoxybenzoylpropylamide, 3,4,5trimethoxybenzoylpropylamide, p-hydroxymethylbenzoylpropylamide, p-methylbenzoylpropylamide, mmethylbenzoylpropylamide, p-ethylbenzoyl propylamide, p-carboxybenzoylpropylamide, mmethoxycarbonylbenzoylpropylamide, o-carboxybenzoylpropylamide, o-hydroxybenzoylpropylamide, pchlorobenzoylbutylamide, m-chlorobenzoylbutylamide, 2,4-dichlorobenzoylbutylamide, 2,4,6trichlorobenzoylbutylamide, m-nitrobenzoylmethylamide, p-nitrobenzoylbutylamide, pmethoxybenzoylbutylamide, 2,4-dimethoxybenzoylbutyl-amide, 3,4,5-trimethoxybenzoylbutylamide, phydroxymethylbenzoylbutyl-amide, p-methylbenzoylbutyamide, m-methylbenzoylbutylamide, p-ethylbenzoylbutylamide, m-methylbenzoylbutylamide, p-ethylbenzoylbutyl-amide, pcarboxybenzoylbutylamide, m-methoxycarbonylbenzoylbutylamide, o-carboxybenzoylbutylamide, o- hydroxybenzoylmethylamide.Amides within the scope of pyridylamino are a-pyridylamide, p pyridylamide, and y-pyridylamide. Amides within the scope of substituted pyridylamino are 4-methyl-a- pyridylamide, 4-methyl-ss-pyridylamide, 4-chloro-α-pyridylamide, and 4-chloro-ss-pyridylamide. Amides within the scope of pyridylalkylamino are a-pyridylmethylamide, p-pyridylmethylamide, y pyridylmethylam ide, a-pyridylethyla mide, ppyridylethylamide, y-pyridylethyla mide, apyridylpropylamide, p-pyridylpropylamide, y-pyridylpropylamide, a-pyridylbutyla mide, p pyridylbutylamide, and y-pyridylbutylamide.Amides within the scope of substituted pyridylalkylamido are 4-methyl-α-pyridylmethylamide, 4-methyl-ss-pyridylmethylamide, 4-chloro-α-pyridylmethylamide, 4-chloro-ss-pyridylmethylamide, 4-methyl-α-pyridylpropylamide, 4-methyl-ss-pyridylpropylamide, 4chloro-α-pyridylpropylamide, 4-chloro-ss-pyridylpropylamide, 4-methyl-α-pyridylbutylamide, 4-methyl
P-pyridylbutylamide, 4-chloro-a-pyridylbutylamide, 4-chloro-P-pyridylbutylamide, L-chloro-y- pyridylbutyl-amide. Amides within the scope of hydroxyalkylamino are hydroxymethylamide, ss- hydroxyethylamide, /3-hydroxypropylamide, y-hydroxypropylamide, 1 (hydroxymethyl)ethyl-amide, 1 (hydroxymethyl)propylamide, (2-hydroxymethyl)propylamide, and α,α-dimethyl-hydroxyéethylamide.
Amides within the scope of dihydroxyalkylamino are dihydroxymethylamide, p dihydroxypropylamide, 1 -(hydroxymethyl)2-hydroxymethylamide, ,y-dihydroxybutyÃamidet P,6- dihydroxybutyl-amide, y,6-dihydroxybutylamide, and 1,1 bis(hydroxymethyl)ethylamide. Amides within the scope of trihydroxyalkylamino are tris(hydroxy-methyl)methylamide and 1,3-dihydroxy-2hydroxymethylpropylamide.
(2) Amides within the scope of cycloamino groups described above are pyrrolidylamide, piperidylamide, morpholinylamide, hexamethyleneiminylamide, piperazinylamide, pyrrolinylamide, and 3,4-didehydropiperidinylamide.
(3) Amides within the scope of carbonylamino of the formulaNRs3COR51 are methylcarbonylamide, ethylcarbonylamide, phenylcarbonylamide, and benzylcarbonylamide.
(4) Amides within the scope of sulfonylamino of the formula -NR53S02R51 are methyisu Ifonylamide, ethylsulfonylamide, phenylsulfonylamide, p tolylsulfonylamide, benzylsulfonylamide.
Examples of alkyl of one to 12 carbon atoms, inclusive, are methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, isomeric forms thereof.
Examples of (C3 C10)cycloalkyl which includes alkyl substituted cycloalkyl, are cyclopropyl, 2- methylcyclopropyl, 2,2-dimethylcyclopropyl, 2,3-diethylcyclopropyl, 2-butylcyclopropyl, cyclobutyl, 2- methylcyclobuty, 3-propylcyclobutyl, 2,3,4-triethylcyclobutyl, cyclopentyl, 2,2-dimethylcyclopentyl, 2pentylcycloentyl, 3-tert-butylcyclopentyl, cyclohexyl, 4-tert-butylcyclohexyl, 3-isopropylcyclohexyl, 2,2-dimethylcyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl.
Examples of (C7-C12)aralkyl are benzyl, 2-phenylethyl, 1-phenylethyl, 2-phenylpropyl, 4- phenylbutyl, 3-phenylbutyl, 2-(1 -naphthylethyl),and 1 -(2-naphthylmethyl).
Examples of phenyl substituted by one to 3 chloro or alkyl of one to 4 carbon atoms, inclusive, are p-chlorophenyl, m-chlorophenyl, 2,4-dichlorophenyl, 2,4,6-trichlorophenyl, p-tolyl, m-tolyl, o-tolyl, pethylphenyl, p-tert-butylphenyl, 2,5-dimethylphenyl, 4-chloro-2-methylphenyl, and 2,4-dichloro-3methylphenyl.
Examples of (C4-C7)cycloalkyl optionally substituted by (C1-C5)alkyl are cyclobutyl, 1propylcyclobutyl, 1-butylcyclobuty, 1-pentylcyclobuty, 2-methylcyclobuty, 2-propylcyclobutyl, 3ethylcyclobutyl, 3-propylcyclobutyl, 2,3,4-triethylcyclobuty, cyclopentyl, 2,2-dimethylcyclopentyl, 3 ethylcyclopentyl, 3-propylcyclopentyl, 3-butylcyclopentyl, 3-tert-butylcyclopentyl, 1-methyl-3propylcyclopentyl, 2-methyl-3-propylcyclopentyl, 2-methyl-4-propylcyclopentyl, cyclohexyl, 3 ethylcyclohexyl, 3-isopropylcyclohexyl, 4-methylcyclohexyl, 4-ethylcyclohexyl, 4-propylcyclohexyl, 4- butylcyclohexyl, 4-tert-butyicyclohexyl, 2,6-dimethylcyclohexyl, 2,2-dimethylcyclohexyl, 2,6-dimethyl- 4-propylcyclohexyl, and cycloheptyl.
Examples of substituted phenoxy, phenylmethyl, phenylethyl, or phenylpropyl of the R7 moiety are (o-, m-, or p-)tolyl, (o-, m-, or p-(ethylphenyl, 4-ethyl-o-tolyl, 5-ethyl-m-tolyl, (o-, m-, or p-) propylphenyl, 2-propyl-(m- or p-)tolyl, 4-isopropyl-2,6-xylyl, 3-propyl-4-ethylphenyl, (2,3,4-, 2,3,5-, 2,3,6-, or 2,4,5-)trimethylphenyl, (o-, m-, or p-)fluorophenyl, 24luoro-(m- or p-)tolyl, 44luoro-2,5-xylyl, (2,4-, 2,5-, 2,6-, 3,4-, or 3,5-)difluorophenyl, (o-,m-, or p-)chlorophenyl, 2-chloro-p-tolyl, (3-, 4-, 5-, or 6-)-chloro-o-tolyl, 4-chloro-2-propylphenyl, 2-isopropyl-4-chlorophenyl, 4-chloro-3,5-xylyl, (2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-)dichlorophenyl, 4-chloro-3-fluorophenyl, (3- or 4-)chloro-2-fluorophenyl, (o-, mor p-)trifluoromethylphenyl, (o-, m-, or p-)methoxyphenyl, (o-, m-, or p-)ethoxyphenyl, (4- or 5-)chloro-, 2-methoxyphenyl, 2,4-dichloro-(4- or 6-)methylphenyl, (o-, m-, or p-)tolyloxy, (o-, m-, or p-)ethylphenyloxy, 4-ethyl-o-tolyloxy, 5-ethyl-m-tolyloxy, (o-, m-, or p-)propylphenyoxy, 2-propyl-(m- or p-)tolyloxy, 4-isopropyl-2,6-xylyloxy, 3-propyi-4-ethylphenyloxy, (2,3,4-, 2,3,5-, 2,3,6-, or 2,4,5-)trimethylphenoxy, (o-, m-, or p-)fluorophenoxy, 2-fluoro-(m- or p-)tolyloxy, 4-fluoro-2,5-xylyloxy, (2,4-, 2,5-, 2,6-, 3,4-, or 3,5-)-difluorophenoxy, (o-, m-, or p-)-chlorophenoxy, 2-chloro-p-tolyloxy, (3, 4, 5, or 6-)ch loro-o-tolyloxy, 4-ch loro-2-propylphenoxy, 2-isopropyl-4-chlorophenoxy, 4-chloro-3,5-xylyloxy, (2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-)dichlorophenyloxy, 4-chloro-3-fluorophenoxy, (3- or 4-)chloro-2fluorophenoxy, (o-, m-, or p-)trifluoromethyl phenoxy, (o-, m-, or p-)methoxyphenoxy, (o-, m-, or p-)ethoxyphenoxy, (4- or 5-)chloro-2-methoxyphenoxy, 2,4-dichloro-(5- or 6-)methylphenoxy, (o-, m- or p-)tolylmethyl, (o-, m-, or p-)ethylphenyl methyl, 4-ethyl-o-tolylmethyl, 5-ethyl-m-tolylmethyl, (o-, m-, or p-)propylphenylmethyl, 2-propyl-(m- or p-)tolyl methyl, 4-isopropyl-2,6-xylyl methyl, 3-propyl-4- ethylphenylmethyl, (2,3,4-, 2,3,5-, 2,3,6-, or 2,4,5-)trimethylphenylmethyl, (o-, m-, or p-)fluoro phenylmethyl, 24luoro-(m- or p-)tolylmethyl, 44luoro-2,5-xylylmethyl, (2,4-, 2,5-, 2,6-, 3,4-, or 3,5-)difluorophenyl, (o-, m-, or p-)chlorophenylmethyl, 2-chloro-p-tolylmethyl, (3, 4, 5, or 6-)-chloro-o tolylmethyl, 4-chloro-2-propylphenyl methyl, 2-isopropyl-4-chlorophenyl methyl, 4-chloro-3,5- xylylmethyl, (2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-)dichlorophenylmethyl, 4-chloro-3-fluorophenylmethyl, (3- or 4-)chloro-2-fluorophenylmethyl, (o-, m- or p-)trifluoromethylphenylmethyl, (o-, m- or p-)methoxyphenylmethyl, (o-, m- or p-)ethoxyphenylmethyl, and (4- or 5-)chloro-2-methoxyphenylmethyl,
The novel CBA analogs disclosed herein produce certain prostacyclin-like pharmacological responses.
Accordingly, the novel formula X and Xi CBA analogs are used as agents in the study, prevention, control, and treatment of diseases, and other undesirable physiological conditions, in mammals, particularly humans, valuable domestic animals, pets, zoological specimens, and laboratory animals (e.g., mice, rats, rabbits and monkeys). In particular, these compounds have useful application as antithrombotic agents, anti-ulcer agents, and anti-asthma agents, as indicated below.
(a) Platelet Aggregation Inhibition
These novel CBA analogs disclosed herein are useful whenever it is desired to inhibit platelet aggregation, to reduce the adhesive character of platelets, or to remove or prevent the formation of thrombi in mammals, including man. For example, these compounds are useful in the treatment and prevention of myocardial infracts, to treat and prevent post-operative thrombosis, to promote patency of vascular grafts following surgery, to treat peripheral vascuiar diseases, and to treat conditions such as atherosclerosis, arteriosclerosis, blood clotting defects due to lipemia, and other clinical conditions in which the underlying etiology is associated with lipid imbalance or hyperlipidemia.Other in vivo applications include geriatric patients to prevent cerebral ischemic attacks and long term prophylaxis following myocardial infarcts and strokes. For these purposes, these compounds are administered systemically, e.g., intravenously, subcutaneously, intramuscularly, and in the form of sterile implants for prolonged action. For rapid response, especially in emergency situations, the intravenous route of administration is preferred. Doses of from 0.01 to 10 mg per kg of body weight per day are used, the exact dose depending on the age, weight, and condition of the patient or animal, and on the frequency and route of administration.
The preferred dosage form for these compounds is oral, although other non-parenteral routes (e.g., buccal, rectal, sublingual) are likewise employed in preference to parenteral routes. Oral dosage forms are conveniently formulated (tablets, capsules) and administered 2-4 times daily. Doses in the range of about 0.05 to 100 mg per kg of body weight per day are effective.
The addition of these compounds to whole blood provides in vitro applications such as storage of whole blood to be used in heart-lung machines. Additionally whole blood containing these compounds can be circulated through organs, e.g., heart and kidneys, which have been removed from a donor prior to transplant. They are also useful in preparing platelet rich concentrates for use in treating thrombocytopenia, chemotherapy, and radiation therapy. In vitro applications utilize a dose of 0.001-1.0 y9 per ml of whole blood. For treatment of peripheral vascular diseases, see U.S. Patent 4,103,026.
(b) Gastric Secretion Reduction
These novel CBA analogs disclosed herein are also useful in mammals, including man and certain useful animals, e.g., dogs and pigs, to reduce and control gastric secretion, thereby to reduce or avoid gastrointestinal ulcer formation, and accelerate the healing of such ulcers already present in the gastrointestinal tract. For this purpose, these compounds are injected or infused intravenously, subcutaneously, or intramuscularly in an infusion dose range of from 0.1 to 20 ,ug per kg of body weight per minute, or in a total daily dose by injection or infusion in the range of from 0.01 to 10 mg per kg of body weight per day, the exact dose depending on the age, weight, and condition of the patient or animal, and on the frequency and route of administration.
Preferably, however, these novel compounds are administered orally or by other non-parenteral routes. As employed orally, one to 6 administrations daily in a dosage range of from 1.0 to 100 mg per kg of body weight per day is employed. Once healing of the ulcers has been accomplished the maintenance dosage required to prevent recurrence is adjusted downward so long as the patient or animals remains asymptomatic.
(c) NOSAC-lnduced Lesion Inhibition
These novel CBA analogs disclosed herein are also useful in reducing the undesirable gastrointestinal effects resulting from systemic administration of anti-inflammatory prostaglandin synthetase inhibitors, and are useful for that purpose by concomitant administration of the prostaglandin derivative and the anti-inflammatory prostaglandin synthetase inhibitor. See Partridge et al., U.S. Patent No. 3,781,429, for a disclosure that the ulcerogenic effect induced by certain
non-steroidal anti-infiammatory agents in rats is inhibited by concomitant oral administration
of certain prostaglandins. Accordingly these novel CBA analogs herein are useful, for example, in
reducing the undesirable gastrointestinal effects resulting from systemic administration of indomethacin, phenyibutazone, and aspirin.These are substances specifically mentioned in Partridge, et al. as non-steroidal, anti-inflammatory agents. These are also known to be prostaglandin synthetase inhibitors.
The anti-inflammatory synthetase inhibitor, for example, indomethacin, aspirin, or phenylbutazone is administered in any of the ways known in the art to alleviate an inflammatory conditions, for example, in any dosage regimen and by any of the known routes of systemic administration.
(d) Bronchodilation (Anti-asthma)
These novel analogs disclosed herein are also useful in the treatment of asthma. For example, these compounds are useful as bronchodilators or as inhibitors of mediator-induced bronchoconstriction such as SRS-A, and histamine which are released from cells activated by an antigen-antibody complex. Thus, these compounds control spasm and facilitate breathing in conditions such as bronchial bronchitis, bronchiectasis, pneumonia and emphysema.For these purposes, these compounds are administered in a variety of dosage forms, e.g., orally in the form of tablets, capsules or liquids; rectally in the form of suppositories, parenterally, subcutaneously or intramuscularly, with intravenous administration being preferred in emergency situations; by inhalation in the form of aerosols or solutions for nebulizers; or by insufflation in the form of powder. Doses in the range of from 0.01 to 5 mg per kg of body weight are used 1 to 4 times a day, the exact dose depending on the age, weight, and condition of the patient and on the frequency and route of administration. For the above use these CBA analogs can be combined advantageously with other anti-asthmatic agents, such as sympathomimetics (isoproterenol, phenylephrine, ephedrine); xanthine derivatives (theophylline and aminophylline); and corticosteroids (ACTH and prednisolone).
These compounds are effectively administered to human asthma patients by oral inhalation or by
aerosol inhalation. For administration by the oral inhalation route with conventional nebulizers or by
oxygen aerosolization it is convenient to provide the instant active ingredient in dilute solution,
preferably at concentrations of about one part of medicament to from 100 to 200 parts by weight of
total solution. Entirely conventional additives may be employed to stabilize these solutions or to provide
isotonic media, for example, sodium chloride, sodium citrate, citric acid or sodium bisulfite can be
employed.For administration as a self-propelled dosage unit for administering the active ingredient in
aerosol form suitable for inhalation therapy the composition can comprise the active ingredient suspended in an inert propellant (such as a mixture of dichlorodifluoromethane and dichlorotetrafluoroethane) together with a co-solvent, such as ethanol, flavoring materials and stabilizers. Suitable means to employ the aerosol inhalation therapy technique are described fully in
United States Patent 3,868,691, for example.
When X1 is -COOR1, the novel CBA analogs so described are used for the purposes described above in the free acid form, in ester form, or in pharmacologically acceptable salt form. When the ester form is used, the ester is any of those within the above definition of R,. However, it is preferred that the ester be alkyl of one to 1 2 carbon atoms, inclusive. Of the alkyl esters, methyl and ethyl are especially preferred for optimum absorption of the compound by the body or experimental animal system; and straight-chain octyl, nonyl, decyl, undecyl, and dodecyl are especially preferred for prolonged activity.
Pharmacologically acceptable salts of the novel prostaglandin analogs of this invention for the purposes described above are those with pharmacologically acceptable metal cations, ammonia, amine cations, or quaternary ammonium cations.
Especially preferred metal cations are those derived from the alkali metals, e.g., lithium, sodium, and potassium, and from the alkaline earth metals, e.g., magnesium and calcium, although cationic forms of other metals, e.g., aluminium, zinc, and iron are within the scope of this invention.
Pharmacologically acceptable amine cations are those derived from primary, secondary, and tertiary amines. Examples of suitable amines are methylamine, dimethylamine, trimethylamine, ethylamine, dibutylamine, triisopropylamine, N-methylhexylamine, decylamine, dodecylamine, allylamine, crotylamine, cyclopentylamine, dicyclohexylamine, benzylamine, dibenzylamine, a- phenylethylamine, pphenylethylamine, ethylenediamine, diethylenetriamine, adamantylamine, and the like aliphatic, cycloaliphatic, araliphatic amines containing up to and including about 1 8 carbon atoms, as well as heterocyclic amines, e.g., piperidine, morpholine, pyrrolidine, piperazine, and lower-alkyl derivatives thereto, e.g., 1 -methylpiperidine, 4-ethylmorpholine, 1 -isopropylpyrrolidine, 2- methylpyrrolidine, 1 ,4-dimethylpiperazine, 2-methylpiperidine, and as well as amines containing watersolubilizing or hydrophilic groups, e.g., mono-, di-, and triethanolamine, ethyldiethanolamine, Nbutylethanolamine, 2-amino-1 -butanol, 2-amino-2-ethyl- 1 3-propanediol, 2-amino-2-methyl- 1 propanol, tris(hydroxymethyl)aminomethane, N-phenylethanolamine, N-(p-tert-amylphenyl)diethanolamine, galactamine, N-methylglycamine, N-methylglucosamine, ephedrine, phenylephrine, epinephrine and procaine. Further useful amine salts are of the basic amino acids, e.g. lysine and arginine.
Examples of suitable pharmacologically acceptable quaternary ammonium cations are tetramethylammonium, tetraethylammonium, benzyltrimethylammonium and phenyltriethylammonium.
When X, is -CH2NL2L3,the novel CBA analogs so described are used for the purposes described in either free base or pharmacologically acceptable acid addition salt form.
The acid addition salts of the 2-decarboxy-2-aminomethyl- or 2-(substituted aminomethyl)-CBA analogs provided by this invention are the hydrochlorides, hydrobromides, hydroiodides, sulfates, phosphates, cyclohexanesulfamates, methanesulfonates, ethanesulfonates, benzenesulfonates and toluenesulfonates, prepared by reacting the CBA analog with the stoichiometric amount of the acid corresponding to the pharmacologically acceptable acid addition salt.
To obtain the optimum combination of biological response specificity, potency, and duration of ativity, certain compounds within the scope of this invention are preferred.
It is preferred that in the X,-terminated side chain for inter-p-phenylene-CBA compounds, g be zero, for inter-m-phenylene-CBA compounds g be zero or one (especially zero), and for inter-ophenylene CBA compounds g be zero, one, or 2 (especially one). lnter-o- and inter-m-phenylene-CBA compounds, especially inter-m-phenylene-CBA compounds are preferred. Moreover when Z, is CH2(CH2)fC(R2)2, f is preferably one and R2 is preferably hydrogen. When R17 is (C1-C4)alkyl, R17 is preferably methyl. Further, when the C-12 side chain contains-Cm H 2-CH3, it is preferred that m be 3, 4, or 5, most preferably 3. When m is 5, more straight chain isomeric forms are preferred, especially methyl-substituted butyl.Further, it is preferred that, when R7 is aromatic, R7 be phenoxy, phenyl, or benzyl, including substituted forms thereof. For those compounds wherein R7 is substituted phenoxy or phenylalkyl, it is preferred there be only one or 2 substituents selected from the group consisting of chloro, fluoro, or trifluoromethyl. Further, for those compounds wherein R7 is aromatic, it is preferred that R3 and R4 both be hydrogen.
Most especially preferred to biological potency are formula X CBA7 analogous exhibiting the same C-S isomeric configuration as CBA2 itself.
Especially preferred are those compounds which satisfy two or more of the above preferences.
Further, the above preferences are expressly intended to describe the preferred compounds within the scope of any generic formula of novel CBA analogs disclosed herein.
Those protective groups within the scope of R10 are any group which replaces a hydroxy hydrogen and is neither attacked by nor is reactive to the reagents used in the transformations used herein as a hydroxy is and which is subsequently replaceable by acid hydrolysis with hydrogen in the preparation of the prostaglandin-type compounds. Several such protective groups are known in the art, e.g., tetrahydropyranyl and substituted tetrahydropyranyl. See for reference E. J. Corey, Proceedings of the
Robert A. Welch Foundation Conferences on Chemical Research, XII Organic Synthesis, pgs. 51-79 (1969).Those blocking groups which have been found useful include:
(a) tetrahydropyranyl;
(b) tetrahydrofuranyl;
(c) a group of the formula -C(OR11)(R12)-CH(R13)(R13(R14), wherein R1, is alkyl of one to 18 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, aralkyl of 7 to 12 carbon atoms, phenyl or phenyl substituted with one to 3 alkyl of one to 4 carbon atoms, wherein R,2 and R13 are alkyl of one to 4 carbon atoms, phenyl, phenyl substituted with one, 2 or 3 alkyl of one to 4 carbon atoms, or when R12 and R13 are taken together (CH2)a or when R,2 are R13 are taken together (CH2)bO(CH2)C, wherein a is 3, 4, or 5 and b is one, 2, or 3, and c is one, 2, or 3, with the proviso that b plus c is 2, 3, or 4, with the further proviso that R,2 and R13 may be the same or different, and wherein R,4 is hydrogen or phenyl; and
(d) silyl groups according to R2s, as qualified hereinafter.
When the protective group R10 is tetrahydropyranyl, the tetrahydropyranyl ether derivative of any hydroxy moieties of the CBA-type intermediates herein is obtained by reaction of the hydroxycontaining compound with 2,3-dihydropyran in an inert solvent, e.g., dichloromethane, in the presence of an acid condensing agent such as p-toluenesulfonic acid or pyridine hydrochloride. The dihydropyran
is used in large stoichiometric excess, preferably 4 to 100 times the stoichiometric amount. The reaction is normally complete in less than an hour at 20-500C.
When the protective group is tetrahydrofuranyl, 2,3-dihydrofuran is used, as described in the preceding paragraph, in place of the 2,3-dihydropyran.
When the protective group is of the formula -C(OR11)(R12)-CH(R13)(R14), wherein R, R2, R,3, and Ra4 are as defined above, a vinyl ether or an unsaturated cyclic or heterocyclic compound, e.g., 1 cyclohexen-1 -yl methyl ether or 5,6-dihydro-4-methoxy-2H-pyran, is employed. See C. B. Reese et al.,
J. American Chemical Society 89, 3366 (1967). The reaction conditions for such vinyl ethers and unsaturated compounds are similar to those for dihydropyran above.
R28 is a silyl protective group of the formula -Si(G1)3. In some cases, such silylations are general, in that they silylate all hydroxyls of a molecule, while in other cases they are selective, in that while one or more hydroxyls are silylated, at least one other hydroxyl remains unaffected. For any of these silylations, silyl groups within the scope ofSi(G,)3 include trimethylsilyl, dimethylphenylsilyl, triphenylsilyl, t-butyldimethylsilyl and methylphenylbenzylsilyl. With regard to G1, examples of alkyl are methyl, ethyl, propyl, isobutyl, butyl, sec-butyl, tert-butyl and pentyl.Examples of aralkyl are benzyl, phenethyl, a-phenylethyl, 3-phenylpropyl, a-naphthylmethyl, and 2-(a-naphthyl)ethyl. Examples of phenyl substituted with halo or alkyl are p-chlorophenyl, m-fluorophenyl, o-tolyl, 2,4-dichlorophenyl, ptert-butylphenyl, 4-chloro-2-methylphenyl, and 2,4-dichloro-3-methylphenyl.
These silyl groups are known in the art. See for example, Pierce "Silylation of Organic
Compounds," Pierce Chemical Company, Rockford, III. (1968). When silylated products of the charts below are intended to be subjected to chromatographic purification, then the use of silyl groups known to be unstable to chromatography (e.g. trimethylsilyl) is to be avoided. Further, when silyl groups are to be introduced selectively, silylating agents which are readily available and known to be useful in selective silylations are employed. For example, t-butyldimethylsilyl groups are employed wh.en selective introduction is required.Further, when silyl groups are to be selectively hydrolyzed in the presence of protective groups according to R10 or acyl protective groups, then the use of silyl groups which are readily available and known to be easily hydrolyzable with tetra-n-butylammonium fluoride are employed. A particularly useful silyl group for this purpose is t-butyldimethylsilyl, while other silyl groups (e.g. trimethylsilyl) are not employed when selective introduction and/or hydrolysis is required.
The protective groups as defined by R10 are otherwise removed by mild acidic hydrolysis. For example, by reaction with (1) hydrochloric acid in methanol; (2) a mixture of acetic acid, water, and tetrahydrofuran, or (3) aqueous citric acid or aqueous phosphoric acid in tetrahydrofuran, at temperatures below 550C., hydrolysis of the blocking group is achieved.
R31 is a hydroxy-hydrogen protective group, as indicated above. As such, R3, may be an acyl protective group according to R9, an acid hydrolyzable protective group according to R,O, a silyl protective group according to R2B, or an arylmethyl hydroxy hydrogen replacing group according to R34.
Acyl protective groups according to R9 include: (a) benzoyl; (b) benzoyl substituted with one to 5 alkyl of one to 4 carbon atoms, phenylalkyl of 7 to 12 carbon atoms, or nitro, with the proviso that not more than two substituents are other than alkyl, and that the total number of carbon atoms in the substituents does not exceed 10 carbon atoms, with the further proviso that the substituents are the same or different;
(c) benzoyl substituted with alkoxycarbonyl of 2 to 5 carbon atoms;
(d) naphthoyl;;
(e) naphthoyl substituted with one to 9 alkyl of one to 4 carbon atoms, phenylalkyl of 7 to 10 carbon atoms, or nitro, with the proviso that not more than two substituents on either of the fused aromatic rings are other than alkyl and that the total number of carbon atoms in the substituents on either of the fused aromatic rings does not exceed 10 carbon atoms, with the further proviso that the various substituents are the same or different; or
(f) alkanoyl of 2 to 12 carbon atoms.
In preparing these acyl derivatives of a hydroxy-containing compound herein, methods generally known in the art are employed. Thus, for example, an aromatic acid of the formula R9OH, wherein R9 is as defined above (e.g., benzoic acid), is reacted with the hydroxy-containing compound in the presence of a dehydrating agent, e.g. p-toluenesulfonyl chloride or dicyclohexylcarbodiimide; or alternatively an anhydride of the aromatic acid of the formula (R5)OH, e.g., benzoic anhydride, is used.
Preferably, however, the process described in the above paragraph proceeds by use of the appropriate acyl halide, e.g., RgHal, wherein Hal is chloro, bromo or iodo. For example, benzoyl chloride is reacted with the hydroxyl-containing compound in the presence of a hydrogen chloride scavenger, e.g. a tertiary amine such as pyridine or triethylamine. The reaction is carried out under a variety of conditions, using procedures generally known in the art. Generally mild conditions are employed: O-600C., contacting the reactants in a liquid medium (e.g., excess pyridine or an inert solvent such as benzene, toluene, or chloroform). The acylating agent is used either in stoichiometric amount or in substantial stoichiometric excess.
As examples of R9, the following compounds are availabe as acids (RgOH), (R9)2O, or acyl chlorides (RgCI) benzoyl; substituted benzoyl, e.g., (2-, 3-, or 4-)methylbenzoyl, (2-, 3-, or 4-)ethylbenzoyl, (2-, 3-, or 4-)isopropylbenzoyl, (2-, 3-, or 4-)tert-butylbenzoyl, 2,4-dimethylbenzoyl, 3,5-dimethylbenzoyl, 2isopropyltoluyl, 2,4,6-trir ethylbenzoyÃ, pentamehyibenzoyl, phenyl(2-, 3-, or 4-)toÃyÃ, (2-, 3-, or 4-)phenethylbenzoyl, (2-, 3-, or 4-)nitrobenzyl, (2,4, 2,5-, or 2,3-)dinitrobenzoyl, 2,3-dimethyl-2nitrobenzyl, 4,5-dimethyl-2-nitrobenzoyl, 2-nitro-6-phenylethylbenzoyl, 3-nitro-2-phenethylbenzoyl, 2nitro-6-phenethylbenzoyl, 3-nitro-2-phenethylbenzoyl; mono esterified phtha loyl, isophthaloyl, or terephthaloyl; 1- or 2-naphthoyl; substituted naphthoyl, e.g., (2-, 3-, 4-, 5-, 6-, or 7-)methyl-1 - naphthoyl, (2- or 4-)ethyl-1 -naphthoyl, 2-isopropyl-1 -naphthoyl, 4,5-dimethyl- 1 -naphthoyl, 6 isopropyl-4-methyl-1 -naphthoyl, 8-benzyl-1 -naphthoyl, (3-, 4-, 5-, or 8-)nitro-1 -naphthoyl, 4,5-dinitro
1 -naphthoyl, (3-, 4-, 6-, 7-, or 8-)methyl-1 -naphthoyl, 4-ethyl-2-naphthoyl, and (5- or 8-)nitro-2naphthoyl and acetyl.
There may be employed, therefore, benzoyl chloride, 4-nitrobenzoyl chloride, 3,5-dinitrobenzoyl chloride, or the like, i.e. RgCI compounds corresponding to the above R9 groups. If the acyl chloride is not available, it is prepared from the corresponding acid and phosphorus pentachloride as is known in the art. It is preferred that the RgOH, (R9)20, or RgCI reactant does not have bulky hindering substituents, e.g.
tert-butyl on both of the ring carbon atoms adjacent to the carbonyl attaching site.
The acyl protective groups, according to R9, are removed by deacylation. Alkali metal carbonate or hydroxide are employed effectively at ambient temperature for this purpose. For example, potassium carbonate or hydroxide in aqueous methanol at about 250C is advantageously employed.
R34 is defined as any arylmethyl group which replaces the hydroxy hydrogen of the intermediates in the preparation of the various CBA analogs herein which is subsequently replaceable by hydrogen in the processes herein for preparation of these respective prostacyclin analogs, being stable with respect to the various reactions to which R34-containing compounds are subjected and being introduced and subsequently removed by hydrogenolysis under conditions which yield substantially quantitative yields of desired products.
Examples of arylmethyl hydroxy-hydrogen replacing groups are
(a) benzyl;
(b) benzyl substituted by one to 5 alkyl or one to 4 carbon atoms, chloro, bromo, iodo, fluoro, nitro, phenylalkyl of 7 to 1 2 carbon atoms, with the further proviso that the various substituents are the same or different;
(c) benzhydryl;
(d) benzhydryl substituted by one to 10 alkyl of one to 4 carbon atoms, chloro, bromo, iodo, fluoro, nitro, phenylalkyl of 7 to 1 2 carbon atoms, with the further proviso that the various substituents are the same or different on each of the aromatic rings;
(e) trityl;;
(f) trityl substituted by one to 1 5 alkyl of one to 4 carbon atoms, chloro, bromo, iodo, fluoro, nitro, phenylalkyl of 7 to 12 carbon atoms, with the further proviso that the various substituents are the same or different on each of the aromatic rings.
The introduction of such ether linkages to the hydroxy-containing compounds herein, particularly the benzyl or substituted benzyl ether proceeds by methods known in the art, for example by reaction of the hydroxy-containing compound with the benzyl or substituted benzyl halide (chloride, bromide; or iodide) corresponding to the desired ether. This reaction proceeds in the presence of an appropriate condensing agent (e.g., silver oxide). The mixture is stirred and heated to 5080 C. Reaction times of 4 to 20 hours are ordinarily sufficient.
The Charts herein describe the methods whereby the novel intermediates and end products of the present specification are prepared by the novel processes herein. With respect to these charts, g, n, L1,
M1, M6, R7 R8, R10, R15, R16, R17, R18, R20, R21, R22, R23, and24, R28, R31, X1, Y1, Z1 andZ4 are as defined above. R37 is the same as R47, but other than -CH2OH. R38 is -OR31, hydrogen, or-CH2OR31, wherein
R31 is defined as as above. R27 is the same as R7 except that -(CH2)2-CH(0H)-CH3 is -(CH2)2-CH(0R10)-CH3. R37 is the same as R17, but other than hydrogen. Ac is acetyl.Z2 is the same as Z1 but not (Ph)--(CH,), Z8 is the same as Z1 but not trans-CH2-CH=CH-.
With respect to Chart A, a method is provided whereby the known formula XXI bicyclic lactone is transformed to the carbacyclin intermediate of formula XXV useful in the preparation of formula X CBA compounds wherein R17 is alkyl or R18 and R17 taken together are methano or a second valence bond between C-6a and C-9. With respect to Chart A, the formula XXI compound is transformed to the formula XXII compound by treatment with the anion of dimethyl methylphosphonate. Methods for such a reaction are known in the art. See Dauben, W. G., et al., JACS, 97:4973 (1975), describing a reaction of this type.
The formula XXII lactol is transformed to the formula XXI II diketone by oxidation methods known in the art. For example, Collins reagent or Jones reagent is employed in this oxidative transformation.
The formula XXIII diketone is cyclized to the formula XXIV compound by an intramolecular Horner
Emmons reaction. The chemical methodology for analogous transformations is known in the art. See
Piers, E., et al., Tetrahedron Letters, 3279 (1979) and Clark, R.D., et al., Synthetic Communications 5:1 (1975).
The formula XXIV compound is transformed to the novel formula XXV compound wherein R16is hydrogen and R37 is alkyl by treatment with lithium dialkyl cuprate. The lithium dialkyl cuprate is prepared by conventional means, e.g., reaction of anhydrous copper iodide in diethyl ether with an alkyllithium in diethyl ether, and thereafter reacted with the formula XXIV compounds, e.g., in diethyl ether.
The formula XXIV compound is transferred to the novel formula XXV compound wherein R16and R37ta taken together are methylene (-CH2-) by one of two methods. By the first method, the formula
XXV compound is prepared by treatment of the formula XXIV compound with the anion of trimethyloxosulfonium iodide. See for reference E. J. Corey, et al., JACS 87:1353 (1965). By this method, the anion is conveniently generated by treatment of trimethyloxosulfonium iodide in sodium hydride.
By a second method, the formula XXIV compound is converted to the formula XXV compound wherein R16 and R37 taken together are methylene by first converting the formula XXIV compound to the corresponding formula XXVI hydroxymethyl compound by photochemical addition of methanol (e.g., see G. L. Bundy, Tetr. Lett. 1 957, 1 975), thereafter treating the resulting hydroxymethyl compound with an excess (e.g., two equivalents) of p-toluenesulfonyl chloride in a tertiary amine base to yield the corresponding formula XXVII tosylate, and finally treating the resulting formula XXVII tosylate with base (e.g., potassium t-butoxide) to yield the formula XXV cyclopropyl compound.
With respect to Chart B, a method is provided whereby the formula XXXI compound prepared in accordance with methods of Chart A is transformed to the novel CBA2 analogs of formula XXXVI.
The formula XXXI compound is transformed to the formula XXXVI compound by methods known in the art for preparing carbacyclin. See for example, British published applications referred to above.
Alternatively, the formula XXXI compound is reacted with formula XXXI I compound and thereby successively transformed to the formula XXXIII, formula XXXIV and formula XXXV compounds.
The reaction of the formula XXXI compound employing the formula XXXI I compound is accomplished by methods known in the art. See Moersch, G. W., J. Organic Chemistry, 36:1149 (1971) and Mulzer, J., et al., Tetrahedron Letters, 2949 (1978). The formula XXXI I reactants are known in the art or are prepared by methods known in the art. See Example 4 describing one such method of preparation of a formula XXXII compound.
The formula XXXIII compound is then transformed to the formula XXXIV compound by decarboxylative dehydration. Procedures for this reaction are known in the art. See Eschenmoser, A., et al., Helv. Chim. Acta. 58:1450 (1975), Hara, S., et al., Tetrahedron Letters, 1545 (1975) and Mulzer, J., et al., Tetrahedron Letters, 2953 (1978) and 1909 (1979).
Finally, the formula XXXV compound is prepared from formula XXXIV compound by selective desilylation. Such procedures are known in the art and typically employ the use of tetra-n-butyl ammonium fluoride and tetrahydrofuran. See Corey, E. J., et al., JACS 94:6190 (1972).
The formula XXXV compound is transformed to various acids, esters, amides, and amines of a formula XXXVI by methods known in the art. Particularly useful in this regard are methods described in the aforementioned British published specifications describing the preparation of carbacyclin analogs.
The preparation of formula XXXVI compounds from the formula XXXV compounds proceeds by, for example, oxidation to the corresponding carboxylic acid, followed by hydrolysis of any protective groups at the C-1 1 or C-l 5 position of the molecule. Such carboxylic acids are then esterified by conventional means or amidized by conventional means. Such amides may, for example, then be reduced to corresponding amines (X1 is -CH2NL2L3 by reduction by lithium aluminum hydride. See U.S.
Patent 4,073,808. In a preparation of the primary alcohols according to formula XXXVI from the formula XXXV compound, hydrolysis of any protective groups at C-1 1 or C-1 5 yields such products directly. Hydrolysis is accomplished by procedures described above, e.g., mild acidic conditions at elevated temperatures.
Chart C provides a method whereby the known formula XLI compounds are transformed to the formula XLIV aldehydes employed in Chart D in the preparation of inter-phenylene-CBA2 compounds therein.
With respect to Chart C, the formula XLII compound is prepared from the formula XLI compounds by reduction. Conventional methods known in the art for the transformation of carboxylic acids to corresponding primary alcohols are employed. For example, one extremely useful conventional means for this reduction is employing lithium aluminum hydride as a reducing agent.
The formula XLII I compound is then prepared from the formula XLII compound by monosilylation.
Particularly, formula XLI II compounds are prepared wherein R28 represents a relatively stable silyl group, most preferably being t-butyldimethylsilyl or phenyldimethylsilyl. Other silyl groups, particularly trimethyl-silyl (TMS) are not preferred for use in connection with the methods of Chart C.
The formula XLI II monosilyl derivatives are prepared from the formula XLII compound by reacting the formula XLII compounds with about an equal molar amount of the silylating agent. For example, when R28 is t-butyldimethylsilyl, a single equivalent of t-butyldimethylsilyl chloride is employed in the transformation. Accordingly, there are prepared both monsilyl derivatives of the formula XLII compound as well as the bis-silyl derivatives corresponding to formula XLI I. From this mixture of products, the formula XLI II compound is recovered by conventional means, e.g., column chromatography. Otherwise, the silylation proceeds under conditions conventionally employed for silylating hydroxyl groups. Refer to the discussion hereinabove.
The formula XLIV compound is then prepared from the formula XLII I compound by oxidation of the formula XLIII alcohol to the corresponding aldehyde. Conventional oxidizing agents are employed, e.g., manganese dioxide.
Chart D provides a method whereby the known formula LI ketones are transformed to the formula
LX inter-phenylene CBA2 analogs disclosed herein.
In accordance with Chart D the formula LII compound is prepared from the formula LI compound by reduction of the formula LI ketone to the corresponding secondary alcohol. This reduction proceeds by conventional means, employing readily available reducing agents. Accordingly, sodium, potassium, or lithium borohydride is conveniently employed in this reduction.
Thereafter, the formula LII alcohol is transformed to the corresponding mesylate (methanesulfonate). Conventional methods for the transformation of alcohols to corresponding mesylates are employed. Thus, the formula LII alcohol is reacted with methane-sulfonyl chloride in the presence of a tertiary amine (e.g., tri-ethylamine) in the preparation of the formula LIII compound.
Other sulfonyl derivatives corresponding to the formula LII alcohol may be employed in place of the formula LIII compound in the transformations of Chart D. These other sulfonyl derivatives are preferably those derived from readily available sulfonylating reagents, i.e., the corresponding sulfonyl chlorides. One especially important alternative to the formula LIII compound is the tosylate (toluenesulfonate) corresponding to the formula LII compound.
The formula LIII compound, or an alternate sulfonate corresponding thereto, is transformed to the formula LIV compound by treatment with sodium lithium or potassium thiophenoxide. The thiophenoxide is conveniently prepared just prior to the transformation by mixing approximately equal molar amounts of thiophenol and base, e.g., potassium t-butoxide.
This formula LIV compound is then oxidized to the corresponding formula LV compound by oxidation with a readily available oxidizing agent such as m-chloroperbenzoic acid.
The formula LV compound is then condensed with the formula XLIV compound prepared according te Chart C by first treatment of the formula LV compound with a strong base, e.g., nbutyllithium, to generate the anion corresponding to the formula LV compound, treatment of the corresponding anion with the aldehyde of formula XLIV and finally treating the resulting adduct with acetic anhydride to yield the formula LVI acetyl compound.
The formula LVI compound is then transformed to the formula LVII compound by reaction with a sodium amalgam. Methods by which the formula LVII olefin is formed from the formula LV compound are analogous to known methods described by Kocienski, P.J., et al., "Scope and Stereochemistry of an
Olefin Synthesis from pHydrnxysulphones", JCS Perkin I, 829-834 (1978).
The formula LVII compound is then transformed to the formula LVIII compound by selective hydrolysis of the silyl group according to R2s. Conventional means for this hydrolysis are employed, e.g., tetra-n-butyl ammonium fluoride. Refer to the discussion above for a - description of this hydrolysis.
The formula LVIII C-S diastereomers thusly prepared are conveniently purified into (5-E) and (5-Z) isomeric forms. This transformation proceeds by conventional means, e.g. column chromatography.
Thereafter either the (5E) or (5Z) isomeric formula LVIII is transformed to the formula LIX carboxylic acid or ester by conventional oxidation, followed by optional esterification. One especially convenient means of oxidation is employing the Jones reagent, although other oxidizing agents are employed. Esterification then proceeds by methods hereinafter described.
Finally, the formula LX products are prepared from the formula LIX compound by first hydrolyzing the protective groups under acidic conditions, e.g. mixtures of water, tetrahydrofuran, and acetic acid.
Thereafter, the formula LIX acids and esters are transformed to various other C-i derivatives by methods hereinafter described.
One especially convenient means of preparing the formula LX compound as a free carboxylic acid (X1 is -COOH), is by purification of the corresponding methyl ester, followed by saponification under basic conditions (e.g., the treatment with potassium carbonate or sodium or potassium hydroxide).
Chart E provides a method whereby the known formula LXI compound is transformed into formula
LXIII intermediate useful in the preparation of the novel CBA2 analogs.
The procedures for the transformation of the formula LXI compound to the formula LXI II compound are analogous to those describing the transformation in Charts A, B, and D of the formula XXI compound to the formula XXXVI and LX compounds (i.e., corresponding to the transformation of formula LXI compound to the formula LXII compound is the transformation in Chart A of the formula XXI compound to the formula XXV compound and corresponding to the transformation of the formula LXII compound to the formula LXIII compound is the transformation in Chart D of the formula LI compound to the formula LX compound.). For convenience, the protective groups R31 and R38 may be the same or different, although preferably such protective groups are different, whereby the hydrolysis of a protective group according to R31 is accomplished in the presence of a protective group according to R38* Chart F then provides a method whereby the formula LXXI compound prepared according to Chart
E is transformed to the formula LXXII carbacyclin analog in accordance with the present invention. With respect to Chart F, the formula LXXI compound is transformed to the formula LXXI I compound by selective hydrolysis of the protective group according to R31.Thereafter, the formula LXXI I compound is transformed to formula LXXIII compound by methods known in the art, e.g., oxidation of the formula LXXI I primary alcohol to the còrresponding aldehyde, Wittig oxylacylating the aldehyde, and reduction of the resulting ketone to the secondary or tertiary alcohol corresponding to M,. For an example of the various transformations employed according to Chart F, see Chart A (part VI) of U.S. Patent 4,107,427,
issued 15 August 1978.
Chart G provides a method whereby the novel formula LXXXI intermediate, prepared according to
Chart A, is transformed to the formula LXXXVIII and LXXXIX isomers of the novel C-6a- and/or C-9
substituted CBA2 analogs.
With respect to Chart G, the formula LXXXIII compound is prepared from the formula LXXXI
ketone by a Wittig c()-carboxyalkylation employing a formula LXXXII triphenylphosphonium compound.
The Wittig reaction is undertaken under conventional reaction conditions for preparing prostaglandintype substances. The formula LXXXIII compound is then optionally hydrolyzed to yield the formula X carboxylic acid products or employed in the further transformations of Chart G in ester form.
The formula LXXXIII compound thusly prepared is thereafter preferably separated directly into C-S isomers of formulas LXXXVI II and LXXXIX (e.g., by chromatographic means followed by hydrolysis of any protective groups at C-i 1 or C-1 5 position of the molecule), or is alternatively transformed to the formula LXXXIV ester by conventional esterification techniques, e.g., ethereal diazomethane treatment or treatment with methyl iodide. The formula LXXXIV ester is then reduced to the corresponding primary alcohol by reduction with a suitable reducing agent, e.g. lithium aluminum hydride, by methods known in the art for preparing prostaglandin-type primary alcohols from corresponding prostaglandin esters.
The formula LXXXV compound represents an especially convenient intermediate for the facile separation of the C-S diastereomers. Accordingly, the formula LXXXV compound may be separated by conventional means of separation of diastereomeric mixtures, e.g., column chromatography, whereby the formula LXXVI and formula LXXXVI I compounds are prepared in isomerically pure form. These primary alcohols are then conveniently transformed to the formula LXXXVIII and LXXXIX products by methods described above. Refer to the transformations of the formula XXXV compound to the formula
XXXVI compound in Chart B.
Chart H provides a method whereby the formula XCVII 5-fluoro-CBA2 compounds are prepared from the formula XCIII CBA2 intermediates known in the art. See, for example, British Published
Application 2,014,143, especially the discussion relative to step (b) of Chart A therein. This formula XCI sulfoximine is transformed to the formula XCII fluorinated sulfoximine by first generating an anion of the formula XCII compound, e.g., by treatment with n-butyllithium in hexane, and treating the resulting anion with a fluorine source. Particularly preferred as a source of fluorine is perchloryl fluoride (FCÃO3).
The formula XCII compound thusly prepared and the known formula XCIII compound described above are then employed in the preparation of the formula XCIV compound by known methods. Refer again to step (b) of Chart A of British Published Application 2,014,143.
The formula XCIV compound thusly prepared is then transformed to the formula XCV primary alcohol by hydrolysis under mild acidic conditions (e.g., mixtures of acetic acid, water, and tetrahydrofuran) as is known in the art. Thereafter, the formula XCV primary alcohol is oxidized to the corresponding formula XCVI carboxylic acid employing conventional means. For example, treatment with oxygen and an aqueous suspension of platinum oxide hydrogenated at ambient temperature and pressure yields the formula LXXVI carboxylic acid. Thereafter, the formula XCVI compound is transformed into the various formula XCVI I products by derivatization or transformation of the carboxyl group of the formula XCVI compound.
The C-S isomers of the formula XCIV to formula XCVII compounds are conveniently separated at any step during the process of Chart H, but are most conveniently and preferably separated from the formula XCIV diastereomeric mixture. Conventional means, e.g., column chromatography, are employed in the separation.
Chart I provides an optional method whereby the known formula Cl compound is transformed to the formula CIII products herein. With respect to Chart I, the formula XCII is prepared from the formula
XCI compound by the procedure described in Chart H for the preparation of the formula XCVII compound from the formula XCIII compound. This formula CII CBA2 intermediate is then transformed to the formula CIII compound by the procedures described in Chart F for the transformation of the formula
LXXI to the formula LXXI II compound.
Chart J provides the preferred methods for preparing the formula X CBA analogs wherein Z1 is trans-CH2-CH=CH-. With respect to Chart J, R1 therein is other than hydrogen or a cation, preferably being lower alkyl. The formula CXIV is prepared from the formula CXI compound by first preparing the ct-phenylselenyl derivative thereof, dehydrophenylselenizing, whereby the formula CXIII a"B- unsaturated ester is prepared. This ester is then transformed to the formula CXIV free acid (X1 is COOH) by saponification and this free acid is transformed to the various other formula CXIV compounds as indicated in Chart H (refer to the transformation of the formula XCVI compound to the formula XCVII compound).
Chart K provides the preferred method whereby the formula VI CBA intermediates wherein Z1 is trnns-CH2-CH=CH-- are prepared. With respect to Chart K, the formula CXXI compound is transformed to the formula CXXIII compound by methods analogous to those described in Chart J for the preparation of the formula CXIV compound from the formula CXI compound.
For a detailed description of the methodology employed in Charts J-K, refer to the discussion in
British Patent 2,014,143, and references cited therein.
Charts L-O provide methods whereby CBA2 intermediates and analogs are employed in the synthesis of corresponding CBA1 intermediates and analogs.
Chart L provides the preferred method for preparing the formula VII CBA1 intermediates wherein
Z1 is trans-CH2-CH=CH-. With respect to Chart L the formula CXXXI compound, prepared as the formula CXXI I compound of Chart K, is reduced to the formula CXXXII compound by conventional methods. For a discussion of such methods, and general methodologies for transforming CBA2 intermediates and analogs to corresponding CBA1 intermediates and analogs, refer to British Published
Application 2,017,699. For example, catalytic hydrogenation with conventional catalysts under atmospheric pressure is employed.
Thereafter, this formula CXXXII compound is successively transformed to the formula CXXXIII a,P- unsaturated ester and the formula CXXXIV CBA1 intermediate by methods described in Charts J-K (i.e., the transformation of the formula CXII compound to the corresponding formula CXIV compounds and the transformation of the formula CXXII compound to the formula CXXIII compound).
Otherwise, the formula VII CBA1 intermediates are prepared according to the method of Chart M, wherein the formula CXLI compound, prepared above, is reduced to the formula CXLII intermediates by techniques described in Chart L and references cited therein.
Chart N describes the preparation of the various CBA1 analogs from the formula CLI compounds prepared in Charts L and M. Procedures employed in Chart N are those described in Chart F above.
Finally, Chart 0 provides an alternative method for the preparation of the formula CLXXI CBA1 analogs directly from formula CLXI CBA2 analogs. This transformation of Chart 0 proceeds by direct
reduction of the formula CLXI compound by methods described in Chart M and references cited therein. Chart O is an especially convenient method for the preparation of CBA1 analogs wherein Y1 is -CH2CH2-.
The formula Xl CBA analogs are prepared according to the methods described in Charts P-U.
With respect to Chart P, the formula CLXXI compound is known in the art or prepared by methods known in the art. See United States Patent 4,181,789. This compound is conveniently transformed to the corresponding formula CLXXI I methylene and formula CLXXIII hydroxymethyl compounds by methods known in the art Such procedures are particularly and especially described in United States
Patent 4,012,467 and 4,060,534.
The formula CLXXI II compound thusly prepared is thereafter converted to the formula CLXXIV mesyiate by methods known in the art, e.g., reaction with methanesulfonyl chloride in a tertiary amine base. Alternatively, other sulfonated derivatives corresponding to the formula CLXXIV compound are prepared such as those described in connection with formula LIII in Chart D.
Thereafter, the formula CLXXIV mesylate (or other sulfonate) is selectively hydrolyzed to yield the formula CLXXV phenol derivatives. Selective hydrolysis of R28 silyl ether groups in the presence of protected R18 or M6 hydroxyl groups is accomplished by methods hereinabove described, i.e., the use of tetra-n-butyl ammonium floride by methods known in the art and hereinabove described. The formula
CLXXV phenol derivative is then cyclized to yield the formula CLXXVI compounds. Cyclization proceeds most conveniently by treatment of the formula XVI compound with base at elevated temperatures. For example, n-butyllithium, sodium hydride, or potassium hydride are conveniently employed at reflux temperatures in organic solvent such as tetrahydrofuran or glyme.
The cyclized formula CLXXVI compound is then transformed to the formula CLXXVI I compound by co-carboxyalkylation. Methods known in the art are employed, e.g., methods for preparing 3,7-interphenylene-PGFa compounds and corresponding phenolic intermediates. For example, the preparation of the formula CLXXVI I compound proceeds by reaction of the formula CLXXVI compound with sodium hydride and the alkyl bromoalkanoate corresponding to the -Z4-C00R1 group to be introduced into the molecule. Thereafter, the formula CLXXVIII compound is prepared by deprotection, i.e., hydrolysis under mild acidic conditions of the protective groups, followed by transformation to various other C-1 derivatives by methods hereinafter described.
Chart Q provides a method whereby further formula Xl CBA analogs in accordance with the present invention are prepared. In particular, formula Xl compounds wherein at least one of R20, R21, R23, or R24 is not hydrogen are prepared. In accordance with Chart Q, the formula CLXXXI compound, referred to above in the discussion pertaining to Chart P, is oxidized to the corresponding formula
CLXXXI I aldehyde by methods known in the art. For example, Collins reagent is employed in this oxidation. When conversion of one C-9 stereoisomer of formula CLXXXIII to the other is described, refer to the procedure in Chart R.
Thereafter the formula CLXXXI I aldehyde is hydrolyzed to the corresponding formula CLXXXIII phenol derivative by methods described above for the preparation of the formula CLXXV compound from the formula CLXXIV of Chart P.
Thereafter, cyclization of the formula CLXXXII I to the corresponding formula CLXXXIV compound is accomplished by heating at reflux in an organic solvent the phenoxide anion of the formula CLXXXIII compound. See for reference Casiraghi, G., et al., J. C. S. Perkin 1,2027 (1979). The C-9 isomers of the formula CLXXXIV compound are conveniently separated by conventional techniques, e.g., column chromatography. Thereafter, the formula CLXXXIV compound is transformed to the formula CLXXXV compound by methods described in Chart P for the preparation of the formula CLXXVI I compound from the formula CLXXVI compound.This alcohol is then oxidized to the corresponding formula CLXXXVI ketone (e.g., by methods described above for the preparation of the formula CLXXXII compound from the formula CLXXXI compound) or dehydrated to yield the formula CLXXXVIII compound. Such dehydrations proceed by methods known in the art and include first preparing the mesylate corresponding to the formula CLXXXV compound following by treatment with base.
Thereafter, the formula CLXXXVI or CLXXXVIII compound is transformed, respectively, to the formula CLXXXVII or CLXXIX compound by methods hereinafter described.
Finally, the formula CLXXXIX compound thusly prepared is dehydrogenated to yield the formula
CXC compound by conventional means, e.g., catalytic dehydrogenation (palladium-on-carbon catalyst) or treatment with DDQ (2,3-dichloro-S,6-dicyano-1 ,4-benzoquinone).
Chart R provides a method whereby the C-9 epimeric forms of compounds prepared according to
Chart P are prepared. With respect to Chart R, the formula CXCI aldehyde, prepared as the formula
CLXXXII compound of Chart Q is isomerized by treatment under basic conditions (i.e., the use of an
organic base such as 1 ,8-diazobicyclo[5.4.O]-undec-7-ene in an organic solvent (e.g., methylene
chloride)). Thereafter this 9paldehyde is reduced to the corresponding formula CXCIII alcohol by
treatment with a suitable reducing agent, such as borohydride reducing agent. (e.g., sodium, lithium, or
potassium borohydride).Thereafter, the formula CXCIII alcohol thusly prepared is transformed to the
corresponding 9,B-CBA analogs by methods described in Chart P, e.g., the transformation of the formula
CLXXIII to the formula CLXXVIII compound.
Optionally, the various formula XI CBA analogs prepared according to Charts P, Q, and R are
prepared by the procedure of Chart S. The procedure of Chart S employs the formula CCI starting
material described in Chart P which is thereafter converted to the formula CCII compound prepared in
accordance with methods described for the preparation of the formula CLXXVI II compound from the formula CLXXI compound of Chart P, the formula CLXXXVII, formula CLXXXIX, formula CXC compounds from the formula CLXXXI compound of Chart Q and the formula CXCIV compounds from the formula CXCI compound of Chart R.The formula CCII compound thusly prepared is then transformed to the formula CCIII compounds by methods hereinabove described, e.g., the transformation of the formula LXXI compound to the formula LXXIII compound of Chart F.
Chart T provides a preferred method whereby the 9-deoxo-2',9-metheno-3-oxa-4,5,6-trinor-3,7- (1 ,3-inter-phenylene)-PGE1 compounds of formula CCXIII are prepared. In accordance with Chart T the formula CCXI compound, prepared as the formula CLXXXIII compound of Chart Q, is treated with a methyl Grignard reagent, methyl magnesium bromide and heated at reflux in an organic solvent (e.g., glyme).
The formula CCXI I thusly prepared is then transformed to the formula CCXIII product by the method described in Chart P for the preparation of the formula CLXXVIII product from the formula
CLXXVI phenol intermediate.
Chart U provides a convenient method whereby formula XI compounds wherein Y1 is trans
CH=CH-, the formula CCXXI compound of Chart U, are transformed to corresponding formula CCXXII
aldehyde intermediates. This transformation is accomplished by ozonolysis by methods otherwise
known in the art.
The formula CCXXI I intermediate is then conveniently transformed to various formula Xl products
(the Formula CCXXIII compound of Chart U) by methods described above, i.e., reaction of the formula
CCXXII compound with the appropriate Wittig reagent followed by reduction and hydrolysis.
Accordingly by the procedure described in Chart U the C-i 2 side chains of the various formula CCXXI
compounds is conveniently modified by the formula CCXXI I aldehyde intermediates. As discussed
above, the processes herein described lead variously to carboxylic acids (X1 is -COOR1 and R1 is
hydrogen) or to esters or primary alcohols (X1 is -CH2OH).
When the alkyl ester has been obtained and an acid is desired, saponification procedures, as
known in the art for PGF-type compounds are employed.
When the acid has been prepared and an alkyl, cycloalkyl, or aralkyl ester is desired, esterification
is advantageously accomplished by interaction of the acid with appropriate diazohydrocarbon. For
example, when diazomethane is used, the methyl ester is produced. Similar use of diazoethane,
diazobutane, and 1-diazo-2-ethylhexane, and diazodecane, for example, gives the ethyl, butyl, and 2
ethylhexyl and decyl esters, respectively. Similarly, diazocyclohexane and phenyldiazomethane yield
cyclohexyl and benzyl esters, respectively.
Esterification with diazohydrocarbons is carried out by mixing a solution of the diazohydrocarbon
in a suitable inert solvent, preferably diethyl ether, with the acid reactant, advantageously in the same or
a different inert diluent. After the esterification reaction is complete the solvent is removed by evaporation, and the ester purified if desired by conventional methods, preferably by chromatography. It is preferred that contact of the acid reactants with the diazohydrocarbon be no longer than necessary to effect the desired esterification, preferably about one to about 10 min, to avoid undesired molecular changes. Diazohydrocarbons are known in the art or can be prepared by methods known in the art. See, for example, Organic Reactions, John Wiley and Sons, Inc., New York, N.Y., Vol. 8, pp. 389-394 (1954).
An alternative method for alkyl, cycloalkyl or aralkyl esterification of the carboxy moiety of the acid compounds comprises transformation of the free acid to the corresponding substituted ammonium salt, followed by interaction of that salt with an alkyl iodide. Examples of suitable iodides are methyl iodide, ethyl iodide, butyl iodide, isobutyl iodide, tert-butyl iodide, cyclopropyl iodide, cyclopentyl iodide, benzyl iodide, phenethyl iodide, and the like.
Various methods are available for preparing phenyl or substituted phenyl esters within the scope of the invention from corresponding aromatic alcohols and the free acid, differing as to yield and purity of product.
With regard to the preparation of the phenyl, particularly p-substituted phenyl esters disclosed herein (i.e., X1 is -COO R1 and R1 is p-substituted phenyl), such compounds are prepared by the method described in U.S. Patent No. 3,890,372. Accordingly, by the preferred method described therein, the psubstituted phenyl ester is prepared first by forming a mixed anhydride, particularly following the procedures described below for preparing such anhydrides as the first step in the preparation of amido and cycloamido derivatives.
This anhydride is then reacted with a solution of the phenol corresponding to the p-substituted phenyl ester to be prepared. This reaction proceeds preferably in the presence of a tertiary amine, such as pyridine. When the conversion is complete, the p-substituted phenyl ester has been recovered by conventional techniques.
A preferred method for substituted phenyl esters is that disclosed in U.S. Patent No. 3,890,372 in which a mixed anhydride is reacted with an appropriate phenol or naphthol. The anhydride is formed from the acid with isobutylchloroformate in the presence of a tertiary amine.
Phenacyl-type esters are prepared from the acid using a phenacyl bromide, for example, p
phenylphenacyl bromide, in the presence of a tertiary amine. See, for example, U.S. Patent No.
3,984,454, German Offenlegungsschrift 2,535,693, and Derwent Farmdoc No. 1 6828X.
Carboxyamides (X1 is -COL4) are prepared by one of several amidation methods known in the
prior art. See, for example, U.S. Patent No. 3,981,868, issued 21 September 1976 for a description of the preparation of the present amido and cycloamido derivatives of prostaglandin-type free acids and
U.S. Patent No. 3,954,741 describing the preparation of carbonylamido and sulfonylamido derivatives of prostaglandin-type free acids.
The preferred method by which the present amido and cycloamido derivatives of the acids are prepared is, first, by transformation of such free acids to corresponding mixed acid anhydrides. By this procedure, the prostaglandin-type free acid is first neutralized with an equivalent of an amine base, and thereafter reacted with a slight stoichiometric excess of a chloroformate corresponding to the mixed anhydride to be prepared.
The amine base preferred for neutralization is triethylamine, although other amines (e.g., pyridine, methyldiethylamine) are likewise employed. Further, a convenient, readily available chloroformate for
use in the mixed anhydride production is isobutyl chloroformate.
The mixed anhydride formation proceeds by conventional methods and accordingly the free acid is
mixed with both the tertiary amine base and the chloroformate in a suitable solvent (e.g., aqueous tetrahydrofuran), allowing the reaction to proceed at --100C to 200 C.
Thereafter, the mixed anhydride is converted to the corresponding amido or cycloamido derivatives by reaction with the amine corresponding to the amide to be prepared. In the case where the simple amide (-NH2) is to be prepared, the transformation proceeds by the addition of ammonia.
Accordingly, the corresponding amine (or ammonia) is mixed with the mixed anhydride at or about -10 to + 1 O0C, until the reaction is shown to be complete.
Thereafter, the novel amido or cycloamido derivative is recovered from the reaction mixture by conventional techniques.
The carbonylamido and sulfonylamido derivative of the presently disclosed PG-type compounds
are likewise prepared by known methods. See, for example, U.S. Patent No. 3,954,741 for description of the methods by which such derivatives are prepared. By this known method the acid is reacted with a carboxyacyl or sulfonyl isocyanate, corresponding to the carbonylamido or sulfonylamido derivative to
be prepared.
By another, more preferred method the sulfonylamido derivatives of the present compounds are prepared by first generating the PG-type mixed anhydride, employing the method described above for the preparation of the amido and cycloamido derivatives. Thereafter, the sodium salt of the corresponding sulfonamide is reacted with the mixed anhydride and hexamethylphosphoramide. The pure PG-type sulfonylamido derivative is then obtained from the resulting reaction mixture by conventional techniques.
The sodium salt of the sulfonamide corresponding to the sulfonylamido derivative to be prepared is generated by reacting the sulfonamide with alcoholic sodium methoxide. Thus, by a preferred method
methanolic sodium methoxide is reacted with an equal molar amount of the sulfonamide. The sulfonamide salt is then reacted, as described above, with the mixed anhydride, using about four equivalents of the sodium salt per equivalent of anhydride. Reaction temperatures at or about OOC are employed.
The compounds of this invention prepared by the processes of this invention, in free acid form, are transformed to pharmacologically acceptable salts by neutralization with appropriate amounts of the corresponding inorganic or organic base, examples of which correspond to the cations and amines listed hereinabove. These transformations are carried out by a variety of procedures known in the art to be generally useful for the preparation of inorganic, i.e., metal or ammonium salts. The choice of procedure depends in part upon the solubility characteristics of the particular salt to be prepared. In the case of the inorganic salts, it is usually suitable to dissolve an acid of this invention in water containing the stoichiometric amount of a hydroxide, carbonate, or bicarbonate corresponding to the inorganic salt desired.For example, such use of sodium hydroxide, sodium carbonate, or sodium bicarbonate gives a solution of the sodium salt. Evaporation of the water or addition of a water-miscible solvent of moderate polarity, for example, a lower alkanol or a lower alkanone, gives the solid inorganic salt if that form is desired.
To produce an amine salt, an acid of this invention is dissolved in a suitable solvent of either moderate or low polarity. Examples of the former are ethanol, acetone, and ethyl acetate. Examples of the latter are diethyl ether and benzene. At least a stoichiometric amount of the amine corresponding to the desired cation is then added to that solution. If the resulting salt does not precipitate, it is usually obtained in solid form by evaporation. If the amine is relatively volatile, any excess can easily be removed by evaporation. It is prefered to use stoichiometric amounts of the less volatile amines.
Salts wherein the cation is quaternary ammonium are produced by mixing an acid of this invention with the stoichiometric amount of the corresponding quaternary ammonium hydroxide in water solution, followed by evaporation of the water.
The present invention is more completely understood by the operation of the following examples:
EXAMPLE 1 3-oxo-7ez-tetrahydropyran-2-yloxy-6p(3' S)-3'-tetrahydropyran-2-yloxy-trans- 1 '-octenyl]bicyclo[3.3.0]-oct-1 -ene (Formula XXIV: R18 is tetrahydropyranyloxy; Y1 is trans-CH=CH-, M6 is atetrahydropyranyloxy: pH L1 is -H:,B-H, R27 is n-butyl; and n is the integer one).
Refer to Chart A.
A. To a stirred solution of 19 ml (1 70 mmoles) dimethyl methylphosphonate and 600 ml of dry tetrahydrofuran at -780C under an argon atmosphere is added dropwise over 5 min 110 ml (172 mmoles) of 1.56 M n-butyllithium in hexane. The resulting solution is stirred for 30 min at --780C, treated with 25.4 g of 3a,5a-dihydrnxy-2p(3 a-hydroxy-trans- 1 -octenyl)- 1 -cyciopentaneacetic acid, lactone, bis(tetrahydropyranyl)ether, in 100 ml of dry tetrahydrofuran dropwise over one hr, and stirred for one hr at -780C and four hr at room temperature. The reaction is then quenched by addition of 10 ml glacial acetic acid, diluted with 700 ml of brine, and extracted with diethyl ether (3 x 700 ml).The combined ethereal layers are washed with 200 ml bicarb and 500 ml brine and dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield 37 g of formula XXII compound as an oily white solid: 3-di methylphosphonomethyl-3-hydroxy-2-oxa-7 a-tetrahydrnpyrnn-2-yloxy-6J3[(3' S)- 3'-tetrahydropyran-2-yloxy-trans-1 '-octenyl]-bicyclo[3.3.0]octane. Crystallization of the crude product from hexane and ether yields 22.1 g of purified formula XXII produce. Silica gel TLC Rf is 0.22 in ethyl acetate. The melting range is 89-930C. NMR absorptions are observed at 3.72 (doublet, J=1 1 Hz) and 3.83 (doublet, J=1 1Hz)S. Characteristic infrared absorptions are 3340, 1250, 1185, 130, 1075, and 1030 cm-1.
B. To a solution of 10.0 g of the product of Part A in 75 ml acetone stirring under a nitrogen atmosphere at --100C is added over 30 min 9.0 ml of Jones reagent. The resulting suspension is stirred for 30 min at --1 OOC and then quenched with 4 ml 2-propanol. The solvents are decanted away from the green residue and most of the acetone removed at reduced pressure. The acetone concentrate is then taken up in ethyl acetate and washed with saturated aqueous sodium bicarbonate and then with brine and dried over anhydrous sodium sulfate. Concentration under reduced pressure yields 8.2 g of formula XXI II product: 2-decarboxy-6-desbutyl-6-dimethylphosphonomethyl-6-keto-PGE1,11,15- bis(tetrahydropyranyl ether).Chromatography of formula XXIII product on 600 g silica gel eluting with 20% acetone in methylene chloride yields 4.95 g of pure formula XXIII product. Silica gel TLC RF (in 20% acetone in methylene chloride) is 0.22. Characteristic NMR absorptions are observed at 3.14 (doublet,
J=23 Hz) and 3.80 (doublet, J=1 Hz), 5.4-5.8 (m)a. Characteristic infrared absorptions are observed at1745,1715,1260,1200,1185,1130,1030,970,870cm-1.
C. A suspension of 5.37 g of the product of Example 1, Part B, 1.33 g anhydrous potassium carbonate, and 5.37 g 18-Crown-6 ether in 200 ml toluene is heated at 750C for six hr under a nitrogen atmosphere, cooled to OOC, and washed with 200 ml brine, 200 ml of 3:1 water:brine, and 200 ml brine, and dried over anhydrous sodium sulfate. Most of the solvents are removed under reduced pressure and the residue is filtered through 50 g silica gel eluting with 250 ml ethyl acetate to give 3.9 g of formula XXIV product: 3-oxo-7 a-tetrahydrnpyranyl-2-yloxy-6[(3' S)-3'-tetrahydropyran-2-y - trans-1 '-octenyl]bicyclo[3.3.0]oct-1 -ene. The crude product is chromatographed on 300 g silica gel eluting with 60:40 hexane:ethyl acetate to give 2.39 g of pure title product. Silica gel TLC Ff is 0.22 in 60:40 hexane:ethyl acetate. NMR absorptions are observed at 5.1 8-5.86 (m) and 5.94 (broad singlet)3. Infrared absorptions are observed at 1710 and 1632 cm~1.
Following the procedure of Example 1, but employing the various 3a,5a-hydroxy-2-substituted1 a-cyclopentaneacetic acid 6lactones of formula XXI, there are prepared each of the various corresponding formula XXIV products wherein n is one.
Further, following the procedure of Example 1, but employing each of the various 3a,5a- dihydroxy-2-substituted-1 ct-cyclopentanepropionic acid, lactones of formula XXI, there are prepared each of the various formula XXIV compounds wherein n is 2.
Further, following the procedure of Example 1, but employing each of the various 5a-hydroxy-2- substituted-l a-cyclopentanealkanoic acid lactones of formula XXI, there are prepared each of the various formula XXIV compounds wherein R18 is hydrogen. Finally, following the procedure of Example, 1 but employing each of the various 3a-hydroxymethyl-Sa-hydroxy-2-substituted-1 acyclopentanealkanoic acid lactones of formula XXI, there are prepared each of the various formula XXIV compounds wherein R18 is -CH2OR10.
EXAMPLE 2 3-oxo-8 < x-tetrahydropyra n-2-yloxy-7/3[(3'S)-3'-tetrahydropyran-2-yloxy-trans- 1'- octenyl]bicyclo[4.3.0]non-1 -ene (Formula XXIV: R18,Y1, M6, R7 are defined in Example 1 and n is the integer 2).
Refer to Chart A.
A. A solution of 2.05 ml (18.9 mmoles) of dimethyl methylphosphonate and 100 ml of dry tetrahydrofuran is stirred at -780C under a nitrogen atmosphere and treated dropwise with 11.8 ml (18.9 mmoles) of 1.6 molar n-butyllithium in hexane. After stirring for 30 min at -780C, the resulting mixture is treated dropwise over 25 min with 4.25 g of 3α,5α-dihydroxy-2ss-(3α-hydroxy-trans-1- octenyl) 1 a-cyclopentane propionic acid, #-lactone, 11,15-bis(tetrahydropyranl ether), in 30 ml of dry tetrahydrofuran. The resulting mixture is then stirred for one hr at 780C. The solution is then allowed to stir at ambient temperature for 2 hr and is quenched by addition of 1.2 ml of acetic acid.The mixture is then added to 250 ml of brine and 200 ml of diethyl ether. The aqueous and organic layers are then separated and the aqueous layer extracted twice with diethyl ether. The ethereal extracts are then washed with brine, dried over anhydrous sodium sulfate, and concentrated to yield 5.6 g of crude formula XXII compound, as an oil: 3-(dimethylphosphonomethyl)-3-hydroxy-2-oxa-8a-tetrahydropyran-2-yl-oxy-7ss[(3'S)-3'-tetrahydropyran-2-yloxy-trans 1'-octenyl]-bicyclo[4.3.0]nonane.
Chromatography on silica gel eluting with 4:1 ethyl acetate:acetone yields 4.1 g of purified formula XXII product. Characteristic NMR absorption is observed at 5.15-5.65 [multiplet)#. Silica gel TLC Rf is 0.34 in 4:1 ethyl acetate:acetone. Characteristic infrared absorptions are observed at 3350, 1235, and 1030 cm-1.
B. A suspension of 3.42 g of chromium trioxide and 80 ml of methylene chloride is treated with 5.8 ml of pyridine, stirred at ambient temperature under a nitrogen atmosphere for 30 min, and combined with 3 scoops of dry diatomaceous earth. The resulting mixture is then treated with 3.25 g of the reaction product of Part A and 8 ml of dry dichloromethane, stirred for 30 min at ambient temperature under nitrogen, filtered through 30 g of silica gel (eluting with 200 ml of ethylacetate and acetone, 2:1) and concentrated under reduced pressure. Chromatographing the residue (3.73 g) on 120 g of silica gel, eluting with ethyl acetate and acetone (4:1) yields 2.07 g of formula XXI II product: 2-decarboxy-5-despropyl-6-dimethylphosphonomethyl-S-keto-PGE1, E1,11,15-bis(tetrahydropyranyà ether).Characteristic infrared absorptions are observed at 1 740 and 1 71 5 cm-l.
Characteristic NMR absorptions are observed at 3.1 (doublet, J=23 Hz) and 3.8 (doublet, J=1 1 Hz)S.
C. A suspension of 12 mg of 50% sodium hydride in mineral oil and 3 ml of diglyme is stirred at OOC. under an argon atmosphere. The suspension is then treated with 1 50 mg of the product of Part B in 3 ml of diglyme. After 1 hr, the cooling bath is removed and the resulting solution is stirred at ambient temperature under argon. After a total of 20 hr from addition of the formula XXIII reactant, the resulting solution is then added to 30 ml of water and extracted with 90 ml of diethyl ether. The ethereal extract is washed with brine (30 ml), dried over anhydrous sodium sulfate, concentrated under reduced pressure to a brown oil (110 mg) and chromatographed on 10 g of silica gel eluting with hexane and ethyl acetate (1 :1).There is accordingly prepared 1 5 mg of formula XXIV compound: 3-oxo-8- tetrahydropyran-2-yloxy-7ss-[(3'S)-3'-tetrahydropyran-2-yloxy-trans-1'-octenyl]bicyclo[4.3.0]non-1ene. NMR absorptions are observed at 4.7 (broad singlet) and 5.3-6.0 (multiplet)#. IR absorption is observed at 1670 cm-'.
Alternatively, the formula XXIV compound above is prepared as follows:
A solution of 1 50 mg of the product of Part B and 5 ml of dry tetrahydrofuran at 0 C under an argon atmosphere is treated dropwise with 0.5 ml of 0.52 M potassium hydride and 1 8-crown-6 ether (Aldrich Chemical Co. Catalog Handbook of Fine Chemicals 1 979-1 980, Milwaukee, Wisconsin, p.
133; Pedersen, J.C. JACS 92:386 (1970)) in tetrahydrofuran (prepared from 800 mg potassium hydride and 1.0 g 18-crown-6 ether in 8.7 ml of dry tetrahydrofuran). After stirring for one hr at 0 C under argon, the mixture is added to 30 ml of water, extracted with 90 mg of diethyl ether and the ethereal extract is washed with brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and chromatographed on 9 g of silica gel eluting with ethyl acetate and hexane. Formula XXIV product (40 mg) is thereby obtained. Silica gel TLC Rf is 0.30 in ethyl acetate and hexane (1:1).
EXAMPLE 3 1,B-Methyl-3-oxo-7 -tetrahydropyran-2-yl-oxy-6p-[(3' S)-3'-tetrahydropyran-2-yloxy-trans- 1 "-octenyl]- bicyclo-[3.3.0]octane (Formula XXV: R,8, Y1, M6, n, L1, R7 are as defined in Example 1, R,6 is hydrogen and R37 is methyl).
Refer to Chart A.
A suspension of 2.70 g of anhdrous copper iodide is stirred in 100 ml of anhydrous diethyl ether at -200C under an argon atmosphere and is treated dropwise with 20.0 ml of 1.4 M ethereal methyllithium. The resulting solution is then stirred for 1 5 min at -2O0C and treated over 2.5 hr at -200C with a solution of 2.00 g of the title product of Example 1 in 100 ml of anhydrous diethyl ether.
Stirring is continued for an additional 1.5 hr at -200C and the resulting mixture added to 200 ml of 1 M aqueous ammonium chloride. The aqueous and organic layers are then separated and the aqueous layer extracted with diethylether (400 ml). The combined organic extracts are then washed with 200 ml of brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure to yield 2.4 g of title product as a pale green oil. Chromatography on 25 g of silica gel eluting with hexane in ethyl acetate (3:1) yields 2.0 g of title product as a colorless oil.Characteristic NMR absorptions (CDCl3) are observed gt 1.18, 3.20-4.43, 4.70, and 5.25.9S. Characteristic infrared absorptions are observed at 1745, 1 665, 1200, 1130, 1110, 1075, 1035, 1020, 980, and 870 cm~1. Silica gel Rf is 0.26 in ethyl acetate and hexane (1:3).
By procedures known in the art, each of the various novel formula XXV intermediates is transformed to a 9pmethyl-CBA2 or CBA1 compound by methods exemplified hereinafter or known from British Published Specifications 2,013,661, 2,014,143, and 2,017,699.
EXAMPLE 4
5-Carboxypentanol, t-butyldimethylsilyl ether
A solution of 4 g of sodium hydroxide in 100 ml of methanol and water (4:1) is treated with 10 ml of caprolactone and stirred at ambient temperature under a nitrogen atmosphere. After 20 hr, solvent is evaporated following addition of toluene, yielding 1 5 g of solid, crude 5-carboxypentanol.
The above solid is suspended in 300 ml of dimethylformamide under a nitrogen atmosphere, cooled to OOC, treated with 35 g of imidazole, stirred for 1 5 min at OOC and 1 5 min at ambient temperature, cooled to OOC and treated with 39 g of t-butyldimethyl silylchloride. The resulting solution is then allowed to warm to ambient temperature under a nitrogen atmosphere. After 26 hr, the resulting solution is treated with 8 g of sodium hydroxide in 40 ml of water and 40 ml of methanol, with stirring maintained under a nitrogen atmosphere. After 13 hr, the suspension is acidified to pH 4 with 500 ml of
1 N aqueous hydrogen chloride, then saturated with sodium chloride and extracted with ethyl acetate.
The ethyl acetate extracts are then washed with 1 N aqueous sodium hydroxide. The basic extracts are then acidified to pH 4 with concentrated hydrochloric acid, saturated with brine, and extracted with ethyl acetate. The ethyl acetate extracts are then washed with brine, dried over sodium sulfate, and
concentrated under reduced pressure to yield 22.6 of a yellow liquid, 5-carboxypentanol,
t-butyldimethylsilyl ether. Chromatography on 800 g of silica gel eluting with ethyl acetate and hexane
(1:9 to 1:1) yields 14.8 g of 5-carboxypentanol, t-butyldimethylsilyl ether. NMR absorptions are observed at 0.05 (singlet) and 0.90 (singlet)b. Infrared absorptions are observed at 3000 (broad) and 1700 cm-1.
Following the procedure of Example 4, but employing each of the various lactones corresponding to the e.)-carboxyalkanol compounds of formula XXXI I there are prepared each of the various formula XXXI I products.
EXAMPLE 5 2-Decarboxy-2-(t-butyldimethylsilyloxy)methyl-5-carboxy-6-hydroxy-9,B-methyl-CBA" 11,15 bis(tetrahydropyran)ether (Formula XXXIII: R28 is t-butyldimethylsilyl, Z2 is -(CH2)3-, n is 1, and Err6, R,8, R37, M6, L1, and R4 are as defined in Example 3).
Refer to Chart B.
A solution of 0.58 ml of dry diisopropylamine and 20 ml of dry tetrahydrofuran at OOC under an argon atmosphere is treated with 2.6 ml of 1.56 M n-butyllithium in hexane, stirred for 5 to 10 min at OOC, treated with 0.50 g of the title product of Example 4 in 5 ml of tetrahydrofuran, stirred for 1 5 min at 0 C and 1 hr at ambient temperature, cooled to OOC, treated with 0.91 g of the title product of
Example 3 in 5 ml of tetrahydrofuran, and allowed to slowly warm to ambient temperature under an argon atmosphere. Thereafter, 130 ml of water and 20 ml of brine are added and the mixture extracted with diethyl ether. The ethereal extracts are then washed with 4 ml of 1 N aqueous hydrochloric acid and 1 50 ml of brine and dried over sodium sulfate, and concentrated under reduced pressure to yield title product
Following the procedure of Example 5, but employing each of the various formula XXXI
compounds described following Example 1, there are prepared each of the various formula XXXIII
compounds wherein R28 is t-butyldimethylsilyl and Z2 is -(CH2)3-.
EXAMPLE 6 2-Decarboxy-2-(t-butyldimethylsilyloxy) methyl-9p-methyl-CBA2 11,1 5-bis-(tetrahydropyranylether) (Formula XXXIV: R2s,Z2, n, R18,Y1, M6, L1 and R7 are as defined for Examples 1 and 5).
The reaction product of Example 5 (1.37 g) and 16 ml of methylene chloride is treated with 2.9 ml of dimethylformamide dineopentyl acetal, stirred for 3 hr at ambient temperature under nitrogen, added to 160 ml of ice water and 40 ml of brine, and extracted with diethyl ether. The ethereal extracts are then washed with 1 50 ml of sodium bicarbonate and 1 50 ml of brine, dried over sodium sulfate, and concentrated under reduced pressure to yield crude title product. Chromatography on 100 g of silica gel eluting with 10% ethyl acetate in hexane yields pure title product.
Following the procedure of Example 6, but employing each of the various formula XXXIII compounds described following Example 5, there are prepared each of the various corresponding formula XXXIV products wherein R28 is t-butyldimethylsilyl and Z2 is -(CH2)3-.
EXAMPLE 7 2-Decarboxy-2-hydrnxymethyl-9p-methyl-CBA 111 5-bis(tetrahydropyranyl)ether (Formula XXXV: Z n, R,6, R37, R,8, Y1, M6, L1, and R7 are as defined in Examples 1 and 5).
Refer to Chart B.
A solution of 0.71 g of the title product of Example 6 and 1 6 ml of dry tetrahydrofuran at OOC under a nitrogen atmosphere is treated with 3.2 ml of 0.75 molar tetra-n-butylammoniumfluoride and tetrahydrofuran. After allowing the reaction mixture to slowly warm to ambient temperature overnight with stirring, 1 50 ml of brine is added and the resulting mixture extracted with ethyl acetate. The ethyl acetate extracts are then washed with 0.5 N aqueous potassium bisulfate, 100 ml of sodium bicarbonate, and 100 ml of brine, dried over sodium sulfate, and concentrated under reduced pressure to yield crude title product. Filtering through 25 g of silica gel with 200 ml of ethyl acetate and hexane yields 0.61 g of further purified product. Chromatography on silica gel eluting with 35% ethyl acetate in hexane yields pure title product.
Following the procedure of Example 7, but employing each of the various formula XXXIV compounds described in and following Example 6, there are prepared each of the various formula XXXV compounds wherein Z2 is -(CH2)3-.
Following the procedure of Examples 5, 6, and 7, and employing the various starting materials described in and following these examples and each of the various formula XXXI I compounds described in and following Example 4, there are prepared each of the various formula XXXV compounds.
EXAMPLE 8 2-Deca rboxy-2-hydrnxymethyl-9pmethyl-CBA2 (Formula XXXVI: X1 is -CH2OH, Z2 is -(CH2)3-, R8 is
hydroxy, Y, is trans-CH=CH--, M, is (r-OH:/3-H, L, is ct-H:P-H and R7 is n-butyl).
Refer to Chart B
The title product of Example 7 (0.25 g) is combined with 9 ml of acetic acid, water and tetrahydrofuran (6:3:1) and heated to 37-4O0C for two hr. Thereafter the resulting mixture is cooled and extracted with diethyl ether. The ethereal extracts are then washed with brine, dried over sodium sulfate and concentrated to yield crude title product. Chromatography on silica gel yields pure title product.
Following the procedure of Example 7, but employing each of the various formula XXXV primary alcohols described in and following Example 7 there are prepared each of the various corresponding formula XXXVI products wherein X1 is -CH2OH.
EXAMPLE 9 o-(t-Butyldimethylsilyloxyethyl)benzaldehyde (Formula XLIV: R28 is t-butyldimethylsilyloxy and g is one).
Refer to Chart C.
A. To a mixture of 7.6 g of lithium aluminum hydride and 400 ml of dry tetrahydrofuran under a nitrogen atmosphere is added dropwise with stirring 1 8 g of homophthalic acid (Aldrich Chemical
Company) in 250 ml of dry tetrahydrofuran. Dropwise addition rate is adjusted such that mild reflux is maintained during the course of the exothermic reaction. The resulting mixture is then heated at reflux for 5 hr, cooled to OOC, and 7.6 g of water in 50 ml of tetrahydrofuran is added dropwise with stirring.
Thereafter 27 ml of 10% aqueous sodium hydroxide is added and the resulting mixture is stirred at ambient temperature for 20 min, filtered, and the filter solids washed with 1 50 ml of tetrahydrofuran.
The filtrate and tetrahydrofuran wash are then concentrated under reduced pressure to yield 14.0 g of crude formula XXXI I diol, 2-(o-hydroxymethylphenyl)ethanol. Chromatography on 1.2 kg of silica gel, deactivated by addition of 240 ml of ethyl acetate, eluting with ethyl acetate, yields 1 3.5 g of formula
XLII product. Melting range is 41 .5-430C.
B. To a solution of 13.5 g of the reaction product of Part A in 50 ml of dry tetrahydrofuran under a nitrogen atmosphere is added with stirring 9.05 g of imidazole. The resulting solution is then cooled to -50C and 13.9 g of t-butyldimethylsilyl chloride is added. The resulting mixture is then maintained for 20 min and thereafter allowed to warm to ambient temperature. After 1 hr, the resulting mixture is then shaken with 500 ml of hexane and diethylether (2:1) and 250 ml of water and brine (1:1). The organic layer is then washed with water and brine, dried over magnesium sulfate, and concentrated under reduced pressure to yield a crude mixture of mono- and bis-silyl ethers corresponding to the starting material of Part A.This mixture of products is then chromatographed on 2 kg of silica gel, deactivated with 400 ml of ethyl acetate and eluted with 25% ethyl acetate and Skellysolve B to yield 6.82 g of formula XLIII product, o-(t-butyldimethylsilyloxyethyl)phenylmethanol. NMR absorptions are observed at 7.20--7.52, 4.57, 3.91 (t, J G.1), 2.93 (t, J 6.1), 0.82, and -0.086. Silica gel TLC Rf is 0.54 in 25% ethyl acetate and hexane.
C. A mixture of 5.0 g of the reaction product of Part B, 100 ml of trichloromethane, and 25 g of activated manganese dioxide (MnO2) is stirred at ambient temperature for 4 hr. Chloroform (100 mi) is then added and the resulting mixture filtered through diatomaceous earth. After washing filter solids with 200 ml of trichioromethane, the resulting filtrate and wash is then concentrated under reduced pressure to yield a residue containing title product. Chromatography on 400 g of silica gel, deactivated
with 80 ml of ethyl acetate and elution with 25% ethyl acetate and hexane yields 2.93 g of pure title product. Silica gel TLC Rf is 0.74 in 25% ethyl acetate and hexane.NMR absorptions are observed at 10.34, 7.25-8.00, 3.89 (t, J 6.0), 3.27 (t, J 6.0), 0.83 and -0.096. The mass spectrum exhibits a peak at 265 (M+1) and other peaks of decreasing intensity at m/e 75, 207, 73, 133, 223, 208, 77, 177, 76 and 105.
Following the procedure described in Chart C, but employing each of the various formula XXXI acids, there is prepared each of the various corresponding formula XXXIV aldehydes wherein R28 is t butyldimethylsilyl.
EXAMPLE 10 m-(t-butyldimethylsilyloxymethyl)benzaldehyde (Formula XLIV: g is zero and R28 is t-butyldimethylsilyl).
Refer to Chart C.
A. To a solution of 10.0 g of m-(hydroxymethyl)phenylmethanol in 40 ml of dry tetrahydrofuran under a nitrogen atmosphere is added with stirring 7.35 g imidazole. The resulting solution is then cooled to OOC and 11.3 g of t-butyldimethylsilyl is added. The resulting mixture is then stirred with cooling for 1 5 min and thereafter allowed to warm to ambient temperature. After 90 min, the resulting mixture is then shaken in 400 ml of hexane and diethyl ether (2:1) and 200 ml of water and brine (1:1).
The organic layer is then washed successively with water and brine (1:1, 300 ml) and brine (150 ml), dried over magnesium sulfate and concentrated under reduced pressure to yield a mixture of mono- and bis-t-butyldimethylsilyloxy ether corresponding to the formula XXXII compound. This mixture of products is then chromatographed on 1.4 kg of silica gel, deactivated by addition of 280 ml of ethyl acetate and eluted with 2540% ethyl acetate in hexane to yield 7.65 g of pure formula XLI II product, m-(t-butyldimethylsilyloxymethyl)phenylmethanol. Silica gel TLC Rf is 0.46 in 25% ethyl acetate and hexane.NMR absorptions are observed at 7.25, 4.72, 4.60, 2.23, 0.92, and 0.098. The mass spectrum exhibits a peak at 251 (M+ -1) and other peaks of decreasing intensity at m/e 235, 121, 195,237, 105, 133, 75, 89,236, and 119.
B. A mixture of 5.0 g of the reaction product of Part A and 100 ml of trichloromethane and 25 g of activated manganese dioxide (MnO2) is stirred at ambient temperature for 4 hr. Chloroform (100 ml) is then added and the resulting mxiture filtered through diatomaceous earth. The filter solids are washed with 200 ml of trichloromethane and the filtrate and trichloromethane wash are then concentrated under reduced pressure to yield 5.2 g of crude title product. Chromatography on 400 g of silica gel, deactivated with 80 ml of ethyl acetate and elution with ethyl acetate and hexane (1:3) yields 3.65 9 of pure title product. Silica gel TLC Rf is 0.46 in 10% ethyl acetate and hexane. NMR absorptions are observed at 10.00, 7.26-7.86,4.81,0.95, and 0.11 gs.
EXAMPLE 11 3-P henylsu lfonyl-7 α-tetrahydropyran-2-yloxy-8 -[(3'S)-3'-tetrahydropyran-2-yloxy-trans- 1 '-octenylj- bicyclo-[3.3.0]octane (Formula LV: n is the integer one, R,8 is tetrahydropyranyloxy, Y, is trans
CH=CH-, M6 is α-tetrahydropyranyloxy : -hydrogen, L is cr-hydrogen:p-hydrogen, R,6 and R17 are both hydrogen, and R27 is n-butyl).
Refer to Chart D.
A. Sodium borohydride (0.38 g) is added with stirring to a solution of 2.90 g of 3-oxo-7a- tetrahydropyran-2-yloxy-6,B-[(3' S)-3'-tetrahydropyran-2-yloxy-trans- 1 '-octenyl]-bicyclo[3.3.0]octane in 25 ml of 95% aqueous ethanol. The resulting mixture is then stirred at ambient temperature for 20 min.
Thereafter the resulting mixture is shaken in 100 ml of brine and 200 ml of ethyl acetate. The organic
layer is then immediately washed in brine, dried over magnesium sulfate, and concentrated under
reduced pressure to yield 2.94 g of formula LII alcohol: (3RS)-3-hydroxy-7a-tetrahydropyran-2-yloxy- 6,B-[(3 'S)-3'-tetrahydropyran-2-yloxy-trans- 1 '-octenyl]bicyclo[3.3.0]-octane. Infrared absorptions are observed at 3600 and 3450 cam~' and no carbonyl absorption. Silica gel TLC Rf is 0.63 and 0.67 in ethyl acetate and hexane (1 :1).
B. To a solution of 2.9 g of the reaction product of Part A in 25 ml of dry dichloromethane and 1.4 ml (1.02 g) of triethylamine at OOC is added with stirring 0.57 ml (0.848 g) of methanesulfonyl chloride over 5 min. The resulting mixture is then stirred an additional 20 min and shaken with 1 60 ml of diethyl ether and 80 ml of cold (OOC) dilute aqueous hydrochloric acid. The organic layer is then washed successively in brine, dilute aqueous potassium bicarbonate, and brine, dried over sodium sulfate, and concentrated under reduced pressure to yield 3.5 g of crude formula LIII compound: (3RS)-3-hydroxy 7a-tetrahydrnpyran-2-yloxy-6p-[(3'S)-3'-tetrahydrnpyran-2-yloxy-trans- 1 '-octenyl]bicyclo [3.3.0]octane, 3-methylsulfonate.
C. Thiophenol (1.13 ml, 1.21 g) is added to a mixture of 1.12 g of potassium t-butoxide in 15 ml of dry dimethylsulfoxide (DMSO) under a nitrogen atmosphere. To the solution of potassium thiophenoxide thus prepared is added 3.5 g of the reaction product of Part B in 8 ml of dimethylsulfoxide. The resulting mixture is then stirred at ambient temperature for 1 6 hr, whereupon additional postassium t-butoxide is added so as to transform the solution to a distinct yellow color.The resulting mixture is then stirred an additional 4 hr at ambient temperature, diluted with 100 ml of diethyl ether and 100 ml of hexane, washed with 5% aqueous potassium hydroxide (200 ml) and brine (200 ml), dried over magnesium sulfate, and concentrated under reduced pressure to yield 5 g of a residue of crude formula LIV compound: 3-phenylthio-7--tetrahydropyran-2-yloxy-6p-[(3' S)-3'-tetrahydropyran-2-yloxy-trans-1 ' octenyl]bicyclo[3.3.0]octane. Chromatography on 300 g of silica gel, deactivated with 40 ml of diethyl ether and 40 ml of trichloromethane and eluted with 5% diethyl ether in trichloromethane yields 3.1 g of pure product. Silica gel TLC Rf is 0.75 in 10% ethyl acetate in dichloromethane.
D. To a solution of 3.1 g of the reaction product of Part C and 50 ml of dichloromethane at OOC is added with stirring over 10 min 2.43 g of 85% m-chloroperbenzoic acid. The resulting mixture is then stirred at 0CC for 30 min, diluted with 1 50 ml of dry ethyl ether, washed with ice cold dilute aqueous potassium hydroxide and brine, dried over magnesium sulfate, and concentrated under reduced pressure to yield 3.4 g of crude title product. Chromatography on 350 g of silica gel, deactivated with 70 ml of ethyl acetate and elution with 500 ml of 3050% ethyl acetate in hexane yields 2.90 g of pure title product as a mixture of C-6 isomers. Silica gel TLC Rf s are 0.41, 0.45 and 0.48 in 30% ethyl acetate in hexane (stereoisomers).NMR absorptions are observed at 7.52-8.02, 5.30-5.67, 4.70, and 3.304.138.
Following the procedure of Example 11, each of the formula LI compounds is transformed to the corresponding formula LV 3-phenyl-sulfonyl compound.
EXAMPLE 12 (SE)-2,5-inter-o-phenylene-3,4-dinor-CBA2 (Formula LX: X, is --COOH, g is one, n is one, R16 and R1, are hydrogen, Ra is hydroxy, Y, is trans-CH=CH-, M, is a-0H:PH, L, is a-H:b-H, and R7 is n-butyl), its methyl ester and the corresponding (5Z) isomers thereof.
Refer to Chart C.
A. To a solution of 1.26 g of the title product of Example 11 in 1 5 ml of dry tetrahydrofuran at -780C under a nitrogen atmosphere is added dropwise with stirring 1.48 ml of 1.6 M n-butyllithium in hexane over 1 min. After 10 min 0.66 g of title product of Example 4 in 5 ml of dry tetrahydrofuran is added. After 45 min 0.26 ml of distilled acetic anhydride is added. Stirring is then continued at -780C for 3 hr and at ambient temperature for an additional 2 hr. The resulting mixture is then shaken with 1 20 ml of diethyl ether and 80 ml of saturated aqueous ammonium chloride.The organic layer is then washed with 1 5 ml of brine, dried over magnesium sulfate, and concentrated under reduced pressure to yield 2.21 g of formula LVI product as a mixture of isomers: 3-[a-acetoxy-o-(t- butyldimethylsilyloxyethyl )-a-tolyl]-3-phenylsulfonyl-7 a-(tetrahydropyra n-2-yl)oxy-6P-[(3' S)-3'- (tetrahydropyran-2-yl)oxy-trans-1 '-octenyl]bicyclo[3.3.0]-octane. R26, g, R17, n, R,8, Ys, M6, L1, and R27 are defined in Examples 9 and 11. Silica gel TLC Rf range is 0.30-0.53 (8 spots) (stereoisomers) in 25% ethyl acetate and hexane.
B. The mixture of isomeric products of Part A (2.21 g) and 40 ml of methanol and 20 ml of ethyl acetate is stirred at -200C with chips of 5.6% sodium amalgam for 60 min. After decanting liquid, excess amalgam and solids are rinsed by decantation employing 200 ml of diethyl ether. The organic solutions are then combined, washed with brine, dried, and concentrated under reduced pressure to yield 1.8 g of crude 2-carboxy-2-(t-butyldimethylsilyloxymethyl)-2,5-inter-o-phenylene-3,4-dinor-CBA2, 11,1 5-bis(tetrahydropyranyl ether). Chromatography on 250 g of silica gel, deactivated with 50 ml of diethyl ether and eluted with 30% diethyl ether in hexane yields 1.06 g of pure product.Silica gel TLC Rf'5 are 0.49, 0.56, and 0.62 (stereoisomers) in 30% diethyl ether and hexane. NMR absorptions are observed at 7.20, 6.54, 5.22 - 5.80, 4.72, 3.38 -4.16 and 2.74-3.00#.
C.A solution of 1.06 g of the reaction product of Part B in 10 ml of dry tetrahydrofuran is treated with 3.2 ml of 0.75 N tetra-n-butylammonium fluoride in tetrahydrofuran at ambient temperature for 40 min. The resulting mixture is then diluted with 125 ml of diethyl ether. The resulting solution is then washed with brine, dried over magnesium sulfate, and concentrated under reduced pressure to yield a residue of isomeric formula LVIII products: (5E)- and (5Z)-2-decarboxy-2-hydroxymethyl-2,5-inter-o phenylene-3,4-dinor-CBA2, 11,1 5-bis-(tetrahydropyranyl ether). Chromatography on 100 g of silica gel,
deactivated with 20 ml of ethyl acetate and eluted with 25-50% ethyl acetate in hexane yields 0.40 g
of (5Z) isomer and 0.51 g of (5E) isomer.For the (5Z) isomer silica gel TLC Rf s are 0.31 and 0.35
(stereoisomers) in 25% ethyl acetate and hexane. NMR absorptions are observed at 7.20, 6.51, 5.10-5.72, 4.69, 3.32-4.1 6, and 2.76--3.006. For the (5E) isomer silica gel TLC Rf s are 0.20 and
0.24 (stereoisomers) in 25% ethyl acetate and hexane. NMR absorptions are observed at 7.19, 6.50, 5.10-5.64,4.70, 3.32-4.10, and 2.883.01S.
D. To a solution of 400 mg of the (5Z) reaction product of Part C in 20 ml of dry acetone at -5O0C is added with stirring 1.0 ml of Jones reagent (prepared as follows: 26.72 g of chromium trioxide in 23
ml of concentrated sulfuric acid diluted with water to a volume of 100 ml). The resulting mixture is then
allowed to warm to -200C over a 20 min period and stirred at -200C for 30 min. Excess Jones reagent
is then destroyed by addition of 0.5 ml of isopropanol. After 5 min the reaction mixture is then shaken in
100 ml of ethyl acetate and 80 ml of brine containing 0.5 ml of concentrated hydrochloric acid. The
organic layer is then washed twice in 50 ml of water containing a trace (10 drops) of concentrated
hydrochloric acid, twice in 50 ml of water and in brine.The organic layer is then dried over magnesium
sulfate and concentrated under reduced pressure to yield 360 mg of crude (5Z)-2,5-inter-o-phenylene 3,4-dinor-CBA2, 11,1 5-bis(tetrahydropyranyl ether), a formula LIX compound. Crude formula LIX
compound is then taken up in 30 ml of diethyl ether and extracted in the mixture of 1 5 ml of water and
5 ml of methanol containing a trace amount (10 drops) of 45% aqueous potassium hydroxide. The
extraction is repeated 6 times, until the acid is completely extracted from the ethereal solution. The
aqueous extracts are then acidified to pH 2 and extracted with ethyl acetate. The organic extract is then
washed with brine, dried over magnesium sulfate, and concentrated under reduced pressure to yield a
residue of pure title product. Silica gel TLC is a streak to about Rf 0.50 in ethyl acetate and hexane (1:1).
Purified acid is then converted to the corresponding ethyl ester by treatment with excess ethereal
diazomethane for 10 min. Following esterification, the resulting reaction mixture is treated with ethyl
acetate and washed with dilute aqueous potassium hydroxide and brine. After drying and concentrating
to a residue, chromatography on 20 g of silica gel deactivated with 4 ml of ethyl acetate and elution
with 10% ethyl acetate in trichloromethane yields 210 mg of (5Z)-2,5-inter-o-phenylene-3,4-dinor
CBA2, methyl ester, 11,1 5-bis(tetrahydropyranyl ether). Silica gel TLC Rf s are 0.52, 0.56, and 0.60
(stereoisomers) in 25% ethyl acetate and hexane.NMR absorptions are observed at 7.20, 6.45, 5.34-5.78,4.70, 3.68, and 3.304.288.
E. A mixture of 200 mg of methyl ester of Part D, 5 ml of acetic acid, 2.5 ml of water, and 1 ml of tetrahydrofuran is heated to 400C and stirred for 4 hr. The resulting mixture is then diluted with 100 ml
of ethyl acetate and washed with a mixture of 6 g of 85% aqueous potassium hydroxide in 20 ml of water and 30 g of ice, washed with brine (40 ml), dried over magnesium sulfate, and concentrated
under reduced pressure to yield 180 mg of crude (5Z)-2,5-inter-o-phenylene-3,4-dinor-CBA2, methyl
ester. Chromatography on 20 g of silica gel deactivated with 4 ml of ethyl acetate and elution with 100
ml of 50% ethyl acetate in trichloromethane and 100 ml of 50% acetone in trichloromethane yields 105
mg of pure product. Silica gel TLC Rf is 0.57 in 40% acetone and trichloromethane and 0.52 in ethyl
acetate.NMR absorptions are observed at 7.20, 6.43, 5.45-5.59, 3.65, 3.40-4.20, and 3.188. The
mass spectrum of the bis TMS derivative exhibits peaks of decreasing intensity at m/e 73, 75, 74, 147, 43, 129,41,45, 167, 59, and an M±C5H11 peak at 485.2513.
F. To a solution of 105 mg of the reaction product of Part E in 5 ml of methanol and 2.5 ml of
water under a nitrogen atmosphere is added 0.33 g of potassium carbonate. The resulting mixture is
stirred at ambient temperature for 20 hr whereupon a small quantity (5 drops) of 45% aqueous
potassium hydroxide is added. The resulting mixture is stirred for an additional 4 hr at ambient
temperature. Thereupon the mixture is shaken with 100 ml of ethyl acetate and excess cold dilute
aqueus hydrochloric acid.The organic layer is then washed with brine, dried, and concentrated under
reduced pressure to yield 100 mg of pure (5Z)-2,5-inter-o-phenylene-3,4-dinor-CBA2. Silica gel TLC R,
is 0.56 in the A--IX solvent system (the organic phase of an equilibrated mixture of ethyl acetate, acetic
acid, cyclohexane, and water,9:2:9:10). The mass spectrum of the tris TMS derivative exhibits peaks of
decreasing intensity at m/e 73, 75, 129, 167, 74, 55, 69, 57, 147, and 45 and an M±CH3 peak at
599.3418.
G. Following the procedure of Part D, 510 mg of the (5E) reaction product of Part C is transformed to 310 mg of (5E)-2,5-inter-o-phenylene-3,4-dinor-CBA2, 11,1 5-bis(tetrahydropyranyl ether). Silica gel
TLC Rf is 0.41 in 25% ethyl acetate and hexane containing 1% acetic acid, and 220 mg of (5E)-2,5 inter-o-phenylene-3,4-dinor-CBA2, 11,1 5-bis(tetrahydropyranyl ether)methyl ester. Silica gel TLC Rf s are 0.48, 0.51, and 0.56 (stereoisomers) in 25% ethyl acetate and hexane. NMR absorptions are
observed at 7.20, 6.43, 5.26--5.64, 4.70, 3.65, and 3.30--4.1 OS.
H. Following the procedure of Part E, the reaction product of Part G (210 mg) is transformed to
110 mg of (5E)-2,5-inter-o-phenylene-3,4-dinor-CBA2, methyl ester. Silica gel TLC Rf is 0.57 in 40%
acetone and trichloromethane and 0.46 in ethyl acetate. NMR absorptions are observed at 7.22, 6.44, 5.32-5.47, 3.68, 3.50-4.08, and 3.10S. The mass spectrum of the bis TMS derivative exhibits peaks
of decreasing intensity at m/e 73, 75, 129, 227, 167, 55, 57, 173, 74, 466 and an M+CH3 peak at
541.3198.
I. Following the procedure of Part F, the reaction product of Part H (110 mg) is transformed to 102 mg of (5E)-2,5-inter-o-phenylene-3,4-dinor-CBA2. Silica gel TLC Rf is 0.50 in the A--IX solvent system.
The mass spectrum of the tris TMS derivative exhibits peaks of decreasing intensity at m/e 73, 75, 1 67, 129, 524, 453, 285, 147, 434, 213, and an M±CH3 peak at 599.3424.
EXAMPLE 13 (5E)-1 ,5-inter-m-phenylene-2,3,4-trinor-CBA2, its methyl ester, and the corresponding (5Z) isomers.
Refer to Chart D.
A. Following the procedure of Example 12, Part A, a solution of 1.26 g of the title product of
Example 6 and 0.62 g of the title product of Example 5 are transformed to 2.3 g of formula LVI compound. Silica gel TLC Rf range is 0.37-0.56 (7 spots) (stereoisomers) in 25% ethyl acetate in hexane.
B. Following the procedure of Example 12, Part B, the reaction product of Part A (2.3 g) is transformed to 1.0 g of isomeric formula LVII compounds: (5E)- and (5Z)-2-decarboxy-2-(tbutyldimethylsilyloxymethyl)-1,5-inter-m-phenylene-2,3,4-trinor-CBA2, 11,15-bis(tetrahydropyranyl ether). Silica gel TLC Rf'S are 0.47, 0.54 and 0.58 (stereoisomers) in 30% diethyl ether and hexane.
C. Following the procedure of Example 12, Part C, 1.0 g of the isomerically mixed reaction product of Part B is transformed to 0.51 g of (5Z)-2-decarboxy-2-hydroxymethyl-1,5-inter-m-phenylene-2,3,4- trinor-CBA2, 11,1 5-bis(tetrahydropyranyl ether) and 0.40 9 of (5E)-2-decarboxy-2-hydroxymethyl-1 ,5- inter-m-phenylene-2,3,4-trinor-CBA2, 11,15-bis(tetrahydropyanyl ether). For the (5Z)-isomer, silica gel
TLC Rf s are 0.31 and 0.35 (stereoisomers) in 25% ethyl acetate and hexane. NMR absorptions are observed at 7.18, 6.36, 5.19-5.65,4.63,4.58, 3.31-4.08, and 2.92â. For the (5E)-isomer, silica gel
TLC R7s are 0.23 and 0.27 (stereoisomers) in 25% ethyl acetate and hexane.NMR absorptions are observed at 7.19, 6.37, 5.29-5.72, 4.67, 4.60, 3.30-4.17, and 2.78â.
D. Following the procedure of Example 12, Part D, 510 mg of the (5Z) reaction product of Part C is transformed to 310 mg of (5Z)-1,5-inter-m-phenylene-2,3,4-trinor CBA2, 11,15-bis(tetrahydropyranyl ether) and 240 mg of (5Z)-1,5-inter-m-phenylene-2,3,4-trinor-CBA2, methyl ester, 11 ,1 5- bis(tetrahydropyranyl ether). For the acid, silica gel TLC streak to about Rf 0.54 in 50% ethyl acetate and hexane. For the methyl ester, silica gel TLC Rf s are 0.58, 0.63, and 0.68 (stereoisomers) in 25% ethyl acetate and hexane. NMR absorptions are observed at 7.28-8.00, 6.40, 5.13-5.73, 4.71, 3.89, and 3.28-4.08#.
E. Following the procedure of Example 12, Part E, 240 mg of the methyl ester product of Part D is transformed to 140 mg of (5Z)-1 ,5-inter-m-phenylene-2,3,4-trinor-CBA2, methyl ester. Silica gel TLC Rf is 0.49 in ethyl acetate. NMR absorptions are observed at 7.28-7.93, 6.40, 5.34-5.48, 3.88, and 3.32â. The mass spectrum of the bis TMS derivative exhibits peaks of decreasing intensity at m/e 83, 85, 73, 47, 213, 75, 129, 48, 87, 77, and an M±CH3 peak at 527.2996.
F. To a solution of 140 mg of the reaction product of Part E in 6 ml of methanol under a nitrogen atmosphere is added a solution of 0.20 g of 85% potassium hydroxide in 2 ml of water. The resulting mixture is then stirred at ambient temperature for 7 hr, shaken with 200 ml of ethyl acetate and excess cold dilute aqueous hydrochloric acid. The organic layer is then washed with brine, dried over magnesium sulfate, concentrated under reduced pressure to yield 110 g of pure (5Z)-1,5-inter-m- phenylene-2,3,4-trinor-CBA2. Silica gel TLC Rf is 0.60 in the A--IX solvent system. The mass spectrum of the tris TMS derivative exhibits peaks of decreasing intensity at m/e 73, 271, 394, 129, 420, 510, 75, 147, 32, 74, and an M±CH3 peak at 585.3234.
G. Following the procedure of Example 12, Part D, 400 mg of the (5E) reaction product of Part C is transformed to 260 mg of (5E)-1,5-inter-m-phenylene-2,3,4-trinor-CBA2,11,15- bis(tetrahydropyranyl ether) and 1 90 mg of (5E)-1 ,5-inter-m-phenylene-2,3,4-trinor-CBA2, methyl ester, 11,1 5-bis(tetrahydropyranyl ether). For the acid silica gel TLC streak to about Rf 0.36 in 50% ethyl acetate and hexane. For the methyl ester, silica gel TLC R;s are 0.50, 0.53, and 0.57 (stereoisomers) in 25% ethyl acetate and hexane. NMR absorptions are observed at 7.38-7.95, 6.42, 5.13 - 5.75, 4.68, 3.89, and 3.30 - 4.09#.
H. Following the procedure of Example 12, Part E, 1 90 mg of the reaction product of Part G is transformed to 81 mg of (5E)-1,5-inter-m-phenylene-2,3,4-trinor-CBA2, methyl ester. Silica gel TLC Rf is 0.51 in ethyl acetate. NMR absorptions are observed at 7.30-7.93, 6.43, 5.45 - 5.59, 3.89, 3.50-4.14, and 3.09#. The mass spectrum of the bis TMS derivatives exhibits peaks of decreasing intensity at m/e 73, 213, 129, 75, 83, 452, 173, 85, 262, 362, and an M±CH3 peak at 527.2996.
I. Following the procedure of Example 13, Part F, 81 mg of the reaction product of Part H is transformed to 65 mg of (5E)-1 ,5-inter-m-phenylene-2,3,4-trinor-CBA2. Silica gel TLC Rf is 0.60 in the A-IX solvent system. The mass spectrum of the tris TMS derivative exhibits peaks of decreasing intensity at m/e 73,271, 394,75, 510, 129, 420, 147, 173, 395 and an M±CH3 at 585.3227.
Following the procedure of Examples 1213, but employing each of the various formula LV compounds described in and following Example 11 in each of the various formula XLIV described in and following Examples 9 and 10, there are prepared each of the various formula L compounds in free acid or methyl ester form.
EXAMPLE 14 9,!3-methyl-CBA2, methyl ester, 1 1,1 5-bis(tetrahydropyranyl ether) (Formula LXXXIV: R,6 is hydrogen,
R37 is methyl, Z2 is -(CH2)3- and Ra8, Y1, Me, L1, and R7 are as defined in Example 3) and the corresponding (5E) and (5Z) free acids (Formula LXXXIII).
Refer to Chart G.
A. A suspension of 57% sodium hydride in mineral oil (1.90 g) is washed with hexane and treated with 1 30 ml of dry dimethyl sulfoxide (DMSO). The resulting suspension is heated at 650C for 1 hr under a nitrogen atmosphere and the resulting solution cooled to 1 50C and treated dropwise over 1 5 min with 10.0 g of 4-carboxybutyltriphenyl-phosphonium bromide. The resulting orange solution is stirred for 1 5 min at 1 O0C and then treated dropwise over 1 5 min with a solution of 2.12 g of the title product of Example 3 in 20 ml of dry DMSO.The resulting solution is then stirred at ambient temperature under a nitrogen atmosphere for 60 hr, treated with 1 5 ml of water, stirred for 30 min at ambient temperature, added to 200 ml of ice water and 100 ml of brine, acidified with 1 N aqueous hydrochloric acid, and extracted with 900 ml of diethyl ether. The ethereal extracts are then washed with 1 I of water and 200 ml of brine, dried over sodium sulfate, and concentrated under reduced pressure to yield 4.8 g of a yellow oil, the formula LXXXIII carboxylic acid.
B. The formula LXXXIII product and 42 ml of diisopropylethylamine in 120 ml of acetonitrile at 100C under a nitrogen atmosphere is treated with 1 5 ml of methyl iodide and allowed to warm slowly to ambient temperature. The resulting suspension is then stirred for 1 6 hr, treated with 3.0 ml of methyl iodide, stirred for an additional 2 hr, added to 500 ml of brine, and extracted with 11 of ethyl acetate.
The organic extracts are then washed with 250 ml of 0.5 N potassium bisulfate, 250 ml of saturated aqueous sodium bicarbonate, 250 ml of brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to yield a solid residue. The residue is then chromatographed on 500 g silica gel, eluting with 8% acetone in hexane to yield 2.25 g of title formula LXXXIV product. NMR absorptions (CDCl3) are observed at 0.9, 1.05, 1.08, 3.66, 3.02-4.35, 4.70, and 4.95â. Infrared absorptions are observed at 1730, 1670, 1645, 1200, 1 164, 1 135, 1080, 1035, 1020, 980, and 870 cm-1. Silica gel
TLC Rf is 0.46 in ethyl acetate and hexane (1:3) and 0.26 in ethyl acetate and hexane (1:6).
C. Alternatively the isomeric formula LXXXIII reaction products of Part A are separated into the (5E) and (5Z) title free acid products by chromatography on acid washed silica gel eluting with 1030% ethyl acetate in hexane.
Following the procedure of Example 9, but employing each of the various formula LXXXI ketones in place of the Example 3 product, there are prepared each of the various formula LXXXIV methyl esters wherein Z2 is -(CH2)3-.
Further following the procedure of Example 14, but employing a formula LXXXII o- carboxytriphenylphosphonium compound wherein Z2 is other than -(CH2)3, each of the various formula
LXXXI ketones is transformed to corresponding formula LXXXIV ester wherein Z2 is other than -(CH2)3.
EXAMPLE 1 5 (5Z)-2-Decarboxy-2-hydroxymethyl-9*methyl-CBA2, 11,1 5-bis(tetrahydropyranyl ether) (Formula
LXXXVI: R6, R37, Z2, Rive, M6, Lr, and R7 are as defined in Example 14) and its (5E) isomer (formula LXXXVI I).
Refer to Chart G.
A suspension of 0.16 g of lithium aluminum hydride in 45 ml of dry tetrahydrofuran at 0 C under a nitrogen atmosphere is treated dropwise with 1.98 g of the title product of Example 14 in 15 ml of dry tetrahydrofuran. The resulting suspension is stirred for 1 hr at 0 C and thereafter for 1 hr at ambient temperature. The resulting mixture is then cooled to OOC, quenched by addition of 0.16 ml of water, 0.16 ml of 1 5% aqueous sodium hydroxide. After stirring for 1 hr at ambient temperature, treatment with magnesium sulfate and filtration with diatomaceous earth, rinsing with diethyl ether, yields a mixture which is concentrated under reduced pressure.The resulting product, 0.25 g, is chromatographed on 180 g of silica gel, eluting with 30% ethyl acetate in hexane to yield 1.03 g of formula LXXXVII product and 1.06 g of formula LXXXVI product. For the formula LXXXVI product NMR absorptions (CDCI3) are observed at 0.90, 1.09, 3.2-4.4, 4.72, 5.0-5.9. Infrared absorptions are observed at 3470, 1760, 1200, 1 135, 1 120, 1075, 1035, 1020, and 980 cm~'. Silica gel TLC Rf is 0.29 in ethyl acetate and hexane (35:65).For the formula LXXXVII product NMR absorptions (CDCl3) are observed at 0.90. 1.05, 3.2--4.4, 4.6--4.95, 5.05--5.976. Infrared absorptions are observed at 3470, 1 670, 1200, 1125, 1110, 1080, 1035, 1020, and 985 cm-'. Silica gel TLC Rf is 0.36 in ethyl acetate and hexane (35:65).
Following the procedure of Example 1 5, but employing each of the various formula LXXXIV esters described following Example 14, there are prepared each of the respective formula LXXXVI and formula
LXXXVI I primary alcohols.
EXAMPLE 16 (5Z)-9p-methyl-CBA2, methyl ester (Formula LXXXVIII; X1 is -COOCH3, Ra is hydroxy, MX is a:-OH:p-H, and Era6, Era7, Lr, R7, Y1, and Z2 are as defined in Example 15).
Refer to Chart G.
A. A solution of the formula LXXXVI title product of Example 1 5 in 38 ml of acetone at -200C under a nitrogen atmosphere is treated over 5 min with 1.9 ml of Jones reagent (prepared by dissolving 133.6 g of chromium trioxide in 11 5 ml concentrated sulfuric acid and diluting with water to a volume of 500 ml), stirred for 2 hr at --200C, quenched by addition of 2.3 ml of isopropanol, stirred for 40 min at -200C, diluted with 200 ml of brine, extracted with 400 ml of ethyl acetate, washed with 600 ml of brine, dried over sodium sulfate, and concentrated under reduced pressure to yield 1.01 g carboxylic acid corresponding to the formula LXXXVI primary alcohol as a pale green oil.
B. A solution of the product of Part A in 11 ml of acetonitrile at 1 50C under a nitrogen atmosphere is treated with 4.1 ml of diisopropylethylamine and 1.5 ml of methyl iodide. The resulting suspension is then stirred at ambient temperature for 17 hr, treated with 0.3 ml of methyl iodide, stirred for 2 hr at ambient temperature, diluted with 50 ml of brine, extracted with 100 ml of ethyl acetate, washed with 50 ml of 0.5 M potassium bisulfate, 50 ml of aqueous sodium bicarbonate and 50 ml of brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to yield 1.02 g of the methyl ester corresponding to the carboxylic acid product of Part A.
C. A solution of the product of Part B in 56 ml of a mixture of tetrahydrofuran, water, and acetic acid (1 :2:4) is heated to 450C under a nitrogen atmosphere for 3 hr, cooled, diluted with 200 ml of brine, and extracted with 400 ml of diethyl acetate. The organic extracts are then washed with 600 ml of saturated aqueous sodium bicarbonate and 400 ml of brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to yield 0.9 g of crude title product as a yellow oil.
Chromatographing on 100 g of silica gel, eluting with hexane and ethyl acetate (3:7) yields 0.39 g of pure title product as a colorless oil. NMR absorptions (CDCl3) are observed at 0.89, 1.08, 3.5--4.35, 3.66, 5.0-5.7#. Infrared absorptions are observed at 3360, 1740, 1670, 1455, 1435, 1370, 1240, 1225, 1195, 1170, 1075, 1020, and 970 cm-1. Silica gel TLC Rf is 0.22 in ethyl acetate and hexane (7:3).
Following the procedure of Example 1 6, but employing each of the various formula LXXXVI compounds described following Example 15, there are prepared each of the various formula LXXXVIII, 9pmethyl-CBA2 compounds wherein X1 is -COOR1.
EXAMPLE 17 (5E)-9pmethyl-CBA2, methyl ester (Formula LXXXIX: R,6, R,7, X, Z2, Rs, R, Mr, La, and R7 are as defined in Example 16).
Refer to Chart G.
A. Following the procedure of Example 1 6, Part A, 0.60 g of the formula LXXXVII product of
Example 15 is transformed to the carboxylic acid corresponding to the formula LXXXVII primary alcohol, yielding 0.66 g of a green oil.
B. Following the procedure of Example 16, Part B, the product of Part A above (0.66 g) is transformed to the methyl ester corresponding to the carboxylic acid product of Part A, yielding 0.58 g of a yellow oil.
C. Following the procedure of Example 16, Part C, the product of Part B above (0.58 g) is transformed to 0.25 g of title product as a colorless oil. NMR absorptions (CDCI3) are observed at 0.90, 1.05, 3.30, 3.66, 3.75-4.25,5.0-5.7#. Infrared absorptions are observed at 3360, 1740, 1670.
1455, 1435, 1250, 1225, 1195, 1170, 1075, 1020, and 970 cm~'. Silica gel TLC Rf is 0.22 in ethyl acetate and hexane (3:7).
Following the procedure of Example 1 7, but employing each of the various formula LXXXVII compounds described following Example 15, there are prepared each of the various formula LXXXIX products wherein X, is -COOCH EXAMPLE 18 (5Z)-9pmethyl-CBA2.
A solution of 0.28 g of the title product of Example 16 in 8 ml of methanol is stirred at ambient temperature under a nitrogen atmosphere and treated with 1 ml of 8 M aqueous sodium hydroxide. The resulting yellow solution is then stirred for 5 hr at ambient temperature under a nitrogen atmosphere, diluted with 90 ml of ice and brine, acidified to pH 2 with 1 N hydrochloric acid, extracted with 360 ml of ethyl acetate, washed with 120 ml of brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to yield 0.25 g of crude title product. Chromatography on 30 g of silica gel, eluting with the A-IX solvent system (the organic phase of an equillibrated mixture of ethyl acetate, acetic acid, cyclohexane, and water, 9:2:5:10), yields 0.235 g of pure title product as a colorless oil.
NMR absorptions (CDCl3) are observed at 0.89, 1.08 3.5-4.35, 5.0-5.7, 6.058. Infrared absorptions are observed at3340, 3340,2660,1710,1240,1205,1175,1130,1075,1055,1020, and 970 cm-1.
Silica gel TLC Rf is 0.25 in the A--IX solvent system.
Following the procedure of Example 18 each of the various methyl esters prepared following
Example 16 is transformed to the corresponding carboxylic acid.
EXAMPLE 19 (5E)-9/3-methyl-CBA2.
Following the procedure of Example 1 8, 0.25 g of the title product of Example 1 7 is transformed to 0.21 g of title product as a colorless oil. NMR absorptions (CDCl3) are observed at 0.90, 1.06, 3.5-4.3, 5.0-5.7, and 5.93S. Infrared absorptions are observed at 3340, 2660, 1710, 1300, 1240,
1 175, 1130, 1075, 1055, 1020, and 970 cm-'. Silica gel TLC Rf is 0.27 in the A-IX solvent system.
Each of the various carboxylic acids corresponding to LXXXVI II and LXXXIX wherein X, is -COOH- can be prepared from the corresponding formula LXXXII I reaction products by acid hydrolysis of the tetrahydropyranyl ether protecting groups of C-1 1 and C-15. [The (5Z) LXXXIII reaction products from Example 14, Part C go to formula LXXXVII I products; and the (5E) LXXXIII reaction products from Example 14, Part C go to formula LXXXIX products.]
Following the procedure of Example 19, but employing each of the various formula LXXXIX methyl esters described following Example 17, there are prepared each of the various corresponding carboxylic acids.
EXAMPLE 20 2ss-(t-butyldimethylsilyloxymethyl)-5ss-methyl-7-oxo-3α-tetrahydropyran-2-yl-oxy-bicyclo[3.3.0]octane (Formula LXII : n is the integer one, R31 is t-butyldimethylsilyl, and R38 is tetrahydropyranyloxy).
Refer to Chart E.
A. A solution of 40.6 g of 3α-benzoyloxy-5α-hydroxy-2ss-hydroxymethyl-1 a-cyclopentaneacetic acid, co-lactone in 250 ml of dimethylformamide, stirring at 0 C under a nitrogen atmosphere, is treated with 25 g of imidazole in 28 g of t-butyldimethylsilyl chloride. The resulting solution is then stirred for 67 hr at ambient temperature, added to 500 ml of water, extracted with three 500 ml portions of diethyl ether, washed with 500 ml of 10% aqueous potassium bisulfate, 500 ml of aqueous sodium bicarbonate and 500 ml of brine, dried over sodium sulfate, and concentrated under reduced pressure to yield 59.9 g of 3α-benzoyloxy-5α-hydroxy-2ss-(t-butyldimethylsilyloxymethyl)-1α-cyclopentaneacetic acid, @ lactone as a white solid.NMR absorptions (CDCI3) are observed at 0.06, 0.91, 2.1-3.12, 3.74, 4.94-5.54, 7.24-7.67, and 7.9-8.2#. infrared absorptions are observed at 1780, 1720, 1600.
1585, 1490a, 1270, 1255, 1180, 1115, 1100, 1070, 1050, 830, 790, and 710 cm-1. Silica gel TLC
Rf is 0.20 in ethyl acetate and hexane (1:4).
B. A solution of 59.1 g of the reaction product of Part A and 500 ml of absolute methanol, stirring at ambient temperature under a nitrogen atmosphere, is treated with 35 ml of a 25% solution of sodium methoxide and methanol. The resulting reaction mixture is then stirred for 90 min at ambient temperature and quenched by addition of 9.5 ml of glacial acetic acid. Methanol is removed under reduced pressure and the resulting residue diluted with 500 ml of saturated aqueous sodium bicarbonate.The resulting mixture is then extracted with two 500 ml portions of ethyl acetate, washed with 300 ml of saturated aqueous sodium bicarbonate in 200 ml of brine, dried over sodium sulfate, and concentrated under reduced pressure to yield 58 g of an oily solid, crude 3α-dihydroxy-2ss-(t- butyldimethylsilyloxymethyl)-1 a-cyclopentaneacetic acid, ct) lactone. This crude product is then chromatographed in 800 g of silica gel, eluting with 2075% ethyl acetate in hexane to yield pure title product as a white crystal solid. Melting range is 60.50C to 620C.NMR absorptions (CDCl3) are
observed at 0.06, 0.90, 1.7-3.0, 3.67, 3.9-4.4, and 4.7-5.1 3. Silica gel TLC Rf is 0.3 in 50% ethyl
acetate in hexane.
C. A solution of 37.3 g of reaction product of Part B in 400 ml of methylene chloride, stirring at OOC under a nitrogen atmosphere, is treated with 18 ml of dihydrogen and 0.14 g of pyridine
hydrochloride. The resulting solution is stirred at ambient temperature for 13 hr, treated with an
additional 3 ml of dihydropyran and 30 mg of pyridine hydrochloride, stirred for an additional 4 hr,
washed with two 400 ml portions of saturated aqueous sodium bicarbonate and 400 ml of brine, dried
over anhydrous sodium sulfate, and concentrated under reduced pressure to yield 49 g of a pale yellow
oil, crude 5.t-hydroxy-3 (@-tetra hydropyran-2-yioxy-2p-(t-butyidimethylsilyloxymethyl)- cr- cyclopentaneacetic acid, w lactone.Chromatography on 800 g of silica gel, eluting with 075% ethyl
acetate in hexane yields 37 g of pure product as a colorless oil; NMR absorptions (CDCl3) are observed
at 0.05, 0.90, 1.62, 21.0-3.0, 3.6, 3.2-4.4,4.67, and 4.85.2S. Infrared absorptions are observed at
1780, 1255, 1175, 1160, 1116, 1080, 1035, 1020, 1005, 975, 835. and 775 cm-1. Silica gel TLC Rf is 0.25 in hexane and ethyl acetate (2:1).
D. A solution of 28 ml of dimethyl methylphosphonate in 800 ml of dry tetrahydrofuran at -7O0C under a nitrogen atmosphere is treated with 180 ml of 1.56 M n-butyllithium in hexane, stirred for 30 min at 700 C. The resulting mixture, maintained at 70C C, is then treated dropwise over 30 min with 41.7 g of reaction product of Part C in 200 ml of tetrahydrofuran. The resulting solution is then stirred at -7O0C for 1 hr, allowed to warm, stirred for an additional 2.5 hr at ambient temperature, quenched by addition of 14 ml of glacial acetic acid, added to 11 of brine, extracted with three 700 ml portions of diethyl ether, washed with 500 ml of brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to yield 63 g of a yellow oil, crude 6ss-(t-butyldimethylsilyloxymethyl)-3- dimethylphosphonomethyl-3-hydroxy-2-oxa-7 a-tetra hydropyranyloxy-bicycloL3.3.0Soctane.
Chromatography on 800 g of silica gel eluting with 5075% ethyl acetate in hexane yields 44.2 g of pure title product as a colorless oil. NMR absorptions (CDCI3) are observed at 0.05, 0.89, 1.23-3.02, 2.2-4.37, 4.70, and 4.99 S. Infrared absorptions are obseved at 3380, 1255, 2235, 1120, 1050, 1035, 835, and 775 cm-1. Silica gel TLC Rf is 0.25 in ethyl acetate.
E. A suspension of 29.2 g of chromium trioxide in 700 ml of methylene chloride, stirring at ambient temperature under a nitrogen atmosphere, is treated rapidly with 50 ml of pyridine, treated with dry diatomaceous earth, stirred for 5 min, and then treated with 23.8 g of title product of Part D in 60 ml of methylene chloride. The resulting suspension is then stirred for 45 min at ambient temperature under a nitrogen atmosphere and filtered through 300 g of silica gel, eluting with 2 l of ethyl acetate in acetone (2:1). Concentration under reduced pressure yields 24 g of a brown yellow oil, crude 313-(t- butyldimethylsilyloxymethyl)-2 a-(2'-di methylphosphonomethyl-2'-oxoethyl)-4a-tetra hydropyra nyloxypentanone.High pressure liquid chromatography of 12 g of the crude product on silica gel eluting with 20% acetone in methylene chloride yields 4.54 g of pure product as a colorless oil. NMR absorptions (CDCl3) are observed at 0.05, 0.88, 2.8-4.5, 3.77, and 4.86S. Infrared absorptions are observed at 1745, 1715, 1255, 1130, 1115, 1060, 1025,835,810, and 775 cm1. Silica gel TLC Rf is 0.27 in 20% acetone in methylene chloride and 0.3 in ethyl acetate.
F. A degassed suspension of 0.52 g reaction product of Part E, 0.15 g anhydrous potassium carbonate, and 0.59 g 18-crown-6 ether in 20 ml toiuene are stirred at 750C for 6 hr under a nitrogen atmosphere and thereafter cooled to OOC. The resulting solution is then washed successively with 20 ml brine, a solution of 15 ml water and 5 ml brine, and 20 ml brine, dried over an hydros sodium sulfate, and concentrated to yield a brown residue crude 6p-t-butyldimethylsilyloxymethyl-7a-tetrahydrnpyran- 2-yl-oxybicyclo[3.3.0]oct-1 -en-2-one, filtering through 7 g of silica gel and eluting -with hexane and ethyl acetate (70 ml,1 1:1) yields 0.31 g of product as an oil.High pressure liquid chromatography (10 ml fractions, 3.8 ml/minute flow rate) on silica gel, eluting with hexane and ethyl acetate (3:1) yields 0.20 g of pure product as a colorless oil. NMR absorption (CDCl3) of the trimethylsilyl derivative are observed at 0.06, 0.90, 1.20-3.20, 3.20-4.85, and 5.856.0S. Infrared absorptions are observed at 1710, 1630, 1250, 1130, 1115, 1075, 1030, 965, 870, 835, 810, 775 cm1. Silica gel TLC Rf is 0.34 in hexane and ethyl acetate (2:1).
G. A suspension of 0.35 g of anhydrous copper iodide in 12 ml of anhydrous diethyl ether at -200C under an argon atmosphere is treated dropwise with 2.0 ml of 1.4 M methyllithium. The resulting solution is then stirred at -200C for 15 min, treated at 20 C dropwise over 1.5 hr with a solution of 0.22 g of the reaction product of Part F in 12 ml of anhydrous diethyl ether. The resulting suspension is then stirred at -200C for 2 hr, added to 50 ml of 1 M aqueous ammonium chloride, extracted with 1 50 ml of diethyl ether, washed with 50 ml of brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to yield 0.23 g of crude title product as a pale yellow oil.Chromatography on 30 g of silica gel, eluting with ethyl acetate and hexane (1 :4) yields 0.22 g of pure title product as a colorless oil. NMR absorptions (CDCl3) are observed at 0.05, 0.90, 1.16, 1.3-2.9, 3.3-4.4, and 4.63S. Infrared absorptions are observed at 1745, 1255, 1135, 1110, 1095, 1075,1035,1020,835, and 775 cm-1. Silica gei TLC Rf is 0.32 in ethyl acetate and hexane (1 :4).
EXAMPLE 21 N-methyl-( 1 -fluoro-5-tetrahydropyranyloxypentyl)-phenylsulfoximine (Formula XCII: Z2 is -(CH2)32- and R10 is tetrahydropyranyl.
Refer to Chart H.
Diisopropylamine (0.59 g) is dissolved in 21 ml of tetrahydrofuran and the resulting mixture cooled to -780C with stirring under an argon atmosphere. Thereafter triphenylmethane is added, for use as an indicator, and a solution of n-butyllithium and hexane is added dropwise until the resulting mixture attains a pink color. After stirring for an additional 75 min, the resulting mixture is treated with
1.50 g of N-methyl-(5-tetrahydropyranyloxypentyl)-phenylsulfoximine dissolved in 6 ml of dry tetrahydrofuran. The resulting mixture is then stirred for an additional 30 min at -780C. Thereafter excess perchoryl fluoride (FC103) is bubbled through the solution for 4-5 min, during which time a stream of argon is also bubbled through the mixture for safety reasons.The resulting mixture is then stirred at additional 90 min at -780C and then the reaction is quenched by addition of 5% aqueous sodium bicarbonate. After equilibration of the reaction mixture to ambient temperature, the mixture is diluted with additional 5% aqueous sodium bicarbonate and extracted with methylene chloride. The organic extracts are then washed with brine, dried over magnesium sulfate, and concentrated under reduced pressure to yield 1.64 g of a yellow oil. Chromatography on silica gel columns in a series, eluting with ethyl acetate and hexane (1:1) yields 0.18 g of the formula XCII title product as a mixture of diastereomers. Silica gel TLC Rf in ethyl acetate and hexane (1:1) are 0.54 (less polar isomer) and 0.45 (more polar isomer). NMR absorptions (CDCl3) for the less polar isomer are 1.2-2.1 5, 3.65, 3.68, 3.1-4.1,4.4-4.8, 5.5, and 7.4-8.1 b. NMR absorptions (CDCl3) for the more polar isomer are 1.15-2.20, 3.63, 3.1-4.1,4.45-4.65, 5.27, and 7.4-8.1 .
Following the procedure of Example 21, but employing each of the various formula XCI phenylsulfoxamines, there are prepared each of the various corresponding formula XCII fluorinated phenylsulfoxamines.
EXAMPLE 22 5-Fluoro-2-decarboxy-2-hydroxymethyl-CBA2, 1,11,1 5-tris(tetrahydropyranyl ether). (Formula XC IV: R.6 and R17 are both hydrogen, R10 is tetrahydropyranyl, Z2 is -(CH2)3-, n is the integer one, R18 is tetrahydropyranyloxy, Y1 is trans-CH=CH-, M6 is α- tetrahydropyranyloxy;ss-hydrogen, R3 andR4 of the
L, moiety are both hydrogen, and R7 is n-butyl).
Refer to Chart H.
Diisopropylamine (164 mg) and triphenylmethane (1.5 mg) are dissolved in 4 ml of dry tetrahydrofuran and the resulting solution is cooled to -780C under a nitrogen atmosphere. A solution of n-butyl-lithium and hexane is added until a faint pink color is attained. This solution is then stirred an additional 80 min. Thereafter, 0.488 g of the title product of Example 21 in 4 ml of dry tetrahydrofuran is added dropwise. Thereafter 608 mg of 7-oxo-3α-tetrahydropyran-2-yl-oxy-2ss-[(3'S)-3'- tetrahydropyran-2-yloxy-trans-1 '-octenyl]bicyclo[3.3.0]octane (Formula XCIII: R,6, R,7! n, RIB, Y1, M6, L1, and R7 are as defined for the title product) in 4 ml of tetrahydrofuran is added to the reaction mixture.
After 4 min, the resulting mixture is quenched by addition of saturated aqueous ammonium chloride and ethyl acetate is thereafter added to the reaction mixture, which is maintained at -780C. The resulting mixture is then allowed to warm until solids separate. Thereupon additional ethyl acetate is added, the reaction extracted with brine. The ethyl acetate layer is then dried over sodium sulfate and concentrated under reduced pressure.
An aluminum amalgam is then prepared by reacting 0.31 g of 20 mesh aluminum with 2.5 ml of aqueous mercuric chloride followed by washing with ethyl acetate and diethyl ether. The residue from the ethyl acetate layer (described in the preceeding paragraph) is dissolved in 5 ml of tetrahydrofuran and the solution cooled to 0 C. This cooled solution is then treated with aluminum amalgam, 2 ml of water, and 1 ml of glacial acetic acid. The resulting mxiture is then stirred for 2 hr at 0 C and 16 hr at 200C. The reaction is then diluted with ethyl acetate and filtered with diatomaceous earth. The ethyl acetate layer is then washed with 5% aqueous sodium bicarbanate and saturated brine, dried over sodium sulfate, and concentrated under reduced pressure to yield 0.96 g as an oily residue.
Chromatographing over 100 g of silica gel and eluting with 500 ml of 15% ethyl acetate in mixed hexanes, 500 ml of 25% ethyl acetate in mixed hexanes, 300 ml of 50% ethyl acetate in mixed hexanes, and 800 ml of 50% acetone in methylene chloride, taking 20 ml fractions, yields a less polar isomer in fractions 22-26 (80 mg) and a more polar isomer in fractions 30-36 (74 mg). These isomers represent the C-S diastereomers of the formula XCIV product.For the less polar isomer, NMR absorptions (CDCl3) are observed at 0.65-2.65, 3.15-4.15, 4.35-4.75, and 5.25-5.75#. For the more polar isomer, NMR absorptions (CDCl3) are observed at 0.6-2.65, 3.10-4.15, 4.40-4.7, and 5.2-5.7#. Silica gel TLC Rf for the less polar isomer is 0.66 and for the more polar isomer is 0.57 in ethyl acetate and mixed hexanes (3:7).
Following the procedure of Example 22, but employing each of the various formula XCIII ketones, there are obtained each of the various formula XCIV intermediates wherein Z2 is -(CH2)3-.
Further following the procedure of Example 22, but substituting each of the various fluorinated phenylsulfoximines described following Example 21, there are prepared from the various formula XCIII ketones each of the various formula XCIV products wherein Z2 is other than -(CH2)3-.
EXAMPLE 23 5-Fluoro-2-Decarboxy-2-hydroxymethyl-CBA2 (more polar isomer) (Formula XCV: R,6, R17,Z2, n, RB, Mr, L1, and R7 are as defined in Example 17).
Refer to Chart H.
The title product of Example 22 (74 mg) is dissolved in 2 ml of a mixture of tetrahydrofuran, water, and glacial acetic acid (2:2:1) and the resulting mixture stirred under a nitrogen atmosphere. The reaction mixture is maintained at ambient temperature for 17 hr, thereafter at 400C for 7 hr, and finally at 230C for an additional 24 hr. The resulting mixture is then diluted with ethyl acetate, washed with
5% aqueous sodium bicarbonate and saturated brine, dried over sodium sulfate, and concentrated under reduced pressure to yield 52 mg of crude title product. Chromatography over silica gel, eluting with acetone and methylene chloride (60:40) yields 10 mg of pure title product.NMR absorptions (CDCl3) are observed at 0.6-2.60, 2.60-3.30, 3.30-4.15, 5.1-5.9#. 13C-NMR absorptions (CDCl3) are
observed at 135.8, 133.0, 117.5 (d J=18Hz), 77.4, 73.3, 62.6, 57.6, 46.4, 41.1,38.0, 37.2, 36.2 (D J=5Hz), 31 ., 31.8, 31.2, 29.5 (d J=29Hz), 25.2, 22.5, 14.OS. Silica gel TLC Rf is 0.280 in acetone and
methylene chloride (1:1).
EXAMPLE 24
5-Fluoro-2-decarboxy-2-hydroxymethyl-CBA2 (less polar isomer)
Following the procedure of Example 23, 85 mg of less polar title product of Example 22 are transformed to 25 mg of pure title product. NMR absorptions (CDCl3) are observed at 0.5-2.5, 3.1-4.75, and 5.05-5.8#. 13C-NMR absorptions (CDCI) are observed at 137.0, 132.6,77.0,73.6, 62.3, 57.4, 45.5,41.6, 36.9,36.5, 34.4 (d J=3.1 Hz), 32.5 (d J=5.4 Hz). 31.8, 31.7,29.2
(d J=28.9Hz), 25.4, 22.6, 22.4, and 14.0#. Silica gel TLC R, is 0.33 in acetone and methylene chloride.
Following the procedure of Examples 23 and 24, but employing the various diastereomeric products described following Example 22, there are prepared each of the various diastereomers corresponding to formula XCV.
EXAMPLE 25
5-Fluoro-CBA2 (more polar isomer) Formula LXXVI: Z2 n, R8, Y1, M1, L1, and R7 are as defined in Example
23).
Refer to Chart H.
The platinum oxide catalyst is prepared by suspending 46 mg of 85% platinum oxide in 9 ml of water and hydrogenating the resulting mixture at ambient temperature and pressure for 34 min. To this suspension is added 58 mg of sodium bicarbonate and 1 8 mg of the title product of Example 23 dissolved in 2 ml of acetone. The resulting mixture is then warmed to 600C and oxygen bubbled therethrough for 80 min. The reaction mixture is then filtered through diatomaceous earth and the filter
cake washed in water. The filtrate is then acidified to pH4 with 5% aqueous sodium hydrogen sulfate
and extracted with ethyl acetate. The organic extracts are then dried over magnesium sulfate and
concentrated under reduced pressure to yield 21 mg of pure title product.NMR absorptions (CDCI3) are observed at 0.6-2.8, 3.0-4.2, and 4.65-5.8. 13C-NMR absorptions (CDCl3) are observed at 176.9,135.5,133.2,118.5 (d J=17.5Hz), 77.7, 73.5, 57.3, 46.5, 41.0, 38.2, 37.0, 36.2 (d J=4.8Hz),
32.3, 31.7, 31.1 (d J=13.5Hz), 28.5 (d J=28.3Hz), 25.2, 22.6, 21.0, and 14.08. Silica gel TLC Rf is 0.39 in the A--IX solvent system.
EXAMPLE 26
5-Fluoro-CBA2 (less polar isomer).
Following the procedure of Example 25, 24 mg of the title product of Example 24 yields 23 mg of
pure title product. NMR absorptions (CDCI3) are observed at 0.6--2.9, 3.3--4.2, 5.0--6.06. 13C-NMR absorptions (CDCla) are observed at 176.8, 135.4, 132.9, 118.3 (d J=18.2Hz), 77.6, 73.4, 57.2, 46.3, 41.2, 37.8, 36.8, 34.6 (d J=2.7Hz), 32.8, 32.4, 31.7, 28.7 (d J=28.4Hz), 25.2, 22.6, 21.1, and 14.03.TLC Rf is 0.50 in the A--IX solvent system.
The reaction products of Example 25-26 are obtained as diastereomeric mixtures of (5E) and (5Z) geometric isomers. These geometric isomers are characterized herein as "less polar" and "more
polar" isomers based on TLC motilities. The isomers of these 5-fluoro-CBA2 compounds correspond to the (5E) and (5Z) geometric isomers of CBA2 itself. On the basis of relative biological activities, the more polar 5-fluoro-CBA2 isomer yields more potent pharmacological effects and on this basis could be
assigned the (5Z) structure based on pharmacological considerations alone. However, the '3C--NMR data suggests the more polar isomer corresponds to the (5E) structure of the 5-fluoro-CBA2 compound.
Following the procedure of Examples 25-26, there are prepared each of the various formula
XCVI 5-fluoro-CBA2 diastereomers from the starting materials described following Example 24.
Further following the procedures known in the art, each of the various 5-fluoro-CBA2 compounds described in and following Examples 24-25 is transformed to the corresponding formula XCVII 5fluoro-CBA2 analogs.
EXAMPLE 27 (SZ)-9pmethyl-CBA2 adamantylamine salt
The title product of Example 18 (54 mg), (SZ)-9pmethyl-CBA2 in 6 ml of diethyl ether is combined with 23 mg of adamantylamine. After 10 min the precipitate forms which is thereafter stirred for 12 hr, decanted, and concentrated under reduced pressure to yield 68 mg of a solid, pure title product. Melting
range is 110-1 140C.
EXAMPLE 28 (5Z)-9pmethyl-CBA2, calcium salt hydrate
The title product of Example 18 (0.95 g), 9k-methyl-(5Z)-CBA2. calcium oxide (0.064 g), freshly
boiled water (9.2 ml), and distilled tetrahydrofuran (6 ml), are combined by heating to 500C under a nitrogen atmosphere with stirring for 20 min. The resulting mixture is then filtered, washed with tetrahydrofuran, and concentrated under reduced pressure to yield a residue.The residue is then dissolved in tetrahydrofuran (10 ml) and concentrated 8 times to yield a cream-colored foam. This foam is then dissolved in 6 ml of tetrahydrofuran which is dripped into an hydros diethyl ether (95 ml). The resulting suspension is then stirred for 15 min at ambient temperature under a nitrogen atmosphere and filtered.The filter cake is then washed with anhydrous diethyl ether and dried for 20 hr under reduced pressure at ambient temperature to yield 0.686 g of title product. Melting range is 101-1 080C.
Following atmospheric equillibration melting range is 80-11 70C. Infrared absorptions ae observed at 3330,1670,1555,1455, 1345,1310, 127O,1075,1O20,97Ocm1.
EXAMPLE 29 8α-hydroxy-7ss-(3α-hydroxy-trans- 1 -octenyl)-tricyclo[4.3. 1] nonan-4-one, 8,3' -bis(tetrahydropyranyl ether) (Formula XXV: RIB, Y,, M6, L1, R27, and n are as defined in Example 1, R16 and R37 taken together are -CH2-).
Refer to Chart A.
A. The formula XXIV title product of Example 1 (4.0 g) and benzophenone (2 g) in one liter of methanol is photolyzed (3500 A lamp) for 3 hr while argon is bubbled through the solution. The methanol is then removed by concentration under reduced pressure and the residue chromatographed on 600 g of silica gel eluting with a mixture ranging from ethyl acetate in hexane (1 :3) to 100% ethyl acetate. Compund XXVI, 1ss-hydroxymethyl-7α-hydroxy-6ss-(6'α-hydroxy-trans-1'- octenyl)bicyclo[3.0] octan-3-one, 7,3"0bis(tetrahydropyranyl ether) is obtained as a white solid (3.45 g). Crystallization from ethyl acetate in hexane yields a white solid with melting range 65-700C.
NMR absorptions (CDCI3) are observed at 0.89, 1.17-2.90,2.92-4.40, 4.69, and 5.24-5.77.
Infrared absorptions are observed at 3420, 1730, 1200, 1125, 1110, 1070, 1040, 1020. and 970 cm~1. Silica gel TLC Rf is 0.29 in hexane and ethyl acetate (1 :4).
B. A solution of 0.6 g of the reaction product of Part A and 0.49 g of p-toluenesulfonyl chloride in 30 ml of pyridine is cooled to OOC under argon for 70 hr, added to 100 ml of ice, diluted with 300 ml of water, and extracted with diethyl ether (800 ml). The ethereal extracts are then washed with brine, dried over magnesium sulfate, concentrated under reduced pressure, and chromatographed eluting with 50% to 80% hexane in ethyl acetate to yield 0.49 g of formula XXVII compound, 3-oxo-7α-tetrahydropyran- 2-yloxy-6p[(3 's)-3'-tetrahydropyran-2-yloxy-trans- 1 '-octenyl]- 1 p-(p-toluenesolfonyl)-oxymethylbicyclo[3.3.0]octane, as a colorless oil.NMR absorptions (CDCl3) are observed at 0.88, 1.06-2.9, 2.45,3.17-4.35, 4.52-4.83, 5.2-5.8, 7.37, and 7.81#. Infrared absorptions are observed at 1740, 1600, 1360, 1200, 1190, 1175, 1130, 1110, 1075, 1035, 1020, 970, and 820 cm~'. Silica gel TLC
Rf is 0.45 or 0.26 in ethyl acetate and hexane (1:1 or 1:2).
C. A degassed solution of 0.49 g of the reaction product of Part B and 1 mi of t-butanol in 50 ml of dry tetrahydrofuran at 0 C under an argon atmosphere is treated with 0.8 ml of 1.7 M potassium tbutoxide in tetrahydrofuran. After 5 min the reaction is allowed to warm and the resulting brown solution stirred for 3 hr at ambient temperature. Thereafter 90 ml of brine is added and the mixture is extracted with 270 ml of ethyl acetate. The ethyl acetate extracts are then washed with 100 ml of saturated aqueous sodium bicarbonate, 100 ml of brine, dried over anhydrous magnesium sulfate, concentrated under reduced pressure, yielding 0.37 g of a brown oil, and chromatographed on 40 g of silica gel eluting with hexane and ethyl acetate (2:1) to yield 0.32 g of pure formula XXV title product as a colorless oil.
D. Alternatively, a suspension of 207 mg of 57% sodium hydride in mineral oil and 1.08 g of trimethyloxosulfonium iodide is treated dropwise under a nitrogen atmosphere with 6 ml of dimethylsulfoxide. The resulting grey slurry is then stirred at ambient temperature for 20 min, treated with 2.03 g of the title product of Example 1 in 4 ml of dry dimethylsulfoxide and stirred for 2 hr at ambient temperature. Thereafter stirring is continued for 1 hr at 500 C, the reaction mixture is cooled and diluted with 200 ml of water and thereafter extracted with three 100 ml portions of diethyl ether.
The combined ethereal extracts are then washed with 200 ml of water, washed with 100 ml of brine, dried over an hydros magnesium sulfate, concentrated under reduced pressure, yielding a brown oil, and chromatographed on 250 g of silica gel eluting with ethyl acetate and hexane (1:2) to yield 453 mg of pure title product.
E. For title product prepared according to Part C or Part D above, NMR absorptions (CDCl3) are observed at 0.25-2.75, 3.15-4.39, 4.68, and 5.2-5.8#. Infrared absorptions are observed at 1725, 1665, 1135, 1080, 1040, 1020, 980 cm-1.
The mass spectrum exhibits a molecular ion at 446 and silica gel TLC Rf is 0.30 in ethyl acetate and hexane.
EXAMPLE 30 (5Z) and (5E)-6e ,9l3-methano-CBA2 (Formula X: X1 is --COOH, Z1 is -(CH2)3-, R15 is hydrogen, R16 and R17 taken together are methano, n is one, RB is hydroxy, Y, istrans-CH=CH-, M1 is α-CH:ss-H, L1 is a-H:k,-H, R7 is n-butyl, and the C-5, C-6 positions are unsaturated).
Refer to Chart G.
A. A suspension of 452 mg of 57% sodium hydride in mineral oil and 30 ml of dimethylsulfoxide is heated to 650C for 1 hr under a nitrogen atmosphere, cooled to 1 70C and thereafter treated over 1 5 min with 2.39 g of 4-carboxybuthyltriphenylphosphonium bromide. The resulting red solution is then stirred for 1 5 min at 1 7-200C, treated with a solution of 71 6 mg of the title product of Example 29, 6 ml of dry dimethylsulfoxide, stirred for 43 hr at 400 C, cooled to OOC, treated with 3.5 ml of water, stirred for 30 min at OOC, added to 75 ml of water and brine (2:1), acidified with one N aqueous hydrochloric acid, and extracted with 225 ml of diethyl ether. The ethereal extracts are then washed with 375 ml of water and 75 ml of brine, dried over magnesium sulfate, concentrated under reduced pressure, and chromatographed on 150 g of acid-washed silica gel eluting with 1 0-25% ethyl acetate in hexane to yield 290 mg of (5Z)-6αss,9ss-methano-CBA2, 11,15-bis(tetrahydropyramyl ether), 70 mg of (5E)- 6aC3,9p-methano-CHA2,11,15-bis(tetrahydropyranyl ether), and 400 mg of a mixture of (5E) and (5Z) formula LXXXII I isomers. Rechromatographing the isomeric mixture on 150 g of acid-washed silica gel yields an additional 50 mg of (5E) isomer and 180 mg of (5Z) isomer.
For the (5Z) isomer NMR absorptions (CDCl3) are observed at 0.5-2.85, 3.22-4.4,4.70, 4.9-5.75, and 10.1S. Infrared absorptions are observed at36003000 (a broad band), 1740,1710, 1240, 1210, 1135, 1080, 1035, 1020, 980, and 870 cm~1. Silica gel TLC Rf is 0.27 in hexane, ethyl acetate, and acetic acid (65:34:1).For the (5E) isomer NMR absorptions are observed at 0.40-2.70, 3.2-4.4,4.70, 5.0-5.8, and 8.82#. Infrared absorptions are observed at 3600-3000, 1740, 1710, 1460, 1445, 1200, 1135, 1075, 1035, 1020, and 980 cm~'. Silica gel TLC Rf is 0.32 in hexane, ethyl acetate, and acetic acid (65:34:1).
B. A solution of 446 mg of the (5Z) reaction product of Part A in 44 ml of acetic acid, water, and tetrahydrofuran (6:3:2) is heated at 450C under a nitrogen atmosphere for 3 hr, cooled, added to 200 ml of brine, extracted with 160 ml of ethyl acetate in hexane (3:2), washed with 500 ml of brine, extracted with 120 ml of ethyl acetate and hexane (3:2) dried over sodium sulfate, concentrated under reduced pressure, yielding 0.38 g of a yellow oil and chromatographed on 60 g of acid washed silica gel eluting with 70% ethyl acetate in hexane to yield 170 mg of pure (5Z) title product as a colorless oil.
NMR absorptions are observed at 0.5-2.90, 0.89, 4.05, 4.85-5.8, and 6.13#. Infrared absorptions are observed at 3360, 2260, 1710, 1245, 1240, 1075, 1025, and 970 cm~1. The mass spectrum for the tris-trimethylsilyl derivative exhibits a high resolution peak at 578.3653. Silica gel TLC Rf is 0.30 in the A-IX solvent system (the organic phase of an equilibrated mixture of ethyl acetate, acetic acid, cyclohexane, and water; 9:2:5:10).
C. Following the procedure of Part B above 90 mg of the (5E) reaction product of Part A is converted to 46 mg of (5E) title product as a colorless oil. NMR absorptions are observed at 4.40-2.8, 0.89, 4.06, and S.0-S.8S. Infrared absorptions are observed at 3340, 2630, 1710, 1070, 970 cm~1.
The mass spectrum exhibits a high resolution peak at 578.3664. Silica gel TLC Rf is 0.32 in the A-IX solvent system.
Following the procedure of Examples 27-29, each of the various formula X products is prepared wherein R,6 and R,7 are methano from the corresponding formula LXXXI reactants of Chart G.
Accordingly, the above examples provide methods for preparing each of the various formula X
CBA analogs of the present invention.
EXAMPLE 31 9-deoxy-2',9α-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-inter-phenylene)-PGF1 α (Formula XI : X1 is COOH,
R20, R2, R23, and R24 are all hydrogen, Z4 is -CH2-, R22isphydrngen, R8, Y1, M1, L1, and R7 are as defined in Example 8) and its corresponding methyl ester (X, is COOCHs).
Refer to Chart P.
A. A solution of methyl phenyl-N-methyl sulfoximine (3.39 g) in dry tetrahydrofuran (60 ml), is alternately degassed and flushed with nitrogen, cooled to -780C and treated dropwise over 7 min with 2.8 M methyl magnesium chloride (7.16 ml). The resulting solution is stirred at -780C for 30 min, then at 0 C for 15 min. The reaction is cooled to -780C and treated with a solution of 3-oxa-1,2,4,5,6pentanor-3,7-inter-m-phenylene-PGE1, 3-(t-butyldimethylsilyl ether), 11,15-bis(tetrahydropyranyl ether) (6.05 g), a formula CLXXI compound, in dry tetrahydrofuran (35 ml). The resulting mixture is stirred for 1.75 hr while the temperature permitted to go from -780C to 0 C and then stirred for one hr at 0 C. The reaction mixture is then diluted with brine (170 ml) and extracted with diethyl ether.The ethereal extracts are then washed successively with brine 1170 ml), 0.5 M aqueous potassium bisulfate (170 ml), saturated aqueous sodium bicarbonate (170 ml) and brine (170 ml), dried over magnesium sulfate, filtered and concentrated to a yellow oil (8.0 g), 9-[(N-methyl)-phenylsulfoximinomethyl]-3-oxa-
1,2,4,5,6-pentanor-3,7-inter-m-phenylene-PGF1,3-(t-butyldimethylsilyl ether), 11,15bis(tetrahydropyranyl ether).A degassed solution of 9-[(N-methyl)phenylsulfoximinomethyl] -3-oxa 1 ,2,4,5,6-pentanor-3,7-inter-m-phenylene- 3-(t-butyldimethylsilyl ether), 11,15- bis(tetrahydropyranyl ether) (8.0 g) in tetrahydrofuran (150 ml) is cooled to OOC, treated with 50% acetic acid/water (45 ml) then immediately with aluminum amalgam under nitrogen. (The aluminum amalgam is prepared by washing 20 mesh aluminum, 8.00 g. with diethyl ether, 170 ml, methanol, 340 ml, mercuric chloride, 8.03 g, in water, 275 ml, methanol, 170 ml, and diethyl ether, 170 ml).
The resulting black suspension is stirred for 1.75 hr during which the reaction temperature is permitted to go from 0 to 1 50C (slowly) then cooled to 00, treated with ethyl acetate (210 ml) and stirred for an additional 30 min at OOC. The suspension is filtered through diatomaeous earth and the filter cake washed with ethyl acetate. The combined filtrate is then washed with brine (300 ml), 0.5 M aqueous potassium bisulfate (300 ml), saturated aqueous sodium bicarbonate (300 ml) and brine (300 ml), dried, filtered, and concentrated to a yellow oil, crude formula CLXXII compound (6.03 g), 9deoxy-9-methylene-3-oxa-1,2,4,5,6-pentanor-3,7-inter-m-phenylene-PGF1, 3-(t-butyldimethylsilyl ether), 11,15-bis(tetrahydropyranyl ether). The crude product is combined with that from a repeat preparation to yield 10.1 g of formula CLXXII product which is chromatographed on silica gel eluting with 5% ethyl acetate in Skellysolve B (SSB, isomeric hexanes) to yield 6.93 g of 9-deoxy-9-methylene- 3-oxa-1,2,4,5,6-pentanor-3,7-inter-m-phenylene-PGF1, 3-(t-butyldimethylsilyl ether), 11,15 bis(tetrahydropyranyl ether). NMR absorptions are observed at 4.52-5.12 and 6.53--7.306. Infrared absorptions are observed at 1 600 and 1 655 cm~'. Silica gel TLC Rf is 0.39 in 10% ethyl acetate in hexane.
B. A degassed solution of 9-deoxy-9-methylene-3-oxa-1,2,4,5,6-pentanor-3,7-inter-m- phenylene-PGF1, 3-(t-butyldimethylsilyl ether), 11,1 5-bis(tetrahydropyranyl ether), the reaction product of Part A, (1.33 g) in dry tetrahydrofuran (70 ml) is cooled to OOC and treated under nitrogen with 0.5 M 9-borabicyclo[3.3.1]nonane (14 ml), dropwise over 5 min. The colorless solution is stirred for 4.5 hr at 0 and treated with 30% hydrogen peroxide (6 ml) followed by 3 N potassium hydroxide (6 ml). The resulting suspension is stirred for an additional 30 min at OOC and for 75 min while warming to room temperature. The reaction mixture is transferred to a separatory funnel, diluted with brine (300 ml) and ethyl acetate (300 ml).The layers are separated, and the aqueous layer extracted with ethyl acetate (600 ml). The organic extracts are washed with brine (6 ml), dried, filtered, and concentrated to formula CLXXIII product, a colorless oil (3.3 9), 9-deoxy-9α-(hydroxymethyl)-3-oxa-1,2,4,5,6-pentanor-3,7-inter-m- phenylene-PGF1, 3-(t-butyldimethylsilyl ether), 1 1,1 5-bis(tetrahydropyranyl ether). The crude formula
CLXXII I product is chromatographed on silica gel (300 g) in 35% ethyl acetate in hexane to yield 1.26 g of 9-deoxy-9a-(hydroxymethyl)-3-oxa- 1,2,4, 5,6-pentanor-3,7-inter-m-phenylene-PGF1, 3-(t- butyldimethylsilyl ether), 11,1 5-bis(tetrahydropyranyl ether) as a colorless oil.NMR absorptions are observed at 4.73, 5.12--5.70, 6.52--7.236. Infrared absorptions are observed at 3480 and 1670 cm~'. Silica gel TLC Rf is 0.21 in 35% ethyl acetate in hexane.
C. A degassed solution of 9-deoxy-9α-hydroxymethyl-3-oxa-1,2,4,4,5-pentanor-3,7-inter-m- phenylene-PGF,, 3-(t-butyldimethylsilyl ether), 11,1 5-bis(tetrahydropyranyl ether) (2.01 g), reaction product of Part B, in dry methylene chloride (45 ml) is cooled to -50C under nitrogen and treated with triethylamine (0.72 ml), then with methanesulfonyl chloride (0.76 ml). The resulting solution is stirred at -50C for 5 min then for 75 min while warming to ambient temperature. The reaction solution is poured over ice, and the resulting mixture swirled for a few minutes then transferred to a separatory funnel and partitioned between diethyl ether and brine. The layers are separated, and the aqueous layer extracted with ether (400 ml).The organic layer is washed with brine (200 ml) and saturated aqueous sodium bicarbonate (400 ml), dried, filtered and concentrated to a formula CLXXIV product, a colorless oil
(2.69 g), 9-deoxy-9a-mesyloxymethyl-3-oxa- 1 ,2,4,5,6-pentanor-3,7-inter-m-phenylene-P GF1, 3-(t-butyldimethylsilyl ether), 11,1 5-bis(tetrahydropyranyl ether). This product (2.69 g) is chromatographed on silica gel (185 g) eluting with 25% ethyl acetate in Skellysolve B to yield 1.99 g of 9-deoxy-9a'-mesyloxymethyl-3-oxa- 1 ,2,4,5,6-pentanor-3,7-inter-m-phenylene-P GF1), 11,1 5-bis(tetrahydropyranyl ether). NMR absorptions are observed at 2.95,4.70,5.20-5.70, and 6.52-7.22 S. Silica gel TLC Rf is 0.30 in 35% ethyl acetate in hexane.
D. A degassed solution of 9-deoxy-9a-mesyloxymethyl-3-oxa- 1 ,2,4,5,6-pentanor-3,7-inter-m phenylene-PGF1, 3-(t-butyldimethylsilyl ether), 11,1 5-bis(tetrahydropyranyl ether) (0.971 g), the reaction product of Part C, in dry tetrahydrofuran (35 ml) is cooled to 0 C and treated under nitrogen with 0.75 M tetrabutylammonium fluoride (2.6 ml). The resulting amber solution is stirred for 2.5 hr at 0-SCC and is partitioned between ethyl acetate (150 ml) and brine (150 ml). The layers are separated, and the aqueous layer extracted with ethyl acetate (300 ml).The organic layer is then washed with 0.5 M aqueous ammonium chloride (150 ml), saturated aqueous sodium bicarbonate (300 ml) and brine (150 ml), dried, filtered and concentrated to give 0.82 g of formula CLXXV product, 9-deoxy-9a- mesyloxymethyl-3-oxa- 1 ,2,4,5,6-pentanor-3,7-inter-m-phenylene- 11,1 5-bis(tetrahydropyranyl ether). Infrared absorptions are observed at 3330 cm-1. Silica gel TLC Rf is 0.37 in 50% ethyl acetate in hexane.
E. A degassed solution of 9-deoxy-9α-mesyloxymethyl-3-oxa-1,2,4,5,6-pentanor-3,7-inter-m- phenylene-PGF1, 11,1 5-bis(tetrahydropyranyl ether) (0.82 g), reaction product of Part D, is cooled to -400C under argon and treated with 57% sodium hydride (0.67 g). The resulting suspension is then stirred for 40 min at -400C then 1 5 min at OOC. The suspension is stirred for an additional 20 min while warming to room temperature and then stirred for 2.5 hr at reflux. The reaction is then cooled to 1 OOC, diluted with ice cold brine (200 ml) and extracted with ethyl acetate (450 ml). The ethyl acetate extracts are then washed with brine (300 ml), dried, filtered and concentrated to give 0.72 g of the formula CLXXVI crude product.The crude product is chroamtographed in silica gel (175 g) in 25% ethyl acetate in Skellysolve B to yield 0.49 g of 9-deoxy-2',9α-methano-3-oxa-1,2,4,5,6-pentanor-3,7- (1 ',3'-inter-phenylene)-PGF,, 11,1 5-bis(tetrahydropyranyl ether). NMR absorptions are observed at 4.77, 5.32-6.03, and 6.52--7.226. Infrared absorptions are observed at 3340 and 1670 cm~'. Silica gel TLC Rf is 0.56 in 35% ethyl acetate in hexane.
F. A degassed solution of 9-deoxy-2',9a-methano-3-oxa-1 ,2,4,5,6-pentanor-3,7-(1 ',3'-inter phenylene)-PGF1, 11,1 5-bis(tetrahydropyranyl ether) (0.47 g), reaction product of Part E, in dry glyme (15 ml) is cooled to 0 C and treated under nitrogen with methyl bromoacetate (0.26 mi) followed by 57% sodium hydride suspension (0.136 g). Following vigorous effervescence, a white precipitate is formed. The resulting suspension is stirred for 2.5 hr at O-50C, diluted with ice cold brine (200 ml) and extracted with ethyl acetate (450 ml). The ethyl acetate extracts are washed with brine (300 ml), dried over magnesium sulfate, filtered and concentrated to a pale yellow oil (0.62 g), formula CLXXVII compound, 9-deoxy-2',9a-methano-3-oxa- 1 ,2,4,5,6-pentanor-3,7-( 1 ',3'-internhenvlene-PGF,. methvl ester, 1 1,1 5-bis(tetrahydropyranyl ether). infrared absorptions are observed at 1765 and 1740 cm~'.
G.A solution of 9-deoxy-2',9α-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-inter-phenylene)-PFG1, methyl ester, 11,15-bis(tetrahydropyranyl ether) (0.62 g), reaction product of Part F, in acetic acid (1 5 ml), water (7.5 ml) and tetrahydrofuran (5 ml) is reacted at 45 C under nitrogen for 2.75 hr, cooled and diluted with ice cold brine (200 ml). The resulting suspension is extracted with ethyl acetate (400 ml), and the organic extracts washed with brine (400 ml), saturated aqueous sodium bicarbonate (600 ml) and brine (200 ml). The ethyl acetate extracts are then dried over magnesium sulfate, filtered and concentrated to give 0.44 g of pale yellow oil.
This crude product is chromatographed on silica gel (60 g) in 50% ethyl acetate in Skellysolve B to yield 0.37 g of product which was crystallized to yield 0.216 g of title product, 9-deoxy-2',9a-methano
3-oxa-4,5,6-trinor-3,7-(1',3'-inter-phenylene)-PGF1, methyl ester. Melting range is 82 - 84 C. NMR absorptions are observed at 3.77, 4.62, 5.42-5,63, and 6.53-7.25#. Infrared absorptions are
observed at 3520, 3400, and 1735 cm-1. Silica gel TLCR1 is 0.30 in 35% acetone in methylene
chloride.
H. A solution of 9-deoxy-2',9α-methano-3-oxa-4,5,6-trinor-3,7-(1 ',3'-inter-phenylene)-PGF,, methyl ester (0.15 g), reaction product of Part G, in 5% potassium hydroxide in 9:1 methanol-water
(5.5 ml) is stirred at 0 C under nitrogen. The solution is turbid initially and a precipitate forms within 5
min. The reaction is then stirred for one hr at 0 C, diluted with ice cold brine (90 ml), acidified with 1 N
hydrochloric acid, and extracted with ethyl acetate (180 ml).The ethyl acetate extract is then washed
with brine (270 ml), dried over magnesium sulfate, and concentrated under reduced pressure to yield a
waxy, semi-solid (0.131 g), which is crystallized to yield 0.105 g of title product, 9-deoxy-2',9α- methano-3-oxa-4,5,-6trinor-3,7-(1',3'-inter-phenylene)-PGF1, Melting range is 131-133 C. NMR
absorptions are observed at 4.68, 5.48-5.72, 6.68-7.22. Infrared absorptions are observed at 3460, 3280,1735,1720, and 1700 cm~'.
I. The dosage at which the title compounds should be administered to achieve their effect, chiefly
anti-platelet aggregation or blood pressure lowering, will vary according to the potency of the particular
compound under study. When given orally, the compounds will show a desired effect in man at a dose
from about 0.05 to about 50 mg/kg orally, preferably from about 0.1 to about 5 mg/kg. The compounds 9-deoxy-2',9α-methano-3-oxa-4,5,6-trinor-3,7-(1 ',3'-inter-phenylene)-PGF1, methyl ester, given to a
rat orally at a dose of 1 mg/kg lowered blood pressure 44 mmHg. After 52 min the blood pressure was
still lower 14 mm. Intravenous dosages for the desired effect are from about 1 to about 500 ng/kg/min
in man, preferably from about 10 to about 100 ng/kg/min.
EXAMPLE 32 9-Deoxy-2',9a-methano-3-oxa-4,5,6-trinor-3,7-( 1 ',3'-inter-phenylene)-1 6,16-difluoro-PGF, (Formula
XIX1 is - COOH, L1 is α-fluoro:ss-fluoro, R20, R20, R21 R23, and R24 are all hydrogen, Z is - CH2 -, R22 is
ss-hydrogen, R8, Y1, M1, and R7 are as defined in Example 8) and its corresponding methyl ester (X1 is -COOCH3).
Refer to Chart P.
A. Diethyl ether (55 ml) tri-n-butylphosphine (2.28 g) and cuprous iodide (2.13 g) are combined with stirring with the resulting mixture being alternately degassed and flushed with nitrogen at 250C 'for 1 hr. The resulting solution is then cooled to 780C and is hereafter referred to as solution 32-l.
Thereafter 60 ml of anhydrous diethyl ether and 6.47 g of m-bromo-phenol, t-butyldimethylsilyl ether
are combined and the resulting solution alternately degassed and flushed with nitrogen and cooled to --780C. After cooling, the resulting mixture is treated with 44.16 ml of a 1.02 M solution of t
butyllithium in n-pentane. This reaction mixture is then stirred at -780C for 1 hr and hereinafter referred
to as solution 32-ll.Solution 32-ll is then transferred with stirring over 15 min to solution 32-l under a
nitrogen atmosphere. The resulting solution changed in color from clear to yellow to an orange-brown
to tan. The resulting mixture is then stirred at - 78 C. for 30 min and labelled solution 32-III.Thereafter 4a-hydrnxy-3p(41,4'-difl uoro-3' a-hydroxy-trans- 1 '-octenyl)-2-methylene-cyclopentanone, 4,3'- bis(tetrahydropyran-2-yl ether), 4 g, Example 25 of United States Patent 4,181,798, and 38 ml of
anhydrous dry ethyl ether are combined with stirring and the resulting mixture alternately degassed
and flushed with nitrogen and thereafter cooled to -78"C. The resulting solution is referred to herein as
solution 32-IV. Solution 32-IV is then added to solution 32-III with vigorous stirring over 25 min at
- 78 C under a nitrogen atmosphere. The reaction mixture is then stirred at - 78 C for 30 min and
thereafter transferred to 100 ml of 8% glacial acetic acid in diethyl ether (-4O0C) with vigorous stirring
under a nitrogen atmosphere.The resulting mixture is then diluted with brine and extracted with diethyl
ether. The ethereal extracts are then washed with aqueous sodium bicarbonate in brine, dried over
sodium sulfate, concentrated under reduced pressure, and chromatographed on silica gel eluting with
20% ethyl acetate in Skellysolve B to yield 5.56 g of pure formula CLXXI compound: 16,16-difiuoro-3 oxa-1 ,2,4,5,6-pentanor-3,7-inter-m-phenylene-PGF1, 3-(t-butyldimethylsilyl ether), 11.15- bis(tetrahydropyran-2-yl ether). NMR absorptions (CDCl3) are observed at 0.18, 3.1-5.0, 5.67,
6.52-6.88, and 6.88-7.2#. Infrared absorptions are observed at 1745, 1600, 1585, 1490, 1275, 1260, 1200, 1155, 1125, 1075, 1035, 1025, 975, 840, and 780 cm~1. Silica gel TLC Rf is 0.36 and
0.41 in 25% ethyl acetate in Skellysolve B. Silica gel TLC Rf is 0.5 in 5% acetone in methylene chloride.
B. Following the procedure of Example 31, Part A, 3.47 g of the reaction product of Part A of this example is converted to 2.98 g of formula CLXXII product as a colorless oil, 9-deoxy-9-methylene-3- oxa-1 ,2,4,5,6-pentanor-3,7-inter-m-phenylene-1 6,1 6-difluoro-PGF1, 3-(t-butylsilyl ether), 11,15- bis(tetrahydropyranyl ether). NMR absorptions are observed at 0.17, 0.97, 1.0-3.2, 3.2-4.4 4.4-5.0, 5.3-6.0, and 6.4-7.3#. frared absorptions are observed at 1655, 1605, 1585, 1485, 1275, 1260, 1200, 1144, 1125, 10, 0 1025, 970, 870, and 780 cm-1. Silica gel TLCR, is 0.31 and at 0.36 in 10% ethyl acetate in hexane.
C. Following the procedure of Example 31, Part B, 2.83 g of the reaction product of Part B of this example is converted to 2.5 g of form8ula CLXXIII product as a colorless oil, 9-deoxy-9α- (hydroxymethyl)-3-oxa-1,2,4,5,6-pentanor-3,7-inter-m-phenylene-16,16-difluoro-PGF1, 3-(tbutyldimethylsilyl ether), 11,15-bis(tetrahydropyranyl ether). NMR absorptions (CDCl3) are observed at 0.18, 0,98, 1.15-3.0, 3.0-4.5, 4.5-5.0, 5.3-5.9, and 6.4-7.3#. Infrared absorptions are observed at 3460, 1670, 1600, 1585, 1485, 1275, 1260, 1160, 1135, 1125, 1075, 1025, 975, 840, and 780 cm~'. Silica gel TLC Rf is 0.28 in 35% ethyl acetate in hexane.
D. Following the procedure of Example 31, Part C, the reaction product of Part C of this example (2.29 g) is converted to 1.83 g of formula CLXXIV product as a colorless oil, 9-deoxy-9a- mesyloxymethyl-3-oxa-1 ,2,4,5,6-pentanor-3,7-inter-m-phenylene-1 6,1 6-difluoro-PGF1, 3-(tbutyldimethylsilyl ether), 11,1 5-bis(tetrahydropyranyl ether). NMR absorptions are observed at 0.18, 0.98, 1.15-2.85, 2.95, 3.1-4.5,4.5-5.0, 5.2-5.9, and 6.57.4S. Infrared absorptions are observed at 2930, 2860, 1605, 1590, 1490, 1465, 1440, 1360, 1275, 1200, 1175, 1120, 1025, 975, and 840 cm-1. Silica gel TLCR, is 0.28 in 30% ethyl acetate and hexane.
E. Following the procedure of Example 31, Part D, 1.7 g of the reaction product of Part D of this example is converted to 1.6 g of formula CLXXV product as a yellow oil, 9-deoxy-9α-mesyloxymethyl- 3-oxa-1,2,4,5,6-pentanor-3,7-inter-m-phenylene-16,16-difluoro-PGF1, 11,15-bis(tetrahydropyranyl ether). Silica gel TLCR, is 0.34 in ethyl acetate and hexane (1:1).
F. Following the procedure of Example 31, Part E, 1.52 g of the reaction product of Part D of this example is converted to 0.83 g of formula CLXXVI product as a white foam, 9-deoxy-2',9a-methano-3- oxa-1,2,4,5,6-trinor-3,7-)1',3'-inter-phenylene)-16,16-difluoro-PGF1, 11,15-bis(tetrahydropyranyl ether).
NMR absorptions are observed at 0.95, 1.05-2.95, 3.5-5.0 5.3-6.0, and 6.5-7.2#. Infrared absorptions are observed at 3350, 2930, 1670, 1615, 1590, 1465, 1280, 1200, 1120, 1070, and 975 cm-1. The mass spectrum exhibits peaks at 534, 451, 446, 402, and 348. Silica gel TLCR, is 0.26 in ethyl acetate and hexane (1 :3) and 0.40 in acetone and methylene chloride (1:19).
G. Following the procedure of Example 31, Part F, 0.80 g of the reaction product of Part F of this example is converted to 1.06 g of formula CLXXVII product as a colorless oil, 9-deoxy-2',9a-methano- 3-oxa-4,5,6-trinor-3,7-( 1 ',3'-inter-phenylene)-1 6,1 6-difluoro-PGF,, methyl ester, 11,15- bis(tetrahydropyranyl ether). Silica gel TLC Rf is 0.44 in 5% acetone and methylene chloride.
H. Following the procedure of Example 31, Part G, 1.0 g of the reaction product of Part G of this example is converted to 0.62 g of crystalline methyl ester title product, a Formula CLXXVI II white solid.
Recrystallization from hexane in diethyl ether yields a material with melting range 93-950C. NMR absorptions are observed at 3560, 3400, 1765, 1750, 1735, 1720, 1675, 1605, 1585, 1270, 1215.
1205, 1120, 1105, 1080, 1010, 970, and 770 cm-1. The mass spectrum for the bis-trimethylsilyl derivative exhibits a high resolution peak at 582.2997. Silica gel TLCR, is 0.35 in hexane and ethyl acetate (1 :4).
Following the procedure of Example 31, Part H, the reaction product of Part H of this example (0.25 g) is converted to the carboxylic acid title product (158 mg) as a crystalline solid. Melting range is 128-130 C. NMR absorptions (COCD3) are observed at 0.9, 1.3-3.0, 3.0-4.6, 4.68, 4.8-5.5, 6.5-6.9, 5.5-5.9, and 6.6-7.3#. Infrared absorptions are observed at 3570, 3480, 3370, 3220, 2800, 1740, 1720, 1605, 1585, 1235, 1210, 1125, 1105,1080, 1000, and 970 cm-1. The mass spectrum for the tris-trimethylsilyl derivative exhibits a high resclution peak at 640.3232. Silica gel TLC
R1 is 0.18 in the A-IX solvent system.
Following the procedure of Examples 31 and 32, there are prepared each of the various formula
CLXXVIII products in free acid or ester form from corresponding formula CLXXI reactants.
Formula CLXXVIII compounds wherein Y, is unsaturated (trans- or cis-CH=CH-) are transformed to corresponding formula CLXXVIII compounds wherein Y is saturated (-CH2CH2-) by hydrogenation, as exemplified below:
EXAMPLE 33 9-Deoxy-2',9α-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-inter-phenylene)13,14-dihydro-PGF, (Formula Xl: X, is COOH, Y, is -CH2CH2-, R20, R2r, R23, and R24are all hydrogen, This -CH2-, R22 is p hydrogen, R8, M1, L1 and R7 are as defined in Example 8) and its corresponding methyl ester (X1 is -COOCH3).
A. A solution of the methyl ester title product of Example 31 (0.341 g) in ethyl acetate (35 ml) is treated at ambient temperature with 5% palladium-on-charcoal and hydrogenated at atmospheric pressure. The resulting suspension is then stirred for 70 minutes with a hydrogen uptake of 20 ml (atmospheric pressure). The resulting suspension is then filtered through diatomaceous earth and the filter cake washed with ethyl acetate. The combined filtrate is then concentrated under reduced pressure to yield a colorless oil which is chromatographed on silica gel eluting with ethyl acetate in
Skellysolve B to yield 0.306 g of title product (methyl ester), a colorless oil.NMR absorptions (CDCI3) are observed at 0.9, 0, 1.07-1.23, 3.3-4.03, 3.77, 4.62, 6.52, and 7.27 S. Infrared absorptions are observed at 3350, 2930, 2855, 1 760, 1740, 1 605, 1585, 1467, 1435, 1275, 1205, 1120, 1080, 1025, and 775 cm~'. Silica gel TLC Rf is 0.54 in ethyl acetate.
B. Following the procedure of Example 31, Part H, the title product of Part A of this example (0.177 g) is converted to 0.23 g of title product (free acid) as a solid. Recrystallization from ethyl acetate in hexane yields 0.096 g with melting range 121-1 230C. The mass spectrum for the tris-trimethylsilyl derivatives exhibits a high resolution peak at 606.3553 and other peaks at 591-535, 516,427,426, 275, 274, 173, and 1 57. Silica gel TLC Rf is 0.27 in A--IX.
EXAMPLE 34 9-Deoxy-2',9p-methano-3-oxa-4,5,6-trinor-3,7-(1 ',3'-inter-phenylene)-PGF, (Formula XI: X, is COOH,
R20, R2r, R22, and R24 are all hydrogen, Z4 is -CH2-, R22 is a-hydrogen, RB, Y, M, Lr, and R7 are as defined in Example 8) and its corresponding methyl ester (X, is -COOCH3).
Refer to Charts Q and R.
A. A solution of 0.82 g of the reaction product of Example 31, Part B in 1 6 ml of methylene
chloride is stirred at ambient temperature under nitrogen atmosphere and treated with diatomaceous earth followed by 26 ml of Collins reagent prepared from 2.5 ml of pyridine and 1.55 g of chromium trioxide in 50 ml of methylene chloride). The resulting suspension is then stirred for 35 min at ambient temperature under a nitrogen atmosphere and filtered through 30 g of silica gel, eluting with 1 50 ml of ehtyl acetate. Concentration under reduced pressure yields 0.90 g of a pale yellow oil.
Chromatographing on 85 g of silica gel eluting with 20% ethyl acetate in Skellysolve B yields 0.644 g of pure formula CLXXXII aldehyde as a colorless oil, 9-deoxo-9a-formyl-3-oxa-1 ,2,4,S,6-pentanor-3,7- inter-m-phenylene-PGF,, 3-(t-butyldimethylsilyl ether), 11,1 5-bis(tetrahydropyranyl ether). NMR
absorptions are observed at 0.18, 0.88, 0.98, 1.13-3.08, 3.23-4.35, 4.73, 5.25-5.75, 6.57-7.37, and 9.88S. Infrared absorptions are observed at 2730, 1 720, 1600, 1 585, 1485, 1275, 1260, 1075, 1035, 1030, 1020, 975, and 840 cm~'. Silica gel TLC Rf is 0.47 in ethyl acetate and hexane(l3).
B. A degassed solution of 1.5 g of the reaction product of Part A and 0.36 ml of 1,8diazobicyclo[5.4.0]undec-7-ene in 150 ml of methylene chloride is stirred for 40 hr at ambient temperature under a nitrogen atmosphere, washed with 100 ml of ice cold 0.1 5 M aqueous potassium bisulfate, 100 ml of saturated aqueous sodium carbonate, and 100 ml of brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield 1.5 g of formula CXCII product as a yellow oil, 9-deoxy-9pformyl-3-oxa-1 ,2,4,5,6-pentanor-3,7-inter-m-phenylene-PGF1, 3-(tbutyldimethylsilyl ether), 11,1 5-bis(tetrahydropyranyl ether).NMR absorptions (CDCI3) are observed at 0.18,0.89,0.98, 1.1-3.2,3.2-4.4,4.68, 5.2-5.8, 6.58-7.4, and 9.22S. Infrared absorptions are observed at 1725,1600,1585,1485, 1440,1275,1260,1200,1 160,1130,1075,1035, 1020, 975, 870, and 840 cm~'. Silica gel TLC Rf is 0.24 in ethyl acetate and hexane (1:3).
C. A solution of 1.5 g of the reaction product of Part B in 40 ml of methanol is treated with stirring at 200C under a nitrogen atmosphere over several minutes with 400 mg of sodium borohydride, stirred for 20 min at 200 C. The resulting mixture is then added to a cold solution of 200 ml of brine and 32 ml of 0.1 M aqueous potassium sulfate, extracted with 600 ml of ethyl acetate, washed with 200 ml of saturated aqueous sodium bicarbonate in 200 ml of brine, dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and chromatographed on 200 g of silica gel eluting with 35% ethyl acetate in hexane to yield 1.37 g of formula CLCIII product as a colorless oil, 9-deoxy-9p hydroxymethyl-3-oxa-1 ,2,4,5,6-pentanor-3,7-inter-m-phenylene- 3-(t-butyldimethylsilyl ether), 1 1,1 5-bis(tetrahydropyranyl ether). NMR absorptions (CDCl3) are observed at 0.17, 0.88, 0.99, 1.1-3.0,3.0-4.35,4.7, 5.25-5.85, and 6.57.4S. Infrared absorptions are observed at 3460, 1665,1605,1585,1490, 1275,1260,1200,1160,1 1135,1115,1075,1120,1005,975,840,and 780 cm~'. Silica gel TLC Rf is 0.20 in 35% ethyl acetate in hexane.
D. A degassed solution of 1.32 g of the reaction product of Part B in 0.47 ml of methylene chloride at 200C under a nitrogen atmosphere is treated with 0.5 ml of methanesulfonyl chloride, stirred for 5 min at OOC, warmed to 200C over 90 min, added to 50 g of ice, diluted with 150 ml of brine extracted with 450 ml of diethyl ether, washed with 1 50 ml of brine and 300 ml of saturated aqueous sodium bicarbonate, dried over anhydrous magnesium sulfate, concentrated under reduced pressure to yield an oil, and filtered through 70 g of silica gel eluting with 30% ethyl acetate in hexane to yield 1.47 g of mesylate corresponding to the starting material, i.e., the 9P analog of formula CLXXIV. Silica gel TLC Rf is 0.23 in 30% ethyl acetate in hexane.
E. A degassed solution of 1.47 g of the reaction product of Part D and 50 ml of dry tetrahydrofuran at 0 C under a nitrogen atmosphere is treated with 3.9 ml of 0.45 M tetra-n-butylammonium fluoride.
The resulting solution is then stirred at 0 C for 4 hr, treated with another 0.5 ml of tetra-nbutylammonium fluoride, stirred for 30 min at OOC, diluted with 150 ml of brine, extracted with 450 ml of ethyl acetate, washed successively with 1 50 ml of 0.5 M aqueous ammonium chloride, 300 ml of saturated aqueous sodium bicarbonate. and 150 ml of brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to yield 1.3 g of a yellow oil, the phenol corresponding to the starting material, i.e., the 9p isomer of the formula CLXXV compound. Silica gel TLC Rf is 0.1 1 in 35% ethyl acetate in hexane.
F. A degassed solution of 1.3 g of the reaction product of Part E in 75 ml of dry glyme at -400C under a nitrogen atmosphere is treated with 90 mg of 57% sodium hydride dispersion in mineral oil, stirred at -40 to -300C for 40 min, stirred at 0 C for 15 min, stirred at ambient temperature for 15 min, heated and refluxed for 5 hr, cooled to ambient temperature, added to 200 ml of ice cold glyme, extracted with 450 ml of ethyl acetate, washed with 300 ml of brine, dried over anhydrous on 175 g of silica gel eluting with 25% ethyl acetate in hexane to yield 0.61 g of the 9ss isomer corresponding to the formula CLXXVI compound as a viscous oil.NMR absorptions are observed at 0.90, 1.07-3.1, 3.1--4.4, 4.75, 5.33-6.16, and 6.5-7.28. Infrared absorptions are observed at 3340, 1665, 1610, 1585, 1500, 1465, 1 135, 1110, 1075, 1020, and 980 cm~'. Silica gel TLC Rf is 0.26 in 25% ethyl acetate in hexane and 0.23 in 5% acetone in methylene chloride.
G. A solution of 0.50 g of the reaction product of Part F in 28 ml of methyl bromoacetate in 16 ml of dry glyme at 0 C under an argon atmosphere is treated witth 0.14 g of a 57% mineral oil dispersion of sodium hydride. The resulting suspension is then stirred for 2.5 hr at 0 C, quenched with 200 ml of cold brine, extracted with 460 ml of ethyl acetate, washed with 300 ml of brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to yield 0.68 g of an oil, the 9ss isomer corresponding to the formula CLXXVI I compound.
H. A solution of the reaction product of Part G (0.68 g) in 5 ml of tetrahydrofuran, 7.5 ml of water, and 15 ml of acetic acid is heated for 2.5 hr at 450C, cooled, diluted with 200 ml of brine, extracted with 400 ml of ethyl acetate, washed with 400 ml of brine, washed with 200 ml of saturated aqueous sodium bicarbonate, and 200 ml of brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure to yield an oil, chromatographed on 75 g of silica gel eluting with 30% hexane in ethyl acetate to 1 00% ethyl acetate to yield 0.32 g of title methyl ester as a white foam. Crystallization from hot diethyl ether in hexane yields 0.23 g of pure ester product as a white solid.Melting range is 85-870C. NMR absorptions (CDCl3) are observed at 0.90, 1.07-2.9, 2.9-4.5, 4.61, 5.4-5.8, and 6.38-7.34#. Infrared absorptions are observed at 3520, 3420, 1735, 1720, 1605, 1580, 1300,
1240, 1210, 1 1 10, 1085, 1050, 1010, 970, 760, 720, and 710 cm~'. The mass spectrum of the bistrimethylsilyl derivative exhibits a high resolution peak at 546.3182. Silica gel TLC Rf is 0.14 in 30% ethyl acetate in hexane.
I. Following the procedure of Example 31, Part H, the title product of Part H (1 58 mg) is transformed to the title free acid (129 mg) as a white solid. Melting range is 150-1 540C. NMR absorptions are observed at 0.90, 1.07-3.5, 3.85-4.35, 4.70, 5.09-5.9, and 6.5-7.3. Infrared
absorptions are observed a't 3380, 2640, 2560, 1730, 1605, 1580, 1260, 1230, 1 1 15, 1050, 1025, 970, and 770 cm~'.
Following the procedure of Example 34, each of the various formula Xl compounds are prepared wherein R22 is hydrogen. Further following the procedure of Example 33, the various 9,B-methano isomers of Example 34 and corresponding formula XI compounds wherein Y, is cis- or trans-CH=CH- are hydrogenated to corresponding 13,14-dihydro-PGF, compounds.
EXAMPLE 35 9-Deoxo-2',9-methano-3-oxa-4,5,6-trinor-3,7-(1 ',3'-inter-phenylene)-PGF, (Formula XI: X, is COOH,
R20, R21, R23, and R24 are all hydrogen, Z4 is-CH2-, R2, and R22 taken together form a valence bond, R8, Y1,M1, L1, and R, are as defined in Example 8) and its corresponding methyl ester (X, is -COOCH3).
Refer to Chart T.
A. A degassed solution of the product of Example 34, Part A, (1.68 g) in dry tetrahydrofuran (50 ml) is coled to 0 C and treated under a nitrogen atmosphere with 0.75 M tetrabutylammonium fluoride (4.37 ml). The resulting solution is then stirred at 0 C for 2 hr, diluted with brine (300 ml), extracted with ethyl acetate, washed with brine, dried over magnesium sulfate, filtered, and concentrated under reduced pressure to yield 2.3 g of an oil. The oil is chromatographed on silica gel (160 g) in 25% ethyl acetate in Skellysolve B yielding 1.21 g of formula CCXI compound, 9-deoxo-9a- formyl-1 ,2,4,5,6-pentanor-3,7-inter-m-phenylene-PGE1, 11,1 5-bis(tetrahydropyranyl ether).NMR absorptions (CDC13) are observed at 0.88, 1.13-3.15,3.27-4.47, 4.71,6.10,6.53-7.41, 9.27 & Infrared absorptions are observed at 3345, 2930, 2860, 2720, 1 735, 1715, 1 605, 1595, 1 585, 1485, 1450, 1370, 1350, 1255, 1235, and 970 cm~'. Silica gel TLC Rf is 0.12 in 25% ethyl acetate and
hexane and 0.39 in 50% ethyl acetate in hexane.
B. A degassed solution of 0.28 g of the reaction product of Part A in 33 ml of glyme is cooled to -4O0C under argon and treated with 2.95 N methylmagnesium chloride in tetrahydrofuran (0.2 ml).
The reaction mixture is stirred at -400C for 15 min, stirred at O"C for 15 min, permitted to warm to
ambient temperature, stirred at reflux for 11 5 hr under an argon atmosphere, cooled, diluted with ice
cold brine (1 50 ml), extractd with ethyl acetate (300 ml), washed with brine (300 ml), dried over
magnesium sulfate, filtered, concentrated under reduced pressure to yield 0.31 g of an oil, and
chromatographed on silica gel eluting with 25% ethyl acetate in Skellysolve B to yield 0.16 g of the formula CCXII compound, 9-deoxo-2',9-metheno-3-oxa- 1 2.4,5,6-pentanor- 3,7-(1',3' inter phenylene)-PGE1, 1 1,1 5-bis(tetrahydropyranyl ether).The mass spectrum of the trimethylsilyl derivative exhibits a molecular peak at 568 and other peaks at 466, 382, 364, 314, 297, 267, 255, 243, 230, 270, 153, and 85. Silica gel TLC Rf is 0.25 in 25% ethyl acetate in hexane and 0.58 in 50% ethyl acetate in hexane.
C. A degassed solution of the reaction product of Part C (0.1 6 g) in dry glyme (5 ml) is cooled at -50C and treated with methylbromo acetate (0.04 ml) under a nitrogen atmosphere. The resulting solution is then treated with 50% sodium hydride dispersion in mineral oil (0.1 6g). Precipitate forms in 5 min in the resulting suspension is stirred for 1.5 hr at OOC, diluted with brine (100 ml), extracted with ethyl acetate (240 ml), washed with brine (100 ml), dried over magnesium sulfate, filtered, concentrated to yield a brown residue which solidifies on refrigeration, and chromatographed on 25 g of silica gel eluting with 20% ethyl acetate in Skellysolve B to yield 0.136 g of the bis(tetrahydropyranyl ether) of a formula CCXIII compound: 9-deoxy-2',9-metheno-3-oxa-4,5,6-trinor-3,7-(1 ',3'-inter phenylene)-PGE1, methyl ester, 11,1 5-bis(tetrahydropyranyl ether). Melting range is 81-830C.The mass spectrum exhibits peaks at 366, 384, 364, 279, 247, 230, 215, 149, and 85. Silica gel TLC Rf is 0.45 in 5% acetone in methylene chloride.
D. A solution of the reaction product of Part C (0.12 g) in tetrahydrofuran (1 ml), water (2 ml) and acetic acid (4 ml) is heated at 450C under a nitrogen atmosphere for 2.25 hr, cooled, and partitioned between brine (100 ml) in ethyl acetate (90 ml). The layers are separated and the aqueous layer extracted with ethyl acetate (160 ml). The organic layers are then washed successively with brine (100 ml), water (100 ml), saturated aqueous sodium bicarbonate (300 ml) and brine (200 ml), dried over magnesium sulfate, filtered, concentrated to yield 0.97 g of a solid, and chromatographed on 30 g of silica gel, eluting with 85% ethyl acetate in hexane to yield 0.083 g of white crystalline formula CCXIII title product in methyl ester form. Recrystallization from diethyl ether in hexane yields 0.056 g of pure methyl ester title product.Melting range is 96-980C. NMR absorptions (CDCl3) are observed at 0.94, 3,86,3.92-4.28, 4.72, 5.58-5.86, and 6.627.1 8S. Infrared absorptions are observed at 3420, 1765, 1665, 1600, 1575, 1465, 1440, 1275, 1215, 1190, 1 105, 1085, 970 and 770 cm-'. The mass spectrum for the trimethylsilyl derivative exhibits a molecular ion at 554 and other peaks at 454, 383, 365, 364, 230, 229, 225. Silica gel TLC Rf is 0.41 in ethyl acetate.
E. Following the procedure of Example 31, Part H, the reaction product of Part D (0.19 g) is converted to 76 mg of crystalline title product in free acid form. Melting range is 1 50-1 520C. NMR absorptions (CDCI3) are observed at 0.91, 1.2-3.48, 3.88-4.15, 4.70, 5.62-4.66, and 6.63-7.11.
The mass spectrum for the trimethylsilyl derivative exhibits a high resolution peak at 602.3251 and other peaks at 512, 422, 287, 225, 174, and 173. Silica gel TLC Rf is 0.23 in the A-IX solvent system.
EXAMPLE 36 9-Deoxy-2',9a-methano-3-oxa-4,5,6,1 13,14,15,16,17,18,1 9,20-undecanor-3,7-(1 ',3'-inter- phenylene)-1 2-formyl-PGF1, methyl ester (formula CCXXI I: X, is -COOCH3, Z4is-CH2-, R20, R21, and
R23 are hydrogen, R22 is p-hydrogen, and R,8 is tetrahydropyran-2-yl-oxy).
Refer to Chart U.
Ozone is bubbled through a solution of 0.72 g of the reaction product of Example 31, Part F, in 50 ml of absolute methanol at -780C for 5 min. Thereafter oxygen is bubbled through the resulting solution for 5 min and the solution is treated with 16 ml of dimethyl sulfide. After standing at 16 hr for 0 C under a nitrogen atmosphere and 2- hr at ambient temperature, the solution is diluted with 200 ml of ethyl acetate, washed successively with 100 ml of brine, 100 ml of saturated aqueous sodium bicarbonate and 100 ml of brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and chromatographed on 175 g of silica gel eluting with 35% ethyl acetate in hexane to yield 367 mg of title product as a colorless oil.NMR absorptions (CDCI3) are observed at 1.0-3.0, 3.1 4.5, 3.63, 6.45-7.34, and 9.77#. The mass spectrum exhibits peaks at 388 and 304. Silica gel
TLC Rf is 0.19 and 0.22 in 25% and 30% ethyl acetate in hexane.
EXAMPLE 37 9-Deoxy-2',9α-methano-20-methyl-3-oxa-4,5,6-trinor-3,7-( 1 1,3'-inter-phenylene)-PGF1 (Formula Xl:
X1, Z4, R3, R20, R21, R22, R23, R24, Y1, M1, and L1 are as defined in Example 31 and R7 is n-pentyl) its methyl ester (Z1 is - COOCH3), its 15-epimer (M1 is α-H : ss-OH), and 15-epimer methyl ester (M1 is a-H:p-OH and Z isCCOCH).
Refer to Chart U.
A. A suspension of 56 mg of a 57% sodium hydride dispersion in mineral oil and 4 ml of tetrahydrofuran at 0 C under a nitrogen atmosphere is treated with a solution of 286 mg of dimethyl-2octylphosphonate in 4 ml of tetrahydrofuran, stirred for 5 min at OOC, stirred for 1 hr at ambient temperature, cooled to OOC, treated with a solution of 0.39 g of title product of Example 36 and 4 ml of tetrahydrofuran, stirred for 2 hr at ambient temperature, cooled in OOC, added to a solution of 40 ml of ethyl acetate containing several drops of acetic acid), extracted with 120 ml of ethyl acetate, washed with 30 ml of saturated aqueous sodium bicarbonate, washed with 30 ml of brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure to yield an oil, and chromatographed on 60 g of silica gel eluting with 25% ethyl acetate in hexane to yield 0.42 g of a colorless oil, 9,1 5-dideoxy-1 5- keto-2',9α-methano-29-methyl-4,5,6-trinor-3,7-(1',3'-inter-phenylene)-PGF1, methyl ester, 11tetrahydropyranyl ether. NMR absorptions are observed at 0.89, 1.05-3.0, 3.5-4.37, 4.62, and 5.977.30. The mass spectrum exhibits peaks at 414,396, 323, 311, and 301. Silica gel TLC Rf is 0.26 in 25% ethyl acetate in hexane.
B. A degassed solution of 42 mg of sodium borohydride and 4 ml of absolute methanol at -300C under a nitrogen atmosphere is treated dropwise with a solution of 391 mg of the title reaction product of Part A in 0.3 ml of methylene chloride and 3 ml of methanol, stirred for 1 w hr at -300C, quenched by careful addition of 0.2 ml of glacial acetic acid, diluted with 70 ml of brine, extracted with 210 ml of ethyl acetate, washed with 70 ml of saturated aqueous sodium bicarbonate, washed with 70 ml of brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure to yield 0.42 g of a colorless oil, and chromatographed on 60 g of silica gel eluting with 40% ethyl acetate in hexane to yield 0.36 g of an epimeric mixture of C-l 5 alcohols.Silica gel TLC Rf is 0.20 in 40% ethyl acetate in hexane.
C. A solution of the reaction products of Parts B above in 3 ml of tetrahydrofuran, 4.5 ml of water, and 9 ml of acetic acid is heated to 450C under a nitrogen atmosphere for 2.5 hrs, cooled, diluted washed with 100 ml of brine, extracted with 200 ml of ethyl acetate, washed with 100 ml of brine, washed with 300 ml of saturated aqueous sodium bicarbonate and 100 ml of brine, dried over an hydrous sodium sulfate, concentrated under reduced pressure to a yellow oil, and chromatographed on 60 g of silica gel eluting with 20% ethyl acetate in methylene chloride to yield 96 mg of 9-deoxy-2',9a-methano-20-methyl-3-oxa-4,5,6-trinor-3,7-(1 ,3-inter-phenylene)-1 5-epi- PGF1, methyl ester as a colorless oil and 159 mg of 9-deoxy-2',9a-methano-20-methyl-3-oxa-4,5,6- trinor-3,7-(1,3-inter-phenylene)-PGF1, methyl ester as a white solid. Recrystallization of the 1 Sa-hydroxy compound from hot hexane in diethyl ether yields 140 mg as a white solid. Melting range is 79-820C.
For the title product methyl ester, NMR absorptions are observed at 0.92, 1.08-3.0, 3.38-4.5, 4.64, 5.33-5.70, and 6.5-7.4. The mass spectrum of the trimethylsilyl derivative exhibits a high resolution peak at 560.3375. Silica gel TLC Rf is 0.19 in 20% ethyl acetate in methylene chloride and 0.31 in 20% hexane in ethyl acetate. For the 1 5-epi compound, NMR absorptions (CDC13) are observed at 0.89, 1.07-3.0, 3.7-4.33, 4.63, 5.5-5.8, and 6.557.37a. Infrared absorptions are observed at 3360, 1765, 1 750, 1735, 1 605, 1585, 1470, 1440, 1205, 1120, 1080, 970, and 770 cm. The mass spectrum for the trimethylsilyi derivative exhibits a high resolution peak at 560.3385.Silica gel TLC Rf is 0.35 in 20% acetone and methylene chloride and 0.45 in 20% hexane and ethyl acetate.
D. Following the procedure of Example 31, Part H, the 1 Sa-hydroxy title product of Part C (94 mg) is transformed to 9-deoxy-2',9α-methano-20-methyl-3-oxa-4,5,6-trinor-3,7-(1,3-inter-phenylene)- PGF1,title free acid, as a white solid, 81 mg. Melting range is 144-1 460C. NMR absorptions (CD3COCD3) are observed at 0.8, 1.05-2.9, 3.2-4.5, 4.65, 5.38-5.56, and 6.67.2a. The mass spectrum of the trimethylsilyl derivative exhibits a high resolution peak at 618.3576. Silica gel TLC Rf is 0.14 in the A-IX solvent system.
E. Further following the procedure of Example 31, Part H, the 1 5-epi title product of Part C (93 mg) is converted to 9-deoxy-2',9α-methano-20-methyl-3-oxa-4,5,6-trinor-3,7- (1,3-inter-phenylene)- 15-epi-PGF,, a white solid, 72 mg. Melting range is 105-1 08cC. MMR absorptions (CD3COCD3) are observed at 0.90, 1.05-2.9, 3.2-4.3, 4.71, 5.0-5.84, and 6.5-7.34#. Silica gel TLC Rf is 0.19 in the A-IX solvent system.
Following the procedures of Examples 36 and 37, there are substituted C-12 side chains according to the procedure of Chart U for each of the various formula Xl compounds.
Thus, according to procedures described above, there are prepared (5E)-9,B-methyl-CBAz compounds, (5Z)-9,B-methyl-CBA2 compounds, (5E)-5-fluoro-9}3-methyl-CBA2 compounds, (5Z)-5-fluoro-9/3-methyl-CBA2 compounds,
(5E)-5-fluoro-CBA2 compounds,
(5Z)-5-fluoro-CBA2 compounds, (5E)-9,B-methyl-2,5-inter-o-phenylene-3,4-dinor-CBA2 compounds, (5Z)-9p-methyl-2,5-inter-o-phenylene-3,4-dinor-CBA2 compounds,
(5E)-9ss-methyl-1,5-inter-o-phenylene-2,3,4-trinor-CBA, compounds, (5E)-9,B-methyl-1,5-inter-o-phenylene-3,4,5-trinor-CBA2 compounds,
(5E)-2,5-inter-o-phenylene-3,4-dinor-CBA2 compounds,
(5Z)-2,5-inter-o-phenylene-3,4-dinor-CBA2 compounds,
(5E)-1,5-inter-m-phenylene-2,3,4-trinor-CBA, compounds, (5Z)-1,5-inter-m-phenylene-2,3,4-trinor-CBA2 compounds,
2,2-difluoro-(5E)-9ss-methyl-CBA2 compounds, 2,2-difluoro-(5Z)-9ss-methyl-CBA2 compounds,
2,2,5-trifluoro-(5E)-9ss-methyl-CBA2 compounds,
2,2,5-trifluoro-(5Z)-9ss-methyl-CBA2 compounds, 2,2,5-trifluoro-( 5E)-CBA2 compounds, 2 ,2,5-trifluoro-( 5Z)-CBA2 compounds, 2,2-difluoro-(5E)-9p-methyl-2,5-inter-o-phenylene-3,4-dinor-CBA2 compounds, 2,2-difluoro-(5Z)-9p-methyl-2,5-inter-o-phenylene-3,4-dinor-CBA2 compounds,
2,2-difluoro-(5E)-9ss-methyl-1,5-inter-o-phenylene-2,3,4-trinor-CBA2 compounds,
2,2-difluoro-(5E)-9ss-methyl-1,5-inter-o-phenylene-3,4,5-trinor-CBA2 compounds,
2,2-difluoro-(5E)-2,5-inter-o-phenylene-3,4-dinor-CBA2 compounds.
2,2-difluoro-(5Z)-2,5-inter-o-phenylene-3,4-dinor-CBA2 compounds, 2,2-difluoro-(5E)-1,5-inter-m-phenylene-2,3,4-trinor-CBA2 compounds, 2,2-difluoro-(5Z)-1,5-inter-m-phenylene-2,3,4-trinor-CBA2 compounds,
trans-2,3-didehydro-(5E)-9ss-methyl-CBA2 compounds,
trans-2,3-didehydro-(5Z)-9ss-methyl-CBA2 compounds, trans-2,3-didehydro-(5E)-5-fluoro-9,0-methyl-CBA2 compounds, trans-2,3-didehydro-(5Z)-5-fluoro-9p-methyl-CBA2 compounds,
trans-2,3-didehydro-(5E)-5-fluoro-CBA2 compounds,
trans-2,3-didehydro-(5Z)-5-fluoro-CBA2 compounds,
trans-2,3-didehydro-(5E)-9ss-methyl-2,5-inter-o-phenylene-3,4-dinor-CBA3 compounds,
trans-2,3-didehydro-(5Z)-9ss-methyl-2,5-inter-o-phenylene-3,4-dinor-CBA2 compounds,
trans-2,3-didehydro-(5E)-9ss-methyl-1,5-inter-o-phenylene-2,3,4-trinor-CBA2 compounds,
trans-2,3-didehydro-(5 E)-9pmethyl- 1 ,5-inter-o-phenylene-3,4,5-trinor-CBA2 compounds, trans-2,3-didehydro-(5 E)-2,5-inter-o-phenylene-3,4-dinor-CBA2 compounds, trans-2,3-didehydro-(5Z)-2,5-inter-o-phenylene-3,4-dinor-CBA2 compounds,
trans-2,3-didehydro-(5E)-1,5-inter-m-phenylene-2,3,4-trinor-CBA2 compounds,
trans-2,3-didehydro-(5Z)-1,5-inter-m-phenylene-2,3,4-trinor-CBA2 compounds, 9-deoxy-2',9α-methano-3-oxa-4,5,6-trinor-3,7-(1 ',3' -inter-phenylene)-PGF, compounds,
9-deoxy-2',9ss-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-inter-phenylene)-PGF, compounds.
9-deoxy-2',9-methano-3-oxa-3,4,5-trinor-3,7-(1',3'-inter-phenylene)-7,8-didehydro-PGF1 compounds, 9-deoxo-2',9-methano-3-oxa-3,4,5-trinor-3,7-(1',3'-inter-phenylene)-PGF, compounds, 6a-oxo-9-deoxy-2',9a-methano-3-oxa-4,5,6-trinor-3,7-( 1 ',3'-inter-phenylene)-PGF1, compounds, 6a-oxo-9-deoxy-2',9ss-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-inter-phenylene)-PGF, compounds, 6aα-hydroxy-9-deoxy-2',9α-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-inter-phenylene)-PGF1 compounds, 6aα-hydroxy-9-dcoxy-2',9ss methono-3-oxa-4,5,6-trinor-3,7-(1',3'-inter-phenylene)-PGF1 compounds, 6ass-hydroxy-9-deoxy-2',9α;-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-inter-phenylene)-PGF1, and
6ass-hydroxy-9-deoxy-2',9ss-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-inter-phenylene)-PGF1 compounds, in free acid or methyl ester form which exhibit the following side chain substituents: 15-cyclohexyl-l 6,17,18,1 9,20-pentanor-; 17-(2-furyl)-18,19,20-trinor- ; 16-(3-thienyl)oxy-l 7,1 8,19,20-tetra nor-; 17-(3-thienyl)-18,19,20-trinor- ;
15-methyl-;
16-methyl-;
15,16-dimethyl-; 16,1 6-dimethyl-; 17,20-dimethyl-; 1 6-fluoro-;
1 5-methyl-1 6-fluoro-; 16,16-difluoro-; 15-methyl-l 6,16-difluoro-; 17-phenyl-18,19,20-trinor- ;
17-(m-trifluoromethylphenyl)-18,19,20-trinor- ;
1 7-(m-chlorophenyl)- 18,19,20-trinor-;
17-(p-fluorophenyl)-18,19,20-trinor- ; ;
15-methyl-17-phenyl-18,19,20-trinor- ;
16-methyl-17-phenyl-18,19,20-trinor- ;
16,16-dimethyl-17-phenyl-18,19,20-trinor- ;
16-fluoro-17-phenyl-18,19,20-trinor- ;
16,16-difluoro-17-phenyl-18,19,20-trinor- ; 1 6-phenyl-1 7,18,1 9,20-tetranor-; 15-methyl-16-phenyl-17,18,19,20-tetranor- ; 16-(m-trifluoromethylphenyl)-17,18,19,20-tetranor- ; 16-(m-chlorophenyl)-17,18,19,20-tetranor- ; 16-(p-fluorophenyl)-17,18,19,20-tetranor- ; 16-phenyl-18,19,20-trinor- ; 15-methyl-16-phenyl-18,19,20-trinor- ; 16-methyl-16-phenyl-18,19,20-trinor- ; 15,16-dimethyl-16-phenyl-18,19,20-trinor- ; 16-phenoxy-17,18,19,20-tetranor- ; 15-methyl-16-phenoxy-17,18,19,20-tetranor- ; 16-(m-trifluoromethylphenoxy)-17,18,19,20-tetranor- ; 16-(m-chlorophenoxy)-17,18,19,20-tetranor- ; 16-(p-fluorophenoxy)-17,18,19,20-tetranor- ; 16-phenoxy-18,19,20-trinor- ; 15-methyl-16-phenoxy-18,19,20-trinor- ; 16-methyl-16-phenoxy-18,19,20-trinor- ; 15,16-dimethyl-16-phenoxy-18,19,20-trinor- ; 13,14-didehydro- ; 15-cyclohexyl- 16,17,18,19,20-pentanor-13,14-didehydro- ; 17-(2-furyl)-18,19,20-trinor-13,14-didehydro- ; 16-(3-thienyl)oxy-17,18,19,20-tetranor-13,14-didehydro- ; 17-(3-thienyl)-18,19,20-trinor-13,14-didehydro- ; 15-methyl-13,14-didehydro- ; 16-methyl-13,14-didehydro- ; 15,16-dimethyl-13,14-didehydro- ; 16,16-dimethyl-13,14-didehydro- ; 17,20-dimethyl-13,14-didehydro- ; 16-fluoro-13,14-didehydro- ; 15-methyl-16-fluoro-13,14-didehydro- ; 16,16-difluoro-13,14-didehydro- ; 15-methyl-16,16-difluoro-13,14-didehydro- ; 17-phenyl-18,19,20-trinor-13,14-didehydro- ; 17-(m-trifluoromethylphenyl)-18,19,20-trinor-13,14-didehydro- ; 17-(m-chlorophenyl)-18,19,20-trinor-13,14-didehydro- ; 17-(p-fluorophenyl)-18,19,20-trinor-13,14-didehydro- ; 15-methyl-17-phenyl-18,19,20-trinor-13,14-didehydro- ; 16-methyl-17-phenyl-18,19,20-trinor-13,14-didehydro- ; 16,16-dimethyl-17-phenyl-18,19,20-trinor-13,14-didehydro- ; 16-fluoro-17-phenyl-18,19,20-trinor-13,14-didehydro- ; 16,16-difluoro-17-phenyl-18,19,20-trinor-13,14-didehydro- ; 16-phenyl-17,18,19,20-tetranor-13,14-didehydro- ; 15-methyl-16-phenyl-17,18,19,20-tetranor-13,14-didehydro- ; 16-(m-trifluoromethylphenyl)-17,18,19,20-tetranor-13,14-didehydro- ; 16-(m-chlorophenyl)-17,18,19,20-tetranor-13,14-didehydro- ; 16-(p-fluorophenyl)-17,18,19,20-tetranor-13,14-didehydro- ; 16-phenyl-18,19,20-trinor-13,14-didehydro- ; 15-methyl-16-phenyl-18,19,20-trinor-13,14-didehydro- ; 16-methyl-16-phenyl-18,19,20-trinor-13,14-didehydro- ; 15,16-dimethyl-16-phenyl-18,19,20-trinor-13,14-didehydro- ; 16-phenoxy-17,18,19,20-tetranor-13,14-didehydro- ; 15-methyl-16-phenoxy-17,18,19,20-tetranor-13,14-didehydro- ; 16-(m-trifluoromethylphenoxy)-17,18,19,20-tetranor-13,14-didehydro 16-(m-chlorophenoxy)-17,18,19,20-tetranor-13,14-didehydro- ; 16-(p-fluorophenoxy)-17,18,19,20-tetranor-13,14-didehydro- ; 16-phenoxy-18,19,20-trinor-13,14-didehydro- ; 15-methyl-16-phenoxy-18,19,20-trinor-13,14-didehydro- ; 16-methyl-16-phenoxy-18,19,20-trinor-13,14-didehydro- ; 15,16-dimethyl-16-phenoxy-18,19,20-trinor-13,14-didehydro- ; 13,14-dihydro- ; 15-cyclohexyl-16,17,18,19,20-pentanor-13,14-dihydro- ; 17-(2-furyl)-18,19,20-trinor-13,14-dihydro- ; 16-(3-thienyl)oxy-17,18,19,20-tetranor-13,14-dihydro- ; 17-(3-thienyl)-18,19,20-trinor-13,14-dihydro- ; 15-methyl-13,14-dihydro- ; 16-methyl-13,14-dihydro- ; 15,16-dimethyl-13,14-dihydro- ; 16,16-dimethyl-13,14-dihydro- ; 17,20-dimethyl-13,14-dihydro- ; 16-fluoro-13,14-dihydro- ; 15-methyl-16-fluoro-13,14-dihydro- ; 16,16-difluoro-13,14-dihydro- ; 15-methyl-16,16-difluoro-13,14-dihydro- ; 17-phenyl-18,19,20-trinor-13,14-dihydro- ; 17-(m-trifluoromethylphenyl)-18,19,20-trinor-13,14-dihydro- ; 17-(m-chlorophenyl)-18,19,20-trinor-13,14-dihydro- ; 17-(p-fluorophenyl)-18,19,20-trinor-13,14-dihydro- ; 15-methyl-17-phenyl-18,19,20-trinor-13,14-dihydro- ; 16-methyl-17-phenyl-18,19,20-trinor-13,14-dihydro- ; 16,16-dimethyl-17-phenyl-18,19,20-trinor-13,14-dihydro- ; 16-fluoro-17-phenyl-18,19,20-trinor-13,14-dihydro- ; 16,16-difluoro-17-phenyl-18,19,20-trinor-13,14-dihydro- ; 16-phenyl-17,18,19,20-tetranor-13,14-dihydro- ; 15-methyl-16-phenyl-17,18,19,20-tetranor-13,14-dihydro- ; 16-(m-trifluoromethylphenyl)-17,18,19,20-tetranor-13,14-dihydro- ; 16-(m-chlorophenyl)-17,18,19,20-tetranor-13,14-dihydro- ; 16-(p-fluorophenyl)-17,18,19,20-tetranor-13,14-dihydro- ; 16-phenyl-18,19,20-trinor-13,14-dihydro- ; 15-methyl-16-phenyl-18,19,20-trinor-13,14-dihydro- ; 16-methyl-16-phenyl-18,19,20-trinor-13,14-dihydro- ; 15,16-dimethyl-16-phenyl-18,19,20-trinor-13,14-dihydro- ; 16-phenoxy-17,18,19,20-tetranor-13,14-dihydro- ; 15-methyl-16-phenoxy-17,18,19,20-tetranor-13,14-dihydro- ; 16-(m-trifluoromethylphenoxy)-17,18,19,20-tetranor-13,14-dihydro- ; 16-(m-chlorophenoxy)-17,18,19,20-tetranor-13,14-dihydro- ;
16-(p-fluorophenoxy)-17,18,19,20-tetranor-13,14-dihydro- ; 16-phenoxy-18,19,20-trinor-13,14-dihydro- ; 15-methyl-16-phenoxy-18,19,20-trinor-13,14-dihydro- ; 16-methyl-16-phenoxy-18,19,20-trinor-13,14-dihydro- ; 15,16-dimethyl-16phenoxy-18,19,20-trinor-13,14-dihydro- ; 13-cis- ;
15-cyclohexyl-16,17,18,19,20-pentanor-13-cis- ; 17-(2-furyl)-18,19,20-trinor-13-cis- ; 16-(3-thienyl)oxy-17,18,19,20-tetranor-13-cis- ; 17-(3-thienyl)-18,19,20-trinor-13-cis- ; 15-methyl-13-cis- ; 16-methyl-13-cis- ; 15,16-dimethyl-13-cis- ; 16,16-dimethyl-13-cis- ;
17,20-dimethyl-13-cis- ;
16-fluoro-13-cis- ; 15-methyl-16-fluoro-13-cis- ;
16,16-difluoro-13-cis- ;
15-methyl-16,16-difluoro-13-cis- ;
17-phenyl-18,19,20-trinor-13-cis- ;
17-(m-trifluoromethylphenyl)-18,19,20-trinor-13-cis- ;
17-(m-chlorophenyl)-18,19,20-trinor-13-cis- ;
17-(p-fluorophenyl)-18,19,20-trinor-13-cis- ;
15-methyl-17-phenyl-18,19,20-trinor-13-cis- ;
16-methyl-17-phenyl-18,19,20-trinor-13-cis- ;
16,16-dimethyl-17-phenyl-18,19,20-trinor-13-cis- ;
16-fluoro-17-phenyl-18,19,20-trinor-13-cis- ;
16,16-difluoro-17-phenyl-18,19,20-trinor-13-cis- ;
16-phenyl-17,18,19,20-tetranor-13-cis- ;
15-methyl-16-phenyl-17,18,19,20-tetranor- 13-cis- ;
16-(m-trifluoromethylphenyl)-17,18,19,20-tetranor-13-cis- ;;
16-(m-chlorophenyl)-17,18,19,20-tetranor-13-cis- ;
16-(p-fluorophenyl)-17,18,19,20-tetranor-13-cis- ;
16-phenyl-18,19,20-trinor-13-cis- ;
15-methyl-16-phenyl-18,19,20-trinor-13-cis- ;
16-methyl-16-phenyl-18,19,20-trinor-13-cis- ;
15,16-dimethyl-16-phenyl-18,19,20-trinor-13-cis- ; 1 6-phenoxy-1 7,18,1 9,20-tetranor-1 3-cis-; 15-methyl-16-phenoxy-17,18,19,20-tetranor-13-cis- ;
16-(m-trifluoromethylphenoxy)-17,18,19,20-tetranor-13-cis- ;
16-(m-chlorophenoxy)-17,18,19,20-tetranor-13-cis- ; 1 6-(p-fluorophenoxy)-1 7,18,1 9,20-tetranor-l 3-cis-; 16-phenoxy-18,19,20-trinor-13-cis- ;
15-methyl-16-phenoxy-18,19,20-trinor-13-cis- ;
16-methyl-1 6-phenoxy-1 8,1 9,20-trinor-1 3-cis-; and
15,16-dimethyl-16-phenoxy-18,19,20-trinor-13-cis-,
A pharmaceutical composition according to the present invention comprises a compound of the invention in association with a physiologically acceptable excipient.
FORMULAS
FORMULAS (continued)
CHART A
CHART A (continued)
CHART B
CHART B (continued)
CHART C
CHART D
CHART D (continued)
CHART D (continued)
CHARTE
CHART F
CHART G
CHART G (continued)
CHART H
CHART H (continued)
CHART
CHARTJ
CHART K
CHARTL
CHART M
CHART N
CHART O
CHART P
CHART P (continued)
CHART Q
CHART Q (continued)
CHART R
CHART S
CHART T
CHART U
Claims (6)
1. A compound of the formula
wherein either R3 and R4 are independently selected from hydrogen, methyl and fluorine, provided that
CR3R4 is not CFMe, and R7 is C2-6 alkyl, c/s-CH-CH2-CH3, -(CH2)-CHOR10-CH3 and R10 is an acid-hydrolysable blocking group, -(CH2)3-CH=CH (CH3)2 or optionally ring-substituted phenoxy, phenyl, benzyl, phenylethyl or phenylpropyl in which there are no more than 3 ring substituents (no more than 2 of which are alkyl) independently selected from chlorine, fluorine, trifluoromethyl, C1-3 alkyl and C1-3 alkoxy, provided that neither R3 nor R4 is fluorine when R7 is optionally substituted phenoxy;
or CR3R4-R7 is 2-(2-furyl)ethyl, 2-(3-thienyl)ethoxy, 3-thienyloxymethyl, or C4-7 cycloalkyl optionally carrying up to 3 C1-5 alkyl substituents ;
M6 is α-OR10 :: PRB or α-R5 : ss-OR10 in which R5 is hydrogen or methyl and R10 is as defined above;
n is one or2;
Y1 is trans-CH=CH-, cis-CH=CH-, H2CH2 or -C-C-; R18 is H, OH, CH2OH, OR10 or CH2OR1o and This as defined above; and
R47 is C1-4 alkyl or CH2OH.
2. A compound of the formula
wherein n, R3, R4, R7, R18, M6 and X1 are as defined in claim 1.
3. A compound of the formula
wherein n, R3, R4, R7, R18, M6 and Y1 are as defined in claim 1.
4. A compound of the formula
wherein n, R18 and R47 are as defined in claim 1, and R32 is hydrogen or a replaceable blocking group.
5. A compound of the formula
wherein n and R18 are as defined in claim 1, and R32 is as defined in claim 4.
6. A compound of the formula
wherein n and RIB are as defined in claim 1, and R32 is as defined in claim 4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/125,608 US4338457A (en) | 1980-02-28 | 1980-02-28 | Composition and process |
US14054680A | 1980-04-15 | 1980-04-15 |
Publications (3)
Publication Number | Publication Date |
---|---|
GB8319030D0 GB8319030D0 (en) | 1983-08-17 |
GB2122201A true GB2122201A (en) | 1984-01-11 |
GB2122201B GB2122201B (en) | 1984-12-05 |
Family
ID=26823748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB08319030A Expired GB2122201B (en) | 1980-02-28 | 1983-07-14 | Carbacyclin intermediates |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB2122201B (en) |
IE (1) | IE50968B1 (en) |
-
1981
- 1981-02-26 IE IE40281A patent/IE50968B1/en not_active IP Right Cessation
-
1983
- 1983-07-14 GB GB08319030A patent/GB2122201B/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
GB2122201B (en) | 1984-12-05 |
IE810402L (en) | 1981-08-28 |
IE50968B1 (en) | 1986-08-20 |
GB8319030D0 (en) | 1983-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4306075A (en) | Composition and process | |
US4306076A (en) | Inter-phenylene CBA compounds | |
US4349689A (en) | Methano carbacyclin analogs | |
CA1201712A (en) | Carbacyclin analogs | |
US4420632A (en) | Composition and process | |
US4668814A (en) | Interphenylene carbacyclin derivatives | |
US4338457A (en) | Composition and process | |
US4112224A (en) | Biheterocyclic-9,11-trideoxy-PGF compounds | |
EP0159784A1 (en) | Carbacyclin analogues | |
US4487961A (en) | 9-Substituted carbacyclin analogs | |
US4525586A (en) | Composition and process | |
US4588823A (en) | 9-substituted carbacyclin analogs | |
US4294849A (en) | Prostaglandin analogues | |
US4487960A (en) | 9-Substituted carbacyclin analogs | |
US4401824A (en) | Benzopyran compounds, derivatives of prostaglandins | |
US4533749A (en) | 9-Substituted carbacyclin analogs | |
GB2121802A (en) | Benzo-fused carbacyclin analogues | |
GB2122201A (en) | Carbacyclin intermediates | |
US4243592A (en) | 9,11-Dideoxy-10-oxa-TXB compounds | |
CA1313670C (en) | Carbacyclin analogs | |
GB2122202A (en) | Carbacyclin intermediates | |
US4628110A (en) | Novel 9-substituted carbacyclin analogs | |
US4585886A (en) | 9-Substituted carbacyclin analogs | |
US4490555A (en) | 9-Substituted carbacyclin analogs | |
US4590297A (en) | Novel 9-substituted carbacyclin analogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE20 | Patent expired after termination of 20 years |
Effective date: 20010129 |